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Celiac disease (CD) is a serious lifelong condition, in which the immune system attacks an individual’s own tissue when eating 
gluten. This leads to inflammation and damage to the small intestine. Celiac disease often goes undiagnosed because many of its 
symptoms are nonspecific. The prevalence of combined undiagnosed and diagnosed CD is estimated to affect 1 in 100 people 
throughout Europe and USA.  
 
CD is a polygenic disease, it is known that the human leukocyte antigen (HLA) system plays a crucial role. HLA-DQ2/DQ8 risk 
allele genotyping screening test from a whole blood sample (B -HLAKeli) is routinely used to estimate the genetic risk of a patient 
having CD. HLA genotyping test result is routinely used to rule out celiac disease rather than confirming it; if an individual does not 
have celiac disease related risk alleles, it is very unlikely that he or she has celiac disease. The Celiac disease diagnosis decision 
making process is based on the classic triple combination of serological antibody tests, the HLA-DQ2/DQ8 genotyping test and 
duodenal biopsies.  
 
The aim of this master’s thesis was to study evaluate how the two different risk classification praxis for HLA-DQx.5 allele used for 
celiac disease diagnostics in SYNLAB Finland and Estonia central laboratory and in SYNLAB Suomi central laboratory might 
influence the clinical process and final diagnosis. In SYNLAB Suomi central laboratory HLA-DQx.5 is classified and interpreted as 
a risk allele predisposing to celiac disease. In SYNLAB Finland and Estonia central laboratory this allele is classified as CD-non-
risk-allele based on recommendations in international guideline. In addition, the aim was to get a general understanding of celiac 
disease prevalence and risk allele distributions among the study population.  
 
From the study population of 196 celiac disease suspect patients, 9% had a celiac disease positive laboratory result and the HLA 
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indicated that there’s no additional clinical value if HLA-DQx.5 is classified as a celiac disease predisposing risk allele; the study 
data implies that it is very unlikely to find celiac disease positive cases from laboratory test perspective among HLA-DQx.5 carriers. 
Based on the study, approximately 7% of the celiac disease suspects carry the allele HLA-DQx.5 and therefore probably go 
through additional celiac disease related laboratory testing if this allele is interpreted as a risk allele. According to the study findings 
and general recommendations based on international guideline of celiac disease diagnosis, it seems that there is no clear clinical 
benefit if HLA-DQx.5 is classified as a CD risk allele.  
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Keliakia on vakava elinikäinen autoimmuunisairaus jossa ravintoaineena nautittu gluteeni johtaa elimistön immuunijärjestelmän 
hyökkäykseen elimistön omia soluja kohtaan. Keliakiassa tämä näkyy ohutsuolen limakalvolla suolinukkaa vaurioittavana 
tulehdusreaktiona. Keliakia on yleisesti alidiagnosoitu sairaus johtuen pitkälti oireiden monikirjoisuudesta ja yksilötason eroista. 
Sairauden esiintyvyys Euroopassa ja Pohjois-Amerikassa on 1:100 jos otetaan huomioon sekä diagnosoidut tapaukset että 
diagnosoimatta jäävien arvioitu osuus.   
 
Keliakia on polygeeninen sairaus jossa HLA-molekyyleillä (Human Leukocyte Antigen) on merkittävä asema. Potilaan perinnöllistä 
keliakiariskiä voidaan arvioida seulontatestinä käytetyllä kokoverestä tehtävällä keliakiaan liittyvien HLA-DQ2/DQ8-riskialleelien 
genotyypityksellä (B -HLAKeli).  HLA-genotyypitystestiä käytetään tyypillisesti keliakin poissulkuun; jos potilaalla ei ole 
perimässään keliakialle tyypillisiä riskialleeleita, on hyvin epätodennäköistä että oireiden taustalla olisi keliakia. Keliakian kliininen 
laboratoriodiagnosointiprosessi perustuu kolmen eri diagnostisen osa-alueen yhdistelmään. Ensinnäkin määritetään 
seeruminäytteestä keliakialle tyypilliset vasta.aineet, toiseksi tehdään kokoverinäytteestä HLA-DQ2/DQ8-genotyypitys ja lopuksi 
keliakiadiagnoosi varmistetaan suolinäytteen mikroskooppisella tutkimuksella.  
 
Tämän tutkimuksen aiheena oli arvioda mitä vaikutuksia kahdella toisistaan eroavalla HLA-DQx.5 alleelia koskevalla 
riskiluokitusmallilla saattaa olla potilaalle määrättäviin kliinisiin laboratoriotutkimuksiin ja laboratoriotutkimusten perusteella 
annettavaan keliakiadiagnoosiin. SYNLAB Suomen keskuslaboratorio Suomessa luokittelee HLA-DQx.5 alleelin 
keliakiariskialleeliksi perustuen paikalliseen toimintamalliin ja SYNLAB Finland-Estonian keskuslaboratorio Tallinnassa luokittelee 
kyseisen alleelin kansainvälisten suositusten mukaisesti keliakian kannalta matalan riskin alleeliksi, jolla ei ole ratkaisevaa 
merkitystä keliakiaan. Luokitusmallivertailun lisäksi tarkasteltiin keliakin esiintyvyyttä ja alleelijakaumia tutkimuspopulaatiossa.  
 
Tutkimukseen valikoituneesta 196 keliakiaepäilypotilaan otannasta laboratoriotutkimusten perusteella 9%:lla voitiin todeta keliakia. 
Keliakiapositiivisten tapausten keskuudessa HLA-riskigenotyyppijakauma oli hyvin linjassa kirjallisuuden mukaisen 
odotusjakauman suhteen. Tutkimustulosten perusteella voitiin todeta että HLA-DQx.5-alleelin luokitus keliakiariskialleeliksi ei anna 
kliinistä lisäarvoa laboratoriotutkimusprosessin kannalta; tulokset osoittivat hyvin epätodennäköiseksi tilanteen missä HLA-DQx.5-
alleelin kantajalla diagnosoitaisiin keliakia. Voitiin myös osoittaa että noin 7% keliakiaepäillyistä potilaista kantaa HLA-DQx.5-
alleelia, ja jos tämä alleeli luokitellaan keliakiariskialleeliksi, on todennäköistä että heille määrätään keliakiadiagnoosiin tarvittavia 
lisätutkimuksia.  
 
Ottaen huomioon tutkimuksessa tehdyt havainnot ja yleiset kansainväliset keliakiadiagnosointia koskevat suosituksetit, näyttää 
siltä HLA-DQx.5-alleelin luokittelu keliakiariskialleeliksi ei tuo selkeää etua kliinisen päätöksenteon suhteen.   
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1 INTRODUCTION OF RESEARCH OBJECTIVES AND 
QUESTIONS 
The main objective of my thesis is to investigate whether two alternative praxis to 
interpret a celiac disease screening test result lead to significantly different outcomes. 
Besides the main objective, celiac disease prevalence and allele distribution within 
the study population were also evaluated and compared against the expected values 
collected from the literature.  
The celiac disease screening test is a genotyping test to analyse if an individual is a 
carrier of a major histocompatibility complex II class human leukocyte antigen DQ2 
and DQ8 celiac disease-associated alleles that predispose to the disorder. This study 
focused on a certain allele, HLA-DQx.5, which is related to a very low celiac disease 
risk category according to the internationally recommended risk allele interpretation 
guideline, and it is generally interpreted as a non-risk allele. The praxis used in 
SYNLAB Finland and Estonia central laboratory in Tallinn follows the international 
guideline and the allele HLA-DQx.5 is interpreted as a non-risk allele. This praxis 
differs from the country specific routine protocol used in SYNLAB Suomi central 
laboratory in Helsinki, where HLA-DQx.5 is classified and interpreted as a risk allele 
predisposing to celiac disease. The aim of the study is to investigate how these two 
genetic test result interpretation scenarios (country-specific praxis versus international 
recommendation) correlate with celiac disease specific antigen tests and tissue 
biopsy findings.  
This topic has been discussed at great length but there was not a clear understanding 
what is the impact of these differing risk allele handling protocols, especially if no 
further testing will be done based on the HLA screening test result, on the celiac 
disease risk assessment statement. What is the proportion and how big is the risk to 
miss some potential celiac disease cases if HLA-DQx.5 is interpreted as negative, 
almost non-risk finding? And, on the other hand, does it cause an extra, unnecessary, 
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expensive and burdensome confirmatory testing if HLA-DQx.5 is interpreted as a 
positive, celiac disease risk allele?  
2 LITERATURE REVIEW  
2.1 Celiac disease  
Celiac disease (CD) which is also referred to as gluten-sensitive enteropathy, celiac 
spruce and non-tropical sprue, is a serious, lifelong multiorgan autoimmune disease 
associated with the effects of multiple genes (polygenic) in combination with the 
triggering environmental factor, dietary gluten. Gluten is a group of proteins found in 
wheat, barley and rye. When individuals with celiac disease eat gluten or related 
prolamins, it triggers a T cell mediated immune reaction against tissue 
transglutaminase, which is an extracellular matrix enzyme. This leads to a chronic 
inflammation of the small intestinal mucosa. This reaction damages intestinal villi and 
prevents absorption of some nutrients (malabsorption) into the body. At present, the 
only treatment for celiac disease is a lifelong adherence to a strict gluten-free diet, 
although there are several ongoing clinical trials of alternative treatments and 
therapeutic options, such as gluten binding agents, zonulin-inhibitors, oral proteases 
and desensitization strategies. (Luca, et al., 2015) 
Celiac disease can present diverse and non-specific intestinal and extraintestinal 
symptoms, including abdominal pain, vomiting, chronic diarrhea, constipation, weight 
loss, anemia, bone or joint pain, skin disorders, bone loss or osteoporosis and many 
other. In addition to classical, symptomatic celiac disease, many individuals with 
celiac disease may have an asymptomatic or a mild form of the disease. (Rubio-
Tapia, Hill, Kelly, Calderwood, & Murray, 2013)  
The prevalence of combined undiagnosed and diagnosed CD is estimated to affect 1 
in 100 people in Europe and USA (Megiorni & Pizzuti, 2012). Childhood CD 
prevalence in Finland is reported to be 1:67. Studies suggest that the incidence rates 
are increasing but most of these changes are probably explained by availability and 
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increasing use of high sensitivity serological screening tests, which are able to detect 
milder or even asymptomatic forms of CD. (Rewers , 2005) 
Although celiac disease is a relatively common disease, the clinical heterogeneity 
makes it difficult to detect. Population-based screening studies indicate that there is a 
large undiagnosed population. (Mäki, et al., 2003 and Kurppa, et al., 2014) Evidence 
suggests that even 50-90 % of individuals with celiac disorder do not have a celiac 
diagnosis (Goddard & Gillett, 2006). 
2.2 Diagnosis of celiac disease 
2.2.1 Celiac disease diagnostics process today 
Today the clinical decision-making protocol of CD diagnosis is based on a 
combination of patient’s symptoms, family history and clinical laboratory test results. 
Suspected patients are generally screened with two different types of blood tests; 
serological antibody tests and a major histocompatibility complex II class human 
leukocyte antigen (HLA) DQ2 and DQ8 genotyping test. Serological antibody test 
panels are most commonly used as a primary test and the HLA-DQ2/DQ8 genotyping 
test is a supplementary test to add strength to the diagnosis. Finally, a confirmation 
gastroscopy by means of duodenal biopsies, is used in most cases as a confirmatory 
test for the diagnosis of CD. (Husby, et al., 2012) 
However, in year 2012 the guidelines published by the European Society for Pediatric 
Gastroenterology (ESPGHAN) describes an approach to avoid expensive and 
burdensome confirmatory biopsies from symptomatic children under certain 
conditions; characteristic symptoms of CD and levels of immunoglobulin A (IgA) 
against tissue transglutaminase (tTG) 10-fold or more the upper limit of normal and 
positive HLA-DQ2/DQ8 genotyping result. Even in the absence of clinical symptoms, 
the screening for CD should be considered among the children and adolescents who 
have increased risk for celiac disease. Risk groups include those with Down 
syndrome, Turner syndrome, Williams syndrome, autoimmune liver or thyroid 
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disease, selective immunoglobulin A deficiency (SIgAD), type-I diabetes mellitus and 
patients who have first-degree relatives with diagnosed celiac disease. (Husby, et al., 
2012)  Finnish study among several other studies has revealed that ESPGHAN 
criteria can be extended and CD can be diagnosed without biopsies both in children 
and adult population (Kurppa, et al., 2012). Nevertheless, this is not yet a globally 
approved approach and, for example, American College of Gastroenterology Clinical 
guidelines for celiac disease diagnosis stated that there are concerns about 
ESPGHAN criteria, mainly due to poorly standardized antibody tests and the clinical 
laboratory diagnostics field still strongly leans in the decision making process on the 
classic triple combination of serological antibody tests, the HLA-DQ2/DQ8 genotyping 
test and duodenal biopsies. (Rubio-Tapia, Hill, Kelly, Calderwood, & Murray, 2013).  
2.2.2 Current challenges and future direction in celiac disease laboratory diagnostics  
Celiac disease is classified as a polygenic disease, which means that it is caused by 
a combined action of many various genes. Celiac disease associated genes can 
contribute the disease phenotype independently or interact with each other and the 
individual contribution of each existing risk genotype may be very modest. It is widely 
recognized that particular HLA risk genotypes have an association to celiac disease 
and most of the patients (up to 95 %) with celiac disease carry HLA-DQ2 and HLA-
DQ8 risk alleles. These alleles are, nevertheless, present in general population (up to 
35 %) without diagnosed celiac disease. These findings have implied that HLA risk 
genotype alone is not sufficient factor for CD pathogenesis.  (Wijmenga & Gutierrez-
Achury, 2014) HLA genotyping based clinical testing has only 12 % positive predictive 
value (PPV) which means that genotyping should not be used routinely in the initial 
diagnosis of CD. On the other hand, it has a strong negative predictive value (NPV 
>99%) which means, that patients who are negative for both risk alleles, are unlikely 
to suffer from celiac disease. Therefore HLA genotyping is routinely used to rule out 
the celiac disease rather than confirming the disease in the first stage.  (Hadithi, et al., 
2007)  
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The current weakness of the positive predictive value of the HLA-DQ2/DQ8 
genotyping test and the polygenic character of CD has led to increasing interest 
towards genome-wide association studies (GWAS) of which have resulted almost 60 
promising CD associated non-HLA loci candidates. These novel risk loci can improve 
the positive predictive value of genotyping tests and enable more accurate risk 
classification of patients. This GWAS approach still requires further studies to get a 
better understanding of the function and role of thousands of genetic variants inside 
and outside of the coding part of the genome, before the accurate clinical diagnosis 
and prediction models can rely only on genetic tests. (Wijmenga & Gutierrez-Achury, 
2014) 
2.3 Celiac disease associated risk alleles 
2.3.1 Celiac disease specific HLA risk alleles 
Celiac disease is genetically linked to the human leucocyte antigen (HLA) system and 
the HLA risk allele genotyping screening test from a whole blood sample (B -HLAKeli) 
is routinely used to estimate the genetic risk of the patient to have CD. Recent GWAS 
studies have identified several non-HLA genes associated to CD, but, even so, only 
major histocompatibility complex HLA class II heterodimer coding genes HLA-DQA1 
and HLA-DQB1 are genes analysed in the routine clinical diagnosis process for CD. 
They’re located on the short arm of chromosome 6 (6p21.32) in the highly variable 
HLA-D region which is illustrated in picture 1. The HLA-D-region comprehends HLA-
DP (HLA-DPA1 for alpha chain and HLA-DPB1 for beta chain), HLA-DQ (HLA-DQA1 
for alpha chain and HLA-DQB1 for beta chain) and HLA-DR (HLA-DRA for alpha 
chain and HLA-DRB1 for beta chain) genes. (Megiorni & Pizzuti, 2012) 
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Picture 1 CD associated genes HLA-DQA1 and HLA-DQB1 map on chromosome 6 short 
arm HLA gene complex on the posit ion 6p21.3 (Sollid & Thorsby, 1993) 
The association between CD, HLA-DQ2 and HLA-DQ8 risk alleles is well established, 
and the disease develops very rarely if these specific risk alleles are not present. 
European collaboration study regarding HLA risk genotype distribution among celiac 
disease patients showed that approximately 90% of the patients in Northern Europe 
(Finland, Sweden, Norway, UK) carry the DQ2 heterodimer encoded by the alleles 
HLA-DQA1*05 and HLA-DQB1*02 (hereafter called HLA-DQ2.5) either in cis or in 
trans configuration. If alleles are present in cis, they are inherited together on the 
same chromosome on DR3 haplotype and, correspondingly, if they are in trans 
configuration, they are inherited separately on DR5/DR7 haplotype on the two 
homologous chromosomes. The proportion of HLA-DQ2.5 positivity among CD 
patients in Southern European population (France and Italy) was demonstrated to be 
lower, varying approximately from 80% in Italy up to 87 % in France, but the 
proportion of patients carrying more unusual option, one-half of DQ2.5 heterodimer, 
either DQA1*05 (HLA-DQx.5) or DQB1*02 (HLA-DQ2.x), was instead higher. (Karell, 
et al., 2003 and Megiorni, et al., 2009) Up to 10% of celiac disease patients carry the 
DQ8 heterodimer encoded by the alleles HLA-DQB1*03:02 and HLA-DQA1*03 in cis 
(DR4 haplotype) or in trans configuration. Only in a very rare case a CD patient 
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carries a heterodimer without any of formerly mentioned DQA1 or DQB1 variants. 
(Karell, et al., 2003 and Megiorni & Pizzuti, 2012). Table 1 summarizes the different 
CD risk alleles and combinations.  
HLA-DQ CD heterodimers Alpha chain Beta chain 
HLA-DQ2.5  DQA1*05 (α5) DQB1*02 (β2) 
HLA-DQ2.x not α5 DQB1*02 (β2) 
HLA-DQx.5 DQA1*05 (α5) neither β2 nor β03:02 
HLA-DQ8 DQA1*03 (α3) DQB1*0302 (β03:02) 
HLA-DQx.x not α5 neither β2 nor β03:02 
Table 1 Common CD HLA-DQ alpha and beta chain r isk allele combinations and 
heterodimers. Different risk allele combinations form different ly named heterodimers. 
HLA-DQx.x heterodimer does not contain any typical r isk allele and it is very unlikely 
that CD patients carry this heterodimer.  
In summary, all DQ2.5 and DQ8 heterodimers increase the risk of developing CD.  
However, studies has demonstrated that there is a homozygous effect with DQB1 
variant; for DQ2.5 subjects carrying two copies of DQB1*02 allele, the CD risk is 
approximately three times greater (risk 1:10) than if carrying only one copy (risk 1:35). 
Similarly, in the case of HLA-DQ2.x condition, individuals homozygous for DQB1*02 
allele have a remarkably increased CD risk (risk 1:26) if compared to individuals 
heterozygous for the same allele (risk 1:210). Homozygosity of DQB1*02 allele is also 
associated with increased tissue transglutaminase antibody levels and earlier onset of 
the disease. Moreover, the presence of only single DQB1*02 allele within individuals 
with DQ8 genotype leads to almost fourfold CD disease risk (1:89 vs. 1:24). 
(Megiorni, et al., 2009) Table 2 summarizes the evaluated risk of developing CD 
when individual is carrying certain HLA genotypes. The table 2 also illustrates that the 
risk allele HLA-DQx.5, which is in the main focus of this thesis, is classified in a very 
low CD risk category according to the internationally recommended risk allele 
interpretation guideline. 
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Table 2 HLA-DQ risk genotypes, different combinations of heterodimer alpha and beta 
chains, and the evaluated disease risk  in the case cohort when considering the disease 
prevalence of 1:100. (Megiorni, et al., 2009 and Megiorni & Pizzuti, 2012)   
The fact that majority of patients carry either DQ2.5, DQ8 or half of the DQ2 
heterodimer, highlights the role of HLA-DQ molecules as a genetic risk factors for CD 
and the importance of HLA genotyping test in the CD diagnostics protocol to detect 
individuals potentially at risk. (Karell, et al., 2003) Since the DQ8 risk allele HLA-
DQB1*03:02 is almost always linked to HLA-DR4 allele (HLA-DRB1*04), DRB1*04 is 
also routinely genotyped together with DQ2 and DQ8 risk alleles and it is used to 
confirm the DQ8 finding (Megiorni & Pizzuti, 2012).  
2.3.2 Mechanism of HLA-heterodimers in humoral response 
Protein products of HLA-DQA1 and HLA-DQB1 genes play a critical role in the 
immune system by presenting foreign peptides to the immune system, which in turn 
triggers the humoral response. Proteins coded by HLA-DQA1 and HLA-DQB1 genes 
attach to each other and form together a functional DQαβ-heterodimer. This 
heterodimer has a function as a cell surface receptor on antigen presenting B cells 
and plasma cells. (Megiorni & Pizzuti, 2012)  
Gluten is a mixture of prolamin proteins and its two major components are glutenin 
and gliadin proteins. Gluten molecules are digested in the gastrointestinal tract to 33-
HLA-DQ CD disease risk 
genotypes Evaluated risk for CD
HLA-DQ2.5 + HLA-DQ8 α5 α3 β2 β03:02 1:7 (very high)
HLA-DQ2.5, DQB1*02 
homozygosity α5 α5 β2 β2 1:10 (very high)
HLA-DQ8 + HLA-DQ2.x, single 
DQB1*02 allele α3 not α5 β2 β03:02 1:24 (high)
HLA-DQ2.x, DQB1*02 
homozygosity not α5 not α5 β2 β2 1:26 (high)
HLA-DQ2.5, single DQB1*02 allele α5 not α5 β2 not β2/not β03:02 1:35 (high)
HLA-DQ8 α3 not α5 β03:02 not β2/not β03:02 1:89 (high)
HLA-DQ2.x not α5 not α5 β2 not β2/not β03:02 1:210 (low)
HLA-DQx.5 α5 not α5 not β2/not β03:02 not β2/not β03:02 1:1842 (extremely low)
HLA-DQx.x not α5 not α5 not β2/not β03:02 not β2/not β03:02 1:2518 (extremely low)
Alpha chain Beta-chain
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amino acid long gliadin peptides, which are then modified further by tissue 
transglutaminase (tTG) enzyme in the lamina propria, which is a cell rich, thin layer of 
connective tissue in intestinal mucosa. (Russo, Ruchelli, & Piccoli, 2014) Tissue 
transglutaminase steers an enzymatic deamination which converts glutamine 
residues in gliadin peptides into negatively charged glutamic acid residues. As HLA-
DQ2 and HLA-DQ8 dimers have preference for negatively charged amino acids, 
these enzymatically modified gluten derived gliadin peptides bind with a high affinity 
to CD predisposing HLA-DQ2 and HLA-DQ8 dimers. These HLA-DQ dimers then, in 
turn, present gliadin peptides to CD4+ T cells, which play a major role in the humoral 
response triggering process. Dietary gluten initiated humoral responses result in 
cytokine and antibody secretion, in recruitment of other lymphocytes and in damage 
to the intestinal mucosa. (Koning, 2005)    
2.5 Celiac disease specific antibodies 
As described in a previous chapter, gluten derived component gliadin is a key 
activator of the immune system and a driver of CD specific antibody secretion. Many 
studies have shown that the presence of tissue transglutaminase antibodies and 
endomysial antibodies (EMA) in blood circulation is a specific indicator of active celiac 
disease. When a patient has been following a gluten-free diet, these antibody levels 
decrease. Interestingly, studies have demonstrated that antigliadin antibodies (AGA) 
against the trigger antigen gliadin itself are less specific for CD: they are present in 
most CD patients but also in healthy patients. (Picarelli, et al., 1996 and Stenman, et 
al., 2008)  
Antibodies are secreted by B cells and plasma cells. B cells’ tTG specific antibody 
production is dependent on the help of gliadin specific T cells, and therefore a gluten 
intake activates a parallel immune response against gliadin and tTG. Gliadin acts as a 
carrier for tTG and together they form a hapten-carrier complex, which is recognized 
by tTG specific B cells. Gliadin-tTG complex is taken up into the antigen presenting B 
cell and after degradation and processing, gliadin is in the form which can be 
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presented by HLA DQαβ cell surface receptors to specific CD4+ T cells as described 
in the previous chapter. The T cell triggered humoral response, in turn, stimulates the 
antibody secreting B cells, leading to the secretion of tTG-specific antibodies. (Lerner, 
Neidhöfer, & Torsten, 2015) Picture 2 summarizes glute derived gliadin driven tTG 
antibody production interactions between antigen presenting B cells and gliadin 
specific CD4+ T cells.  
 
Picture 2 HLA-DQA1 and HLA-DQB1 genes code protein subunits, which together form 
functional DQαβ-heterodimers. DQαβ-heterodimers are cell surface receptors, which are 
found on the surface of antigen presenting B cells. They have an abil ity to present 
foreign antigens to CD4+ T cells, which tr iggers humoral response.  (Koning, 2005) 
Gluten (carrier) and tTG (hapten) form complexes which are recognized by tTG specif ic 
B cells. Gliadin is brought into the cell by endocytosis and pr ocessed before the 
presentation to T cel l. This sheds a light why the production and secretion of tTG 
antibodies are gluten dependent, and why individuals posit ive for HLA-DQ2 or HLA-DQ8 
produce tTG antibodies. (Lerner, Neidhöfer, & Torsten, 2015) 
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Recently, the routine CD specific antibody test panel used in clinical laboratories has 
extended with deamidated gliadin peptide antibodies (DGPA) along with more 
conventional tTG antibodies. DGPA analysis is recommended as an additional test, 
especially when screening patients are younger than 2 years old. Gliadin peptides are 
deamidated by tTG when crossing the small intestinal mucosa. Deaminated gliadin 
peptides are much more immunogenic than unprocessed gliadin peptides and very 
specific targets for the antibodies against the deaminated peptides. (Husby, et al., 
2012 and Hong, 2015)  
In a routine CD diagnosis pathway, the initial serological test is an assay to measure 
a concentration of tissue transglutaminase immunoglobulin A from a serum sample (S 
-tTGAbA). A total concentration of immunoglobulin A (S -IgA) is also measured as a 
part of routine test panel, and in the case of low concentration due to primary or 
secondary humoral IgA deficiency, it is recommended to add a tissue 
transglutaminase immunoglobulin G (S -tTGAbG) assay to the initial test panel. If S -
tTGAb tests are negative, it is recommended to add tests for deamidated gliadin 
peptide immunoglobulin A and G (S -DGPAbA and S -DGPAbG) or for endomysial 
antibody immunoglobulin A and G (S –EMAbA and S -EMAbG) as additional tests in 
to the testing panel to increase the sensitivity and specificity of serological 
diagnostics. (Husby, et al., 2012 and Duodecim, 2018)  
Even so, Finnish clinical laboratory praxis follow typically Current Care Guidelines 
which do not recommend endomysial antibody immunoglobulin tests for screening 
purposes, because they are laborious from the laboratory analysis perspective. Also 
deamidated gliadin peptide immunoglobulin tests have not become established in the 
celiac disease screening program, because tissue transglutaminase antibody tests 
outperform the deamidated gliadin peptides antibody tests, and therefore they remain 
the preferred serological test for the diagnosis and/or exclusion of celiac disease.  
(Duodecim, 2018)  
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In this study, antibody tests were selected according to the Finnish praxis. Therefore 
S -tTGAbA and S -IgA were analysed from all patients and results were considered in 
the final evaluation.  
2.6 Celiac disease histopathology 
The formalin fixed and hematoxylin and eosin stained small intestine biopsy samples 
are analysed by clinical pathologists through microscopy diagnosis, which shows 
characteristic, though not specific, pathological conditions of celiac disease. The 
inflammatory response causes characteristic mucosal villous atrophy which can be 
variable and patchy, but the overall thickness of the mucosa is not decreased. Most 
symptomatic patients having a fully developed stage of celiac disease have a total 
villous atrophy, which is defined as completely flattened villi. Partial, patchy atrophy is 
more common in patients having a milder form of celiac disease or in post-treatment 
patients. The amount of intraepithelial lymphocytes and plasma cells is typically 
increased. Changes similar to the above, are not specific for celiac disease, and they 
can be seen in several other conditions, like dermatitis herpetiformis, tropical sprue, 
kwashiorkor and various autoimmune diseases. (Rosai & Ackerman, 2004) 
3 AIMS OF THE STUDY 
The specific aims and the structure of the study were: 
- To evaluate the local HLA-DQ allele distribution within the study population 
and compare it to the expected values based on literature 
- To get a general understanding of celiac disease prevalence among the study 
population  
- To study the diagnostic value of different HLA-DQ alleles and their risk 
classification with celiac disease laboratory diagnostics 
- To evaluate the differences between two different risk classification scenarios 
regarding HLA-DQx.5 allele 
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The study was performed by using routinely received celiac disease test samples 
collected from patients who were suffering from celiac disease related symptoms and 
therefore were suspected to have celiac disease. 
4 MATERIALS AND METHODS  
3.1 Samples 
The complete sets of celiac diagnostic panel samples were randomly collected from 
routine celiac disease testing samples and processing was done anonymously in 
SYNLAB Finland and Estonia central laboratory in Tallinn, Estonia and in SYNLAB 
Suomi central laboratory in Helsinki, Finland. Sample sets consist of the following 
types of sample materials: serum sample (3,5 ml serum gel sample tube, Becton 
Dickinson Vacutainer SST, Cat. No. 367957, Becton, Dickinson and Company, 
Plymouth, Devon, UK) for antibody determinations, whole blood sample (3,0 ml 
K2EDTA sample tube, Becton Dickinson Vacutainer K2EDTA, Cat. No. 368856, 
Becton, Dickinson and Company, Plymouth, Devon, UK) for HLA-DQ risk allele 
genotyping and tissue biopsy samples (20 ml CellsStor pre-filled specimen container, 
10% neutral buffered formalin, Cat. No. BAF-5000-08X or 60 ml CellsStor pre-filled 
specimen container, 10% neutral buffered formalin, Cat. No. BAF-6000-08U CellPath 
Ltd, Newtown, Powys, UK) from the upper small intestine for histopathological 
analysis to check the damage to the villi.  
3.1.1 Sample transportation and storage 
Samples were transported to the analyzing laboratory in temperature and 
transportation time controlled conditions, according to the standard ISO 15189. 
Serum samples were transported in cooled environment +2°C…+8°C and tissue 
biopsy and whole blood samples in a cooled or in a room temperature +2°C…+25°C. 
Sample transportation time was varying between 10 to 24 hours. Samples were either 
analysed immediately after arrival to the analyzing laboratory, or they were stored 
short term at +4°C (maximum about 3 days).  
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3.2 Sample preparation methods 
3.2.1 Sample preparation for antibody assays 
In order to obtain serum, the blood sample collected to serum gel sample tube was let 
to clot for 30 minutes and after clotting the whole blood samples were centrifuged at 
2000 g for 15 minutes. The supernatants were stored on the top of gel during the 
transportation and the short term storage. This step was performed in several 
external sample collection centers and therefore the models of centrifuges were 
unknown. Sample material quality was visually inspected for clots, hemolysis, icteria 
and lipemia before analysis and sample tube was decapped manually before 
analysis. General lab equipment and consumables were used if necessary 
(disposable Pasteur pipettes, automatic pipettes, disposable pipette tips) to perform 
sample preparation steps.  
3.2.2 DNA extraction for HLA genotyping analysis 
DNA extraction was performed with MagNA Pure96 DNA extraction instrument 
(Roche Molecular Systems, Pleasanton, California, USA) and MagNA Pure 96 DNA 
and Viral NA Small Volume Kit (Cat. No. 06 543 588 001, Roche Molecular Systems, 
Pleasanton, California, USA).  
All manual sample preparation steps were performed in a laminar flow cabinet. 
Standard protective equipment was used (gloves, lab coats) to prevent contamination 
and safety hazards. General lab equipment and consumables were used (automatic 
pipettes, disposable DNA/RNA free filter tips, microtubes, vortex, microtube 
centrifuge) to perform sample preparation steps.  
DNA extraction step required 200 µl room temperature primary whole blood sample. 
Sample material quality was visually inspected for clots. The following process steps 
are illustrated in a picture 3. Sample material (200 µl whole blood) was pipetted 
carefully to the bottom of the Magna Pure DNA extraction plate well. The plate was 
inserted into the DNA extraction instrument for automated extraction processing. The 
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automated extraction protocol used was “DNA Blood SV”. Lysis/binding buffer (< 6 M 
guanidine thiocyanate,< 30% Triton X-100, < 60 mM Tris HCl) was added to the 
reaction wells to initiate cell/virus lysis and binding of nucleic acids. Proteinase K (2% 
proteinase K, 50% glycerol) addition started the protein digestion. Magnetic glass 
beads were added to the reaction well (MGP suspension containing isopropanol) for 
binding DNA.  
After DNA binding step, unbound substances were washed away with wash buffers 
(Wash buffer I: < 6 M guanidine hydrochloride, < 50% EtOH, < 30 mM Tris HCl, Wash 
buffer III: < 20 mM Na-acetate buffer) by several washing steps. Purified DNA was 
eluted (elution volume 100 µl) from magnetic glass particles with elution buffer (< 60 
mM Tris-HCl buffer) and transferred to a 96-well sample plate (MagNA Pure 96 
Output Plate, Cat. No. 06241611001, Roche Molecular Systems, Pleasanton, 
California, USA).  
 
Picture 3. MagNA Pure96 DNA Blood SV protocol is used for HLA genotyping sample 
preparation. Genotyping analysis is carried out using the isolated, purif ied DNA sample.   
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3.2.3 Tissue sample preparation for a biopsy microscopy  
3.2.3.1 Tissue sample fixation, embedding and glass slide preparation 
Tissue samples were fixed by using immersion fixation technique with 10% neutral 
buffered formalin, which fixes tissue by cross-linking the proteins. Small pieces of the 
upper small intestine were let to soak in the fixative solution at a volume of a 
minimum of 20 times greater than the volume of the tissue and the fixing time was a 
minimum of 2 hours. Following fixation, tissue pieces from the same patient were 
transferred to a tissue cassette for processing, as illustrated in a picture 4. The 
cassette has six separate compartments, each holding one piece of tissue.  
 
 
 
 
Picture 4. Fixed tissue samples are transferred to the tissue cassette for processing. 
Tissue pieces sampled from different locations are placed to the separate cassette 
compartments.  
Cassettes were placed into the tissue processor cage and the cage was then placed 
into the tissue processor chamber filled with formalin solution (10% neutral buffered 
formalin, Algol Diagnostics Oy, Espoo, Finland). Sample processing was done using 
the Tissue-Tek VIP 6 system (Sakura Finetek Europe B.V., Alphen aan den Rijn, The 
Netherlands). Tissue processing program automatically controls the dehydration step 
which removes the water by immersing tissue in a series of ethanol solutions of 
increasing concentrations until 100% alcohol concentration is reached (Absolute 
ethanol ETAX AA, Altia Oyj, Helsinki, Finland, and 96% ethanol ETAX A, Altia Oyj, 
Helsinki, Finland). During the clearing stage, the ethanol was gradually replaced with 
Tissue-Tek Tissue-Clear solution (xylene substitute). This stage changes the 
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appearance of the tissue samples to transparent and clear. It is also a mandatory 
step before an embedding stage, as the ethanol and a paraffin wax does not mix. The 
last tissue processing stage was embedding, at which stage the xylene is replaced by 
the molten paraffin wax (Tissue-Tek III paraffin) during several wax immersion steps. 
Tissue preparation steps are shown in picture 5. 
 
Picture 5. Tissue sample preparation process steps. Upper left picture: t issue samples 
in cassette ready for t issue processor. Upper r i ght picture: t issue samples after t issue 
processor handling. Lower left picture:  t issue samples in molten paraffin wax. Lower 
right picture: t issue samples in paraffin block ready for microtome cutting step.  
The samples which were embedded to the paraffin block were cut with a Microm HM 
355 S rotary microtome (Microm International GmbH, Thermo Fisher Scientific, 
Walldorf, Germany) connected to a heated water bath section transfer system Microm 
STS (Microm International GmbH, Thermo Fisher Scientific, Walldorf, Germany) to 
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obtain thin sections which were placed to microscopy glass slides. Sections from two 
different levels were selected to achieve a representative sample. Cut sections from 
different levels were placed side by side on microscopy glass slides for staining with 
hematoxylin and eosin (HE). 
3.2.3.2 Hematoxylin and eosin staining 
Hematoxylin and eosin staining (HE staining) is a common histopathological staining 
method to reveal different tissue types and morphological changes.  
A deep blue-purple color hematoxylin is an alkaline dye and it stains nucleic acids 
(nuclei of cells).  Hematein, a product of oxidation of hematoxylin, is the active dye-
metal complex. The hematoxylin solution used was Mayer’s hematoxylin, and the 
oxidizing agent used was potassium iodate. In hematoxylin staining, mordant forms 
colored dye-mordant-tissue complexes which are often called “lakes” and the color 
depends on the mordant salt used. In Mayer’s hematoxylin solution, the mordant used 
is potassium aluminium sulfate. During staining the hematoxylin solution first imparts 
to the nuclei of cells a light transparent red stain. During the differentiation step 
hydrochloric acid is used to remove excess stain from tissues. The red color then 
rapidly turns blue on exposure to alkaline solution (tap water). This blueing process 
step neutralizes the acid and forms an insoluble dark blue aluminum hematein 
complex.  
A pink eosin Y is a fluorescent acidic dye and it stains proteins (basic structure of the 
tissue; cytoplasm, collagen and muscle fibers). The addition of acetic acid sharpens 
the staining of the eosin. 
Tissue sample staining and film cover-slipping process is done using the Tissue-Tek 
Prisma and Tissue-Tek Film integrated system (Sakura Finetek Europe B.V., Alphen 
aan den Rijn, The Netherlands). Reagents and liquids used in the process were 96% 
ethanol  (Absolute ethanol ETAX AA, Altia Oyj, Helsinki, Finland, and 96% ethanol 
ETAX A, Altia Oyj, Helsinki, Finland), Tissue-Tek xylene, Tissue-Tek Tissue-Clear 
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solution (xylene substitute), eosin solution (Eosin Solution, Reagena, Toivala, 
Finland), acetic acid ≥90% (Acetic acid ≥90%, GPR Rectapur, Merck KGaA, 
Darmstadt, Germany), 0,08% HCl hydrochloric acid solution (Hydrochloric Acid 37-
38%, J.T. Baker/Avantor Performance Materials B.V., Arnhem, Netherlands) and 
Grade 2 laboratory water fulfilling CLSI (Clinical Laboratory Standards Institute) 
requirements.  
Mayer’s hematoxylin solution for the staining process was prepared by mixing 750 ml 
commercial hematoxylin solution (Mayer's hemalum solution, Merck KGaA, 
Darmstadt, Germany) and 30 ml acetic acid ≥90%.  
The staining protocol was the following: 
Preparation 
1. Fixing  10 min 
Dewaxing step 
2. Tissue-Clear 10 min + 10 min  
Dehydration step 
3. Abs. ethanol 1 min + 1 min 
4. 96% ethanol 30 s + 45 s 
Wash and hematoxylin treatment 
5. Laboratory water 2 min 
6. Mayer’s hematoxylin solution 7 min 
Blueing and differentiation 
7.  Tap water 2 min 
8.  0,08% HCl 10 s 
9.  Tap water 5 min 
10.  Laboratory water 1 min 
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Eosin treatment 
11.  Eosin 10 min 
12.  Laboratory water 1 min 
Dehydration  
13.  96% ethanol 1 min + 1 min 
14.  Abs. ethanol 1 min + 1 min + 1 min 
Clearing 
15.  Xylene 2 min + 3 min 
Cover-slipping 
Prepared microscope slides (examples in picture 6) are analysed by clinical 
pathologists.  
 
Picture 6. Examples of HE-stained duodenal biopsy sample slides.  
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3.3 Analytical methods 
3.3.1 Serum assays 
3.3.1.1 Tissue transglutaminase IgA assay from a serum sample 
Serological antibody analysis to measure a serum sample S -tTGAbA concentration 
was done using the Phadia 250 analyser (Thermo Fisher Scientific/Phadia AB, 
Uppsala, Sweden). The Phadia 250 is a fully automated random-access 
immunoanalyser 
The in vitro measurement of S -tTGAbA in human serum was by the EliA Celikey IgA 
semi-quantitative fluoroenzyme immunoassay.  The assay format is enzyme-linked 
immunosorbent assay (ELISA) and uses recombinant human tissue transglutaminase 
as antigen. The Celikey specific reagents are available in a ready to use format in 
wells.  
Celikey IgA microwells are coated with human recombinant tTG. Prior to sampling, 
the Phadia 250 analyser aspirates 22 μl of non-diluted sample and automatically 
dilutes the sample 1:100 with ready for use on-board diluent (PBS containing BSA, 
detergent and sodium azide (0.095 %)). When the diluted patient sample is added to 
the microwell, antibodies to tTG bind to antigen in the wells. Incubations are 
performed at +37°C. After the first incubation, non-bound antibodies are washed 
away with Phadia phosphate buffer washing solution and enzyme-labeled conjugate 
antibodies against human IgA (ß-galactosidase anti-IgA or anti-IgG, mouse 
monoclonal antibodies in PBS containing BSA and sodium azide (0.06 %)) are added 
to form an antibody-conjugate complex. After the second incubation, non-bound 
conjugate is washed away with Phadia washing solution and the bound complex is 
incubated with a development solution (0.01 % 4-methylumbelliferyl-β-D-galactoside). 
ß-galactosidase enzyme reacts with the 4-methylumbelliferyl-β-D-galactoside and the 
enzymatic reaction produces fluorescence.  
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The reaction is stopped with stopping solution (4 % sodium carbonate) and the 
fluorescence in the reaction mixture is measured. The higher the fluorescence signal, 
the more specific IgA is present in the specimen. Calibration of the assays is 
completed whenever a new kit lot is taken into use and analyser software converts 
the measured signal automatically to EliA U/ml using the calibration curve. Detailed 
description of assay format and steps are described in picture 7.   
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Picture 7. Phadia Celikey IgA assay format.  
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3.3.1.2 Total IgA assay from a serum sample 
Concentration of total serum IgA (S -IgA) was measured by using the Siemens ADVIA 
Chemistry XPT system (Siemens Healthcare GmbH, Erlangen, Germany). The 
ADVIA XPT is a fully automated random-access clinical chemistry analyser.  
The in vitro measurement of S -IgA in human serum was done using the ADVIA 
Chemistry XPT IGA_2 assay reagent which is available as a ready to use format and 
the test principle is a PEG-enhanced immunoturbidimetric method.  
The analyser aspirates 30 μl of the primary serum sample and automatically dilutes 
the sample 1:5 with saline. 4 μl of diluted sample is aspirated to a reaction cuvette 
which contains 80 μl of Reagent 1 (Polyethylene glycol (6%),Tris/HCL buffer, pH 7.4 
(20 mmol/L), sodium chloride (150 mmol/L) and NaN3 (0.09%)). After stirring and 
incubation at +37°C, 16 μl of Reagent 2 (Polyethylene glycol (6%), Antihuman IgA 
(goat), Tris/HCL buffer, pH 7.4 (20 mmol/L), sodium chloride (150 mmol/L), NaN3 
(0.09%)) is added to the reaction cuvette. Sample is left to react with the Reagent 2 
containing the analyte specific antiserum to form a precipitate. After the second 
stirring and incubation steps, sample absorbance is measured turbidimetrically at 
340/694 nm. The analyser software converts the measured absorbance automatically 
to the concentration of IgA (g/l) using a standard curve from the absorbances of 
standards.  
3.3.2 HLA genotyping method 
HLA genotype is analysed from isolated DNA sample using EliGene Coeliac RT kit 
(Elizabeth Pharmacon, Brno-Zidenice, Czech Republic) which is based on real-time 
polymerase chain reaction (RT-PCR) method. The kit consists of primers and labeled 
probes for the detection of HLA-DQ2 (DQA1*05, DQB1*02), HLA-DQ8 (DQA1*03, 
DQB1*03:02) and HLA-DR4 (DRB1*04) alleles. Synaptophylin-like 2 gene (SYPL2) is 
used as an internal control (IC) which monitors if RT-PCR processes are working as 
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expected. RT-PCR technique monitors the amplification reaction of a targeted DNA 
molecule using fluorescence during each amplification cycle in the PCR reaction.  
Probes used for detection are labelled with 2 different type of fluorescent dye labels to 
separate different alleles within the same reaction. RT-PCT instrument runs 3 
reactions and the details of each reaction are listed in the table 3 below.  
  
FAM labeled probe (6-
fluorescein amidite (6-
FAM)) 
JOE labeled probe (4-5-
Dichloro carboxy 
fluorescein) 
HLA-DQ2 
reaction DQA1*05 DQB1*02 
HLA-DQ8 
reaction DQB1*03:02 DQA1*03 
HLA-DRB 
reaction DRB1*04 IC 
 
Table 3. HLA genotyping method RT-PCR run consists of  3 reactions. Probes are 
labelled either with FAM or with JOE to detect different alleles  within the same reaction.  
RT-PCR reaction was with Mic qPCR (Bio Molecular Systems, Upper Coomera, 
Australia) thermocycler and PCR tubes (Mic-Tubes and Caps strip PCR tube, total 
reaction volume 10 - 25 µL, Bio Molecular Systems, Upper Coomera, Australia, Cat. 
No. 60655). All manual sample preparation steps were performed in a laminar flow 
cabinet. Standard protective equipment was used (gloves, lab coats) to prevent 
contamination and safety hazards. General lab equipment and consumables were 
used (automatic pipettes, disposable DNA/RNA free filter tips, microtubes, PCR 
tubes, vortex, microtube centrifuge) to perform sample preparation steps. Liquids 
used were Grade 2 laboratory water fulfilling CLSI (Clinical Laboratory Standards 
Institute) requirements and Tris-EDTA buffer solution (1xTris-EDTA, pH 8,0, diluted 
from 100x concentrate, Sigma-Aldrich, St. Louis, MO, USA).  
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DNA extract was diluted 10x with 1xTris-EDTA buffer (18 µl 1xTris-EDTA and 2 µl 
DNA extract). All reaction runs included positive (SYPL2) and negative (mQH2O sterile 
water) controls. Reaction preparation steps are described in a picture 8. 
 
 
Picture 8. Reaction preparation for HLA genotyping RT-PCR method. DNA extract is 
diluted 10x and 2,5 µl of diluted DNA sample is used per each PCR reaction.   
RT-PCR protocol has a holding stage (initial denaturation) at 95oC for 3 minutes and 
a cycling stage, which consists of a denaturation step at 95oC for 15 seconds and an 
annealing step at 58oC for 40 seconds. The cycling stage is repeated 40 times.  
Intensity of FAM and JOE reporter probes’ fluorescence was read by using two 
different channels, FAM channel (green: absorbance 494 nm – emission 518 nm) and 
JOE channel (yellow: absorbance 525 nm – emission 548 nm).  
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3.4 Result interpretations 
3.4.1 Serum tissue transglutaminase IgA assay results 
S -tTGAbA assay’s reference value of healthy individuals is <7 EliA U/ml. Results 
between 7 and 10 EliA U/ml are intermediate and further investigation is 
recommended. Typically biopsy samples are collected to confirm the diagnosis or 
exclude CD. If S -tTGAbA result is >10 EliA U/ml, it is interpreted as a positive result 
and if S -tTGAbA result is 10 x upper limit of normal value (≥70 EliA U/ml) it is a 
strong predictor of subsequent celiac disease even in patients with normal villi. 
Increased values are highly specific for villous atrophy and therefore used as a 
specific indicator of active celiac disease. When the patient has been on a gluten-free 
diet, antibody levels decrease. 
3.4.2 Serum total IgA test results 
Total IgA reference values for healthy individuals vary by age. Reference values are 
listed in a table 4 below.  
Total Serum IgA concentration 
Age group Reference range (g/l) 
<2 years 0-0,8 
2-3 years 0,2-1 
4-6 years 0,3-2 
7-9 years 0,3-3 
10-11 years 0,5-2 
12-13 years 6-3,6 
14-15 years 5-2,5 
16-19 years 6-3,5 
≥20 years 0,7-4 
 
Table 4. Age specif ic reference values of serum total IgA (S -IgA).  
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3.4.3 HLA genotyping results 
B -HLAKeli results are read from the Mic qPCR interface. Mic qPCR system sets a 
threshold value automatically to eliminate false positivity due to very faint increase of 
signal. In a successful analysis the positive, negative and internal controls are 
passed, and the internal control amplification signal is exponential. In the case of a 
positive genotype result, the positive control has the highest amplification signal and 
the positive genotype has a slightly lower amplification signal than the positive 
control. Both amplification signals increase exponentially before cycle number 35 and 
the negative control amplification signal remains below the threshold value. Examples 
of positive findings are shown in pictures 9, 10 and 11. 
 
 
Picture 9. HLA-DQ2 reaction example. Sample is posit ive for DQA1*05.  
Positive 
control 
FAM 
DQA1*05 
Negative 
control 
Threshold 
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Picture 10. HLA-DQ2 reaction example. Sample is posit ive for DQB1*02.  
 
Picture 11. HLA-DRB reaction example. Sample is posit ive for DRB1*04.  
Results are interpreted following the rules described in tables 5 and 6.   
Genotype 
HLA-DQ2 reaction HLA-DRB reaction 
FAM DQA1*05 JOE DQB1*02 FAM DRB1*04 JOE IC 
HLA-DQ2.5  + + +/- + 
HLA-DQ2.x - + +/- + 
HLA-DQx.5 + - +/- + 
No DQ2 risk alleles - - +/- + 
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Genotype 
HLA-DQ8 reaction HLA-DRB reaction 
FAM DQB1*03:02 JOE DQA1*03 FAM DRB1*04 JOE IC 
HLA-DQ8  + + + + 
No DQ8 risk alleles - + +/- + 
No DQ8 risk alleles + - +/- + 
No DQ8 risk alleles - - +/- + 
 
Table 5. HLA genotyping results are interpreted by combining results from HLA -DQ2, 
HLA-DQ8 and HLA-DRB (control) reactions. Plus (+) symbol means that the allele is 
present (posit ive result)  and in the sample and minus (-) symbol means that the allele 
cannot be detected (negative result)  from the sample. Internal control ’s (IC) positive 
result confirms that the reaction was successful  and DRB1*04 allele should be posit ive 
together with a posit ive HLA-DQ8 finding.  
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Table 6. HLA genotyping result statements and celiac disease risk classif ication are 
given by combining HLA-DQ2 and HLA-DQ8 genotype findings. The method cannot 
make a difference between DQB1*02 homozygosity or heterozygosity if a sample result 
is HLA-DQ2 or HLA-DQ2.5 posit ive but HLA-DQ8 negative. The genotype HLA-DQx.5, 
which has a different result statement protocols between SYNLAB Suomi and SYNLAB 
Finland and Estonia central laboratories, is highlighted with red borders.   
3.4.4 Histological results 
Histological microscopy examination of the duodenal biopsy sample is performed by 
clinical pathologists under microscopy using 2X, 4X, 10X and 40X magnification. 
Genotype
CD risk 
classification Alleles found
Result statement in SYNLAB Finland and Estonia 
central laboratory
Result statement in SYNLAB Suomi central 
laboratory
HLA-DQ2.5 + 
HLA-DQ8 1:7 (very high)
HLA-DQA1*05, 
HLA-DQB1*02, 
HLA-
DQB1*03:02, 
HLA-DQA1*03
HLA-analysis: HLA-DQ2.5 and HLA-DQ8 positive. The 
analysis detected the following risk alleles related to celiac 
disease: HLA-DQA1*05, HLA-DQB1*02 and HLA-DQB1*0302. 
The risk alleles are not sufficient for the diagnosis as HLA-
DQ2 or DQ8 isoforms may occur in up to 30% of healthy 
individuals. The finding of the risk haplotype supports the 
diagnosis of celiac disease if the patient has symptoms similar 
to celiac disease and if the disease-associated antibodies are 
also found.
HLA-analysis: HLA-DQ2.5 and HLA-DQ8 positive. The 
analysis detected the following risk alleles related to celiac 
disease: HLA-DQA1*05, HLA-DQB1*02 and HLA-DQB1*0302. 
The risk alleles are not sufficient for the diagnosis as HLA-
DQ2 or DQ8 isoforms may occur in up to 30% of healthy 
individuals. The finding of the risk haplotype supports the 
diagnosis of celiac disease if the patient has symptoms similar 
to celiac disease and if the disease-associated antibodies are 
also found.
HLA-DQ8 + HLA-
DQ2.x, single 
DQB1*02 allele 1:24 (high)
HLA-DQB1*02, 
HLA-
DQB1*03:02, 
HLA-DQA1*03
HLA-analysis: HLA-DQ2 and HLA-DQ8 positive. The analysis 
detected the following risk alleles related to celiac disease: 
HLA-DQB1*02 and HLA-DQB1*0302. The risk alleles are not 
sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms may 
occur in up to 30% of healthy individuals.The finding of the 
risk haplotype supports the diagnosis of celiac disease if the 
patient has symptoms similar to celiac disease and if the 
disease-associated antibodies are also found.
HLA-analysis: HLA-DQ2 and HLA-DQ8 positive. The analysis 
detected the following risk alleles related to celiac disease: 
HLA-DQB1*02 and HLA-DQB1*0302. The risk alleles are not 
sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms may 
occur in up to 30% of healthy individuals.The finding of the 
risk haplotype supports the diagnosis of celiac disease if the 
patient has symptoms similar to celiac disease and if the 
disease-associated antibodies are also found.
HLA-DQ2.5, 
DQB1*02 
homozygosity or 
single DQB1*02 
allele
1:10 (very high) 
or 1:35 (high)
HLA-DQA1*05, 
HLA-DQB1*02
HLA-analysis: HLA-DQ2.5 positive. The analysis detected the 
following risk alleles related to celiac disease: HLA-DQA1*05 
and HLA-DQB1*02. The risk alleles are not sufficient for the 
diagnosis as HLA-DQ2 or DQ8 isoforms may occur in up to 
30% of healthy individuals. The finding of the risk haplotype 
supports the diagnosis of celiac disease if the patient has 
symptoms similar to celiac disease and if the disease-
associated antibodies are also found.
HLA-analysis: HLA-DQ2.5 positive. The analysis detected the 
following risk alleles related to celiac disease: HLA-DQA1*05 
and HLA-DQB1*02. The risk alleles are not sufficient for the 
diagnosis as HLA-DQ2 or DQ8 isoforms may occur in up to 
30% of healthy individuals. The finding of the risk haplotype 
supports the diagnosis of celiac disease if the patient has 
symptoms similar to celiac disease and if the disease-
associated antibodies are also found.
HLA-DQ2.x, 
DQB1*02 
homozygosity or  
single DQB1*02 
allele 
1:26 (high) or 
1:210 (low) HLA-DQB1*02
HLA-analysis: HLA-DQ2 positive. The analysis detected the 
following risk allele related to celiac disease: HLA-DQB1*02. 
The risk alleles are not sufficient for the diagnosis as HLA-
DQ2 or DQ8 isoforms may occur in up to 30% of healthy 
individuals. The finding of the risk haplotype supports the 
diagnosis of celiac disease if the patient has symptoms similar 
to celiac disease and if the disease-associated antibodies are 
also found.
HLA-analysis: HLA-DQ2 positive. The analysis detected the 
following risk allele related to celiac disease: HLA-DQB1*02. 
The risk alleles are not sufficient for the diagnosis as HLA-
DQ2 or DQ8 isoforms may occur in up to 30% of healthy 
individuals. The finding of the risk haplotype supports the 
diagnosis of celiac disease if the patient has symptoms similar 
to celiac disease and if the disease-associated antibodies are 
also found.
HLA-DQ8 1:89 (high)
HLA-
DQB1*03:02, 
HLA-DQA1*03
HLA-analysis: HLA-DQ8 positive. The analysis detected the 
following risk allele related to celiac disease: HLA-
DQB1*0302. The risk alleles are not sufficient for the 
diagnosis as HLA-DQ2 or DQ8 isoforms may occur in up to 
30% of healthy individuals. The finding of the risk haplotype 
supports the diagnosis of celiac disease if the patient has 
symptoms similar to celiac disease and if the disease-
associated antibodies are also found.
HLA-analysis: HLA-DQ8 positive. The analysis detected the 
following risk allele related to celiac disease: HLA-
DQB1*0302. The risk alleles are not sufficient for the 
diagnosis as HLA-DQ2 or DQ8 isoforms may occur in up to 
30% of healthy individuals. The finding of the risk haplotype 
supports the diagnosis of celiac disease if the patient has 
symptoms similar to celiac disease and if the disease-
associated antibodies are also found.
HLA-DQx.5
1:1842 
(extremely low) HLA-DQA1*05
HLA-analysis: negative. No association was found 
between the risk haplotypes  HLA-DQ2 and HLA-DQ8 
and celiac disease. The patient has no increased risk of 
developing celiac disease.
HLA-analysis: HLA-DQX.5 positive. The analysis 
detected the following low-risk allele related to celiac 
disease: HLA-DQA1*05. The risk alleles are not sufficient 
for the diagnosis as HLA-DQ2 or DQ8 isoforms may 
occur in up to 30% of healthy individuals. The finding of 
the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac 
disease and if the disease-associated antibodies are 
also found.
HLA-DQx.x
1:2518 
(extremely low)
no risk alleles 
found
HLA-analysis: negative. No association was found between 
the risk haplotypes  HLA-DQ2 and HLA-DQ8 and celiac 
disease. The patient has no increased risk of developing 
celiac disease.
HLA-analysis: negative. No association was found between 
the risk haplotypes  HLA-DQ2 and HLA-DQ8 and celiac 
disease. The patient has no increased risk of developing 
celiac disease.
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Examples of normal duodenal tissue morphology and villous atrophy findings are 
shown in pictures 12 and 13.  
 
Picture 12. Examples of duodenal tissue morphology of a normal duodenal t issue. The 
tissue has normal vil lous architecture – vill i  are long, f inger-like tentacles and separated 
with crypts. Magnifications used: 2X, 4X, 10X and 40X.  
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Picture 13. Examples of duodenal tissue morphology of a CD patient duodenal t issue. 
Tissue architecture represents a severe vil lous atrophy – vil l i have eroded away, leaving 
a virtually flat surface missing visible crypts . Magnifications used: 2X, 4X, 10X and 40X.  
There are several different grading systems available to classify the duodenal 
histological findings, for example Oberhuber’s grading system based on Marsh 
Classification of histologic findings (Oberhuber, Granditsch, & Vogelsang, 1999) or 
Corazza’s, Roberts’ & Ensari’s simplified celiac disease grading systems (Ensarı, 
2010). In this study the duodenal tissue morphology grading conforms to the Ensari’s 
and Chief Pathologist Medical Doctor Tuula Kuukasjärvi’s recommendations 
(Kuukasjärvi, 2019) and it is described in the table 7.  
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Grade Description/clinical statement 
- 
Normal tissue, celiac disease highly 
unlikely 
+ 
Inflammation, increased intraepithelial 
lymphocytes but no villous atrophy. Not 
specific, may be seen in infections 
++ 
Villi still present but shortened. Spectrum 
of changes seen in symptomatic celiac 
disease. 
+++ 
Severe/complete villous atrophy. Spectrum 
of changes seen in symptomatic celiac 
disease. 
 
Table 7. Histological f indings and grading system. Histological f indings through 
microscopy examination are classif ied based on the level of villous at rophy and/or 
inflammation.  
4 RESULTS AND DISCUSSION 
4.1 Validation of study population 
The total number of 199 celiac diagnostic panel sample sets (serum, whole blood and 
tissue biopsy) were studied. One celiac diagnostics sample set represents one 
patient. SYNLAB laboratories do not have access to detailed clinical patient data, but 
a common reason for a such a detailed celiac disease test requested by clinician is 
that a patient has gastrointestinal symptoms and is suspected to have a celiac 
disease or another condition with similar symptoms.  
Three sets of samples were omitted from the final comparisons because they were 
known to be disease treatment monitoring samples collected from patients formerly 
diagnosed with celiac disease. The remaining 196 sample sets were estimated to be 
eligible based on the clinical patient data available and included in a final data 
analysis.  
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4.2 Combined serological, genotyping and histological laboratory results  
Clinical diagnostics tests were completed on all samples including B -HLAKeli test 
from a whole blood sample, S -tTGAbA analysis from a serum sample and a 
histological examination of a duodenal biopsy sample. Total serum IgA levels were 
also measured to rule out the possibility of IgA deficiency. None of the samples had 
abnormally low concentration of S -IgA and hence no further investigation such as S -
tTGAbG analysis was required. Appendix 1. has a detailed list of clinical laboratory 
results.  
Sample set results were first divided into groups based on the diagnosed HLA 
genotype. After that results were subdivided into groups representing the outcome of 
histological and serum tissue transglutaminase antibody results. Data is shown in the 
table 8.   
HLA-DQx.x (total 45 samples) 
Histology 
grade - 
Histology 
grade + 
Histology 
grade ++ 
Histology 
grade +++ 
S -tTGAbA  positive >10 EliA U/ml 0 0 0 0 
S -tTGAbA intermediate 7-10 EliA U/ml 0 0 0 0 
S -tTGAbA  normal <7 EliA U/ml 34 8 3 0 
     
HLA-DQx.5 (total 13 samples) 
Histology 
grade - 
Histology 
grade + 
Histology 
grade ++ 
Histology 
grade +++ 
S -tTGAbA  positive >10 EliA U/ml 0 0 0 0 
S -tTGAbA intermediate 7-10 EliA U/ml 0 0 0 0 
S -tTGAbA  normal <7 EliA U/ml 9 3 1 0 
     
HLA-DQ8 (total 39 samples) 
Histology 
grade - 
Histology 
grade + 
Histology 
grade ++ 
Histology 
grade +++ 
S -tTGAbA  positive >10 EliA U/ml 0 0 1 1 
S -tTGAbA intermediate 7-10 EliA U/ml 0 0 0 0 
S -tTGAbA  normal <7 EliA U/ml 33 4 0 0 
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HLA-DQ2.x, single DQB1*02 allele or 
DQB1*02 homozygosity (total 20 
samples) 
Histology 
grade - 
Histology 
grade + 
Histology 
grade ++ 
Histology 
grade +++ 
S -tTGAbA  positive >10 EliA U/ml 0 0 1 0 
S -tTGAbA intermediate 7-10 EliA U/ml 0 0 1 0 
S -tTGAbA  normal <7 EliA U/ml 15 2 1 0 
     
HLA-DQ2.5, single DQB1*02 allele or 
DQB1*02 homozygosity (total 71 
samples) 
Histology 
grade - 
Histology 
grade + 
Histology 
grade ++ 
Histology 
grade +++ 
S -tTGAbA  positive >10 EliA U/ml 0 1 9 4 
S -tTGAbA intermediate 7-10 EliA U/ml 0 3 3 1 
S -tTGAbA  normal <7 EliA U/ml 39 6 5 0 
     
HLA-DQ8 + HLA-DQ2.x, single DQB1*02 
allele (total 3 samples) 
Histology 
grade - 
Histology 
grade + 
Histology 
grade ++ 
Histology 
grade +++ 
S -tTGAbA  positive >10 EliA U/ml 0 0 0 0 
S -tTGAbA intermediate 7-10 EliA U/ml 0 0 0 0 
S -tTGAbA  normal <7 EliA U/ml 2 0 1 0 
     
HLA-DQ2.5 + HLA-DQ8 (total 5 samples) 
Histology 
grade - 
Histology 
grade + 
Histology 
grade ++ 
Histology 
grade +++ 
S -tTGAbA  positive >10 EliA U/ml 0 0 0 0 
S -tTGAbA intermediate 7-10 EliA U/ml 0 0 0 0 
S -tTGAbA  normal <7 EliA U/ml 4 1 0 0 
 
Table 8. B -HLAkeli test data from 199 patients divided to individual tables representing 
different genotypes. All cases in each table are then subdivided by severity grade of 
histological f indings and S -tTGAbA results (number represents the amount of cases 
falling in each category).    
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4.3 Celiac disease likelihood 
Given that SYNLAB laboratories do not have access to the clinician’s final clinical 
decision and patient data, the classification of celiac disease likelihood was defined 
together with SYNLAB laboratories’ clinical specialists, considering both the serum 
antibody test results and histological findings. The clinical test result classification 
matrix is shown in the table 9. Celiac disease laboratory test results shown in the 
table 8 were then classified according to the classification matrix and the final 
summary is shown in table 10.  
Probability - how likely is it that 
patient has a CD? 
Histology 
grade - 
Histology 
grade + 
Histology 
grade ++ 
Histology 
grade +++ 
S -tTGAbA  positive ≥70 EliA U/ml 
(10 x upper limit of normal value) Positive Positive Positive Positive 
S -tTGAbA  positive >10 and <70 
EliA U/ml Intermediate Intermediate Positive Positive 
S -tTGAbA intermediate 7-10 EliA 
U/ml Low Intermediate Intermediate High 
S -tTGAbA  normal <7 EliA U/ml Low Low Intermediate Intermediate 
 
Table 9. Sample set results were classif ied by the likelihood of celiac disease diagnosis  
matrix set by SYNLAB laboratories’ clinical specialists Medical Doctor Glükmann and 
Medical Doctor Kuukasjärvi  according to the guidelines (Glükmann, 2020 and 
Kuukasjärvi, 2019).  
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Table 10. The laboratory test result data classified regarding the celiac disease 
likelihood. 160 sample sets out of 196 were negative and only 17 sample sets were 
posit ive. 19 sample sets were intermediate, which means that the celiac disease cannot 
be confirmed based on clinical laboratory test results . The allele HLA-DQx.5, which’s 
interpretation varies between SYNLAB Suomi and SYNLAB Finland and Estonia central 
laboratories, is marked in the table with red frames.  
4.4 Positive predictive value of B -HLAKeli screening test 
The observed positive predictive value (PPV, the proportion of those with positive B -
HLAKeli screening test result who have the disease) was calculated by using the 
genotype risk classifications from the perspective of two alternative scenarios:  
- the first scenario which considers HLA-DQx.5 and HLA-DQx.x both as 
negative, almost non-risk findings and all the rest of the analysed genotypes as 
positive, celiac disease risk genotype results. This scenario is aligned with the 
interpretation protocol used in SYNLAB Finland and Estonia central laboratory. 
- the second scenario which considers only HLA-DQx.x as a negative result and 
all the rest of the analysed genotypes, also HLA-DQx.5, as positive, celic 
disease risk genotype results. This scenario follows the interpretation protocol 
used in SYNLAB Suomi central laboratory. 
 
Genotype
CD risk 
classification n % from total Negative 
% from the 
genotype Intermediate
% from the 
genotype Positive 
% from the 
genotype
HLA-DQ2.5 + HLA-
DQ8 1:7 (very high) 5 3 % 5 100 % 0 0 % 0 0 %
HLA-DQ8 + HLA-
DQ2.x, single 
DQB1*02 allele 1:24 (high) 3 2 % 2 67 % 1 33 % 0 0 %
HLA-DQ2.5, 
DQB1*02 
homozygosity or 
single DQB1*02 allele
1:10 (very high) or 
1:35 (high) 71 36 % 45 63 % 12 17 % 14 20 %
HLA-DQ2.x, 
DQB1*02 
homozygosity or  
single DQB1*02 allele 
1:26 (high) or 1:210 
(low) 20 10 % 17 85 % 2 10 % 1 5 %
HLA-DQ8 1:89 (high) 39 20 % 37 95 % 0 0 % 2 5 %
HLA-DQx.5
1:1842 (extremely 
low) 13 7 % 12 92 % 1 8 % 0 0 %
HLA-DQx.x
1:2518 (extremely 
low) 45 23 % 42 93 % 3 7 % 0 0 %
Total 196 160 82 % 19 10 % 17 9 %
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The algorithm to calculate positive predictive value is 𝑃𝑃𝑉 = 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑡𝑟𝑢𝑒 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒𝑠 (𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑡𝑟𝑢𝑒 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒𝑠 + 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑓𝑎𝑙𝑠𝑒 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒𝑠)⁄  
Given that SYNLAB laboratories do not have access to the clinician’s final clinical 
decision or the patient diagnosis data, the following definition of true positives and 
false positives were made: 
Number of true positives = positive B-HLAKeli screening cases (carriers of risk 
genotype) which were confirmed to have a high likelihood for celiac disease by 
duodenal biopsy examination and S -tTGAbG serological test (according to the celiac 
disease likelihood diagnosis matrix, table 9). 
Number of false positives = positive B-HLAKeli screening cases (carriers of risk 
genotype) which were confirmed to have a medium or low likelihood for celiac 
disease by duodenal biopsy examination and S -tTGAbG serological test (according 
to the celiac disease likelihood diagnosis matrix, table 9). 
Calculated positive predictive values are shown in table 11. PPV 1 demonstrates the 
value of scenario 1 and, accordingly, PPV 2 demonstrates the value of scenario 2.  
PPV scenario 1  PPV scenario 2 
Number of true positives 
(n) 17  
Number of true positives 
(n) 17 
Number of true positives 
+ number of false 
positives (n) 138  
Number of true positives 
+ number of false 
positives (n) 151 
PPV 1 (%) 12,3 %  PPV 2 (%) 11,3 % 
 
table 11. Posit ive predictive values regarding scenario 1 (HLA-DQx.5 and HLA-DQx.x 
both interpreted as CD negative results) and scenario 2 (only HLA-DQx.x interpreted as 
a CD negative result and all the rest of the analysed genotypes, also HLA -DQx.5, are 
considered as posit ive, risk genotype results).  
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4.5 Negative predictive value of B -HLAKeli screening test 
The observed negative predictive value (NPV, the proportion of those with negative B 
-HLAKeli screening test result who do not have the disease) was calculated in the 
similar manner by using the differing genotype risk classifications from two alternative 
scenarios.  
The algorithm to calculate negative predictive value is 𝑁𝑃𝑉 = 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑡𝑟𝑢𝑒 𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒𝑠 (𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑡𝑟𝑢𝑒 𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒𝑠 + 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑓𝑎𝑙𝑠𝑒 𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒𝑠)⁄  
Given that SYNLAB laboratories do not have access to the clinician’s final clinical 
decision or the patient diagnosis data, the following definition of true negatives and 
false negatives was made: 
Number of true negatives = negative B-HLAKeli screening cases (carriers of very low 
risk genotype) which were confirmed to have a low likelihood for celiac disease by 
duodenal biopsy examination and S -tTGAbG serological test (according to the celiac 
disease likelihood diagnosis matrix, table 9). 
Number of false negatives = negative B-HLAKeli screening cases (carriers of very low 
risk genotype) which were confirmed to have a medium or high likelihood for celiac 
disease by duodenal biopsy examination and S -tTGAbG serological test (according 
to the celiac disease likelihood diagnosis matrix, table 9). 
Calculated negative predictive values are shown in table 12. NPV 1 demonstrates the 
value of scenario 1 and, accordingly, NPV 2 demonstrates the value of scenario 2.  
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NPV scenario 1  NPV scenario 2 
Number of true negatives 
(n) 54  
Number of true negatives 
(n) 42 
Number of true negatives 
+ number of false 
negatives (n) 58  
Number of true negatives 
+ number of false 
negatives (n) 45 
NPV 1 (%) 93,1 %  NPV 2 (%) 93,3 % 
Table 12. Negative predictive values regarding scenario 1 (HLA-DQx.5 and HLA-DQx.x 
both interpreted as CD negative results) and scenario 2 (only HLA-DQx.x interpreted as 
a CD negative result and all the rest of the analysed genotypes, also HLA -DQx.5, are 
considered as posit ive, risk genotype results).  
6 CONCLUSIONS  
6.1 Test result distribution of the study population 
Sample materials used in this study were collected from a selected population of 
almost 200 patients referred for symptoms, signs and for screening of celiac disease.  
Nevertheless 82% of the cohort tested negative for CD by the clinical laboratory tests, 
and 10% of results were classified as intermediate, which typically suggests further 
testing and clinical examination is needed for a final diagnosis. Only 9% of the clinical 
laboratory tests pointed out a clear indication of celiac disease. The result distribution 
is illustrated in picture 14. The primary aim behind the laboratory test request is to 
exclude celiac disease from the pool of possible diseases causing patient’s 
symptoms. These study findings demonstrated the complexity of celiac disease 
nature and diagnostics; symptoms are diverse and non-specific and celiac disease is 
only one of the possible causes for the patient’s condition. 
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Picture 14. Sample sets selected to the study. Three sample sets were excluded 
because they were collected from the patients formerly diagnosed for celiac disease and 
were probably collected for treatment monitoring purposes. Out of 196 sample sets only 
9% resulted in a posit ive celiac disease test result.  
6.2 HLA-DQ allele distribution of the study population and result comparison to 
the literature 
The majority of celiac disease positive subjects present HLA-DQ2.5 heterodimer. 
Most of the remaining CD positive subjects carry HLA-DQ8 heterodimer and one 
subject was homozygous or heterozygous for DQB1*02 allele. The genotype 
distribution of CD positive findings is very well aligned with the expected values 
described in the literature (Karell, et al., 2003 and Megiorni, et al., 2009). These 
values are shown in the table 13. Only the amount of HLA-DQ8 heterodimers among 
all CD positive cases was slightly elevated. However, the data was prone for bias due 
to a limited number of positive cases; there were only two HLA-DQ8 carriers and one 
HLA-DQ2.x carrier among only 17 positive cases. If this in taken in consideration, the 
distribution of CD positive genotypes demonstrated in the study aligned well with 
expected values based on literature.  
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Genotype 
positive 
(n) 
positive 
(%) 
Expected values 
(%) 
HLA-DQ2.5, DQB1*02 homozygosity or 
single DQB1*02 allele 14 82 % 78-90% 
HLA-DQ2.x, DQB1*02 homozygosity or  
single DQB1*02 allele  1 6 % Appr. 6% 
HLA-DQ8  2 12 % 5-10% 
Table 13. Genotype distribution of CD posit ive subjects. Majority of cases carry HLA-
DQ2.5 heterodimer as expected.  
When allele distribution was compared between positive, intermediate and negative 
results, the largest variation was seen among celiac disease negative subjects 
(picture 15). All alternative allele types which can be detected by the used method 
were present. An interesting point was that the allele combination HLA-DQ2.5 + HLA-
DQ8, which has the highest celiac disease predisposing risk, gave neither positive 
nor intermediate final outcomes, but all five cases were negative. The highest 
proportion of celiac disease positive subjects were HLA-DQ2.5 carriers. The method 
used in this study for HLA genotyping was not capable to differentiate between 
homozygosity and heterozygosity of DQB1*02 allele, so the increased celiac disease 
risk impact of homozygosity within the HLA-DQ2.5 or HLA-DQ2.x carriers cannot be 
evaluated in this study.  
 
Picture 15. Allele distr ibution among posit ive, intermediate and negative celiac disease 
test results. 
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6.3 Differences in HLAkeli test results between SYNLAB laboratories 
The main objective of the study was to compare whether the SYNLAB Suomi central 
laboratory’s genetic test result interpretation praxis regarding HLA-DQx.5 allele 
(scenario 2) gives a clinically different result when compared to SYNLAB Finland and 
Estonia central laboratory’s praxis (scenario 1). 
HLA genotyping test’s positive predictive value varied from 11,3% to 12,3%, 
depending on the scenario used. These measured PPV’s were well aligned with the 
12% PPV described by Hadithi in his study of HLA-DQ typing accuracy (Hadithi, et 
al., 2007). Scenario 1 showed a slightly better PPV because of less false positives. 
These additional false positives in scenario 2 are HLA-DQx.5 allele results which are 
interpreted as positive, risk genotype results, but none of these cases were confirmed 
CD positive when combined with S -tTGAbA results and histological findings.  
Negative predictive values from scenario 1 (93,1%) and scenario 2 (93,3%) were 
almost identical. There were no positive results among false negatives, and only 4 
intermediate cases within scenario 1 and 3 intermediate cases within scenario 2. This 
shows that patients who do not carry risk alleles are unlikely to have CD and, 
furthermore, that B-HLAKeli genotyping test can be used to rule out CD diagnosis. 
Nevertheless the measured negative predictive values were strong and somehow 
aligned with expectations, they were still lower than NPV (>99%) published by Hadithi 
(Hadithi, et al., 2007). Our study has some limitations regarding the conclusion of 
intermediate cases, which were handled as false negatives, as we were not able to 
confirm them as negative or positive with the limited extent of the data we had. 
Further examination, more detailed patient data and additional testing after gluten 
free diet might shed a light to the final result and diagnosis. This might change the B-
HLAKeli test NPV value closer to the expected >99%, but unfortunately additional 
information was not available for SYNLAB laboratories.  
Overall, the number of patients carrying HLA-DQx.5 allele was 13 which was 7% of 
the study population. After S -tTGAbA tests and histological examination, none of 
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these 13 cases were classified positive for celiac disease. One patient was classified 
intermediate and 12 were classified negative for celiac disease. In other words, 92% 
of patients carrying HLA-DQx.5 were diagnosed as very unlikely to have celiac 
disease and 0% were diagnosed as having a strong likelihood of celiac disease. 
Percentage of negative, intermediate and positive cases were almost identical if HLA-
DQx.5 carrier results are compared to the HLA-DQx.x carrier results; 92% of HLA-
DQx.5 and 93% of HLA-DQx.x carriers were diagnosed very unlikely to have a celiac 
disease and 0% were diagnosed to have a strong likelihood of celiac disease 
regarding both alleles.  
If HLA-DQx.5 is classified as a CD risk allele, it is very likely to cause increasing 
amounts of, probably unnecessary, laboratory testing and confirmatory biopsies; the 
data from this study shows that additional 7% of the celiac disease suspects carry the 
allele HLA-DQx.5 and therefore probably go through additional celiac disease related 
laboratory testing. On the other hand, if HLA-DQx.5 is classified as a CD non-risk 
allele, the study data implies that it is very unlikely to miss positive cases from 
laboratory test perpective. According to the study findings and general 
recommendations based on international guidelines, it seems that there is no clear 
clinical benefit if HLA-DQx.5 is classified as a CD risk allele.  
6.4 Limitations of the study 
Our study has some limitations and the potential for bias because of the lack of direct 
contact to the clinician and patient. SYNLAB is a commercial clinical laboratory 
providing clinical laboratory testing and consultation services to medical clinics who 
are treating patients. SYNLAB laboratories receive only the minimum required 
information to perform the requested laboratory testing and hence the patient 
background information available was limited. Patient’s final diagnosis was not 
availabe for SYNLAB.  
This study material was observed only from SYNLAB laboratory diagnostics point of 
view and intermediate cases were not analysed any deeper than originally requested 
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by clinicians. This naturally creates limitations to the number of cases selected to this 
study. Only full sets of samples including whole blood sample for genotyping, serum 
sample for antibody testing and biopsy sample for histopathological analysis were 
selected in this study. HLA genotyping test B -HLAKeli should be requested only once 
in a lifetime per patient because the genetic result does not change. Assumption was 
made that B -HLAKeli test request should work as a good marker to filter out the 
celiac disease primary screening cases from all celiac disease related test requests. 
Even so, there were three clear cases, when the clinician mistakenly repeatedly 
requested the genotyping test for the celiac disease diagnosed patient during the 
treatment monitoring phase. These three cases were excluded from the final study 
data, however, there is a risk that the data could contains similar cases. This finding 
also highlights the need for additional information to be shared with clinicians 
regarding celiac disease laboratory diagnostics.  
6.5 Suggestions for further research 
As pointed out before, the limited number of positive cases, incomplete outcomes of 
intermediate cases and inadequate patient background information means that this 
study can be seen as a promising starting material and prelude for a more detailed 
study regarding the deeper insight to the nature of the HLA-DQx.5 allele under 
interest. The primary results can be shared with clinicians and discussed if this study 
could be continued in co-operation with medical clinics and hospitals.   
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APPENDIX 1 – Clinical laboratory diagnostics results
Internal ID Mnemonic 
 Test 
Shortname  B -HLAKeli ValTime Resu
lt ext
erna
l com
ment
 (B -
HLAK
eli)
HLAD
Q2_D
Q8 g
enot
ype
RISK PADGAST statement Histology grade tTGAbA result U/ml
tTGAbA result 
interpretation IgA result g/l
IgA reference 
range (age 
dependent)
IgA result 
interpretation
19740713N B-HLADQ2_DQ8-PCR B -HLAKeli 26.07.2018 15:06
HLA-analysis: HLA-DQ2.5 and HLA-DQ8 positive. The analysis detected the following risk alleles related to celiac 
disease: HLA-DQA1*05, HLA-DQB1*02 and HLA-DQB1*0302. The risk alleles are not sufficient for the diagnosis 
as HLA-DQ2 or DQ8 isoforms may occur in up to 30% of healthy individuals. The finding of the risk haplotype 
supports the diagnosis of celiac disease if the patient has symptoms similar to celiac disease and if the disease-
associated antibodies are also found.
HLA-DQ2.5 + HLA-
DQ8 1:7 (very high)
T64300 DUODENUM M43000 CHRONIC INFLAMMATION
T63600 GASTRIC ANTRUMM43000 CHRONIC GASTRITIS
T63500 GASTRIC CORPUS M43000 CHRONIC GASTRITIS
T62350 CARDIO-ESOPHAGEAL JUNCTION M43000 CHRONIC INFLAMMATION + <0.6 neg 1.17 0.7-4 normal
19740219A B-HLADQ2_DQ8-PCR B -HLAKeli 13.09.2018 15:15
HLA-analysis: HLA-DQ2.5 and HLA-DQ8 positive. The analysis detected the following risk alleles related to celiac 
disease: HLA-DQA1*05, HLA-DQB1*02 and HLA-DQB1*0302. The risk alleles are not sufficient for the diagnosis 
as HLA-DQ2 or DQ8 isoforms may occur in up to 30% of healthy individuals. The finding of the risk haplotype 
supports the diagnosis of celiac disease if the patient has symptoms similar to celiac disease and if the disease-
associated antibodies are also found.
HLA-DQ2.5 + HLA-
DQ8 1:7 (very high)
T64300 DUODENUM M00100 NORMAL TISSUE MORPHOLOGY
T63000 STOMACH M43000 CHRONIC GASTRITIS - <0.6 neg 1.84 0.7-4 normal
19720708H B-HLADQ2_DQ8-PCR B -HLAKeli 07.11.2018 15:55
HLA-analysis: HLA-DQ2.5 and HLA-DQ8 positive. The analysis detected the following risk alleles related to celiac 
disease: HLA-DQA1*05, HLA-DQB1*02 and HLA-DQB1*0302. The risk alleles are not sufficient for the diagnosis 
as HLA-DQ2 or DQ8 isoforms may occur in up to 30% of healthy individuals. The finding of the risk haplotype 
supports the diagnosis of celiac disease if the patient has symptoms similar to celiac disease and if the disease-
associated antibodies are also found.
HLA-DQ2.5 + HLA-
DQ8 1:7 (very high)
T64300 DUODENUM  M00100 NORMAL TISSUE MORPHOLOGY
T63600 GASTRIC ANTRUM  M40000 GASTRITIS  REACTIVE
T63500 GASTRIC CORPUS   M00100 NORMAL TISSUE MORPHOLOGY
T62000 ESOPHAGUS  M40000 ESOPHAGITIS
T62350 GASTROESOPHAGEAL JUNCTION  M40000 INFLAMMATION  ACTIVE
T62350 GASTROESOPHAGEAL JUNCTION  M73320 INTESTINAL METAPLASIA - <0.6 neg 1.71 0.7-4 normal
19730508T B-HLADQ2_DQ8-PCR B -HLAKeli 16.11.2018 15:40
HLA-analysis: HLA-DQ2.5 and HLA-DQ8 positive. The analysis detected the following risk alleles related to celiac 
disease: HLA-DQA1*05, HLA-DQB1*02 and HLA-DQB1*0302. The risk alleles are not sufficient for the diagnosis 
as HLA-DQ2 or DQ8 isoforms may occur in up to 30% of healthy individuals. The finding of the risk haplotype 
supports the diagnosis of celiac disease if the patient has symptoms similar to celiac disease and if the disease-
associated antibodies are also found.
HLA-DQ2.5 + HLA-
DQ8 1:7 (very high)
T64300 DUODENUM M73330 GASTRIC METAPLASIA
T63600 GASTRIC ANTRUM M00100 NORMAL TISSUE MORPHOLOGY
T63500 GASTRIC CORPUS M00100 NORMAL TISSUE MORPHOLOGY - <0.6 neg 2.90 0.7-4 normal
19600904H B-HLADQ2_DQ8-PCR B -HLAKeli 06.06.2019 15:42
HLA-analysis: HLA-DQ2.5 and HLA-DQ8 positive. The analysis detected the following risk alleles related to celiac 
disease: HLA-DQA1*05, HLA-DQB1*02 and HLA-DQB1*0302. The risk alleles are not sufficient for the diagnosis 
as HLA-DQ2 or DQ8 isoforms may occur in up to 30% of healthy individuals. The finding of the risk haplotype 
supports the diagnosis of celiac disease if the patient has symptoms similar to celiac disease and if the disease-
associated antibodies are also found.
HLA-DQ2.5 + HLA-
DQ8 1:7 (very high)
T64300 DUODENUM: M00100 NORMAL TISSUE MORPHOLOGY
T63600 GASTRIC ANTRUM AND CORPUS: M43000 CHRONIC GASTRITIS 
ACTIVE (HP+) - <0.6 neg 3.43 0.7-4 normal
19850303P B-HLADQ2_DQ8-PCR B -HLAKeli 18.09.2019 16:37
HLA-analysis: HLA-DQ2.5 positive. The analysis detected the following risk alleles related to celiac disease: HLA-
DQA1*05 and HLA-DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms 
may occur in up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies are also 
found.
HLA-DQ2.5, DQB1*02 
homozygosity or single 
DQB1*02 allele
1:10 (very high) or 
1:35 (high)
T64300 DUODENUM  M09350 MORPHOLOGICAL DESCRIPTION ONLY (LIEVÄ 
INTRAEPITELIAALINEN LYMFOSYTOOSI)
T63600 GASTRIC ANTRUM  M00100 NORMAL TISSUE MORPHOLOGY
T63500 GASTRIC CORPUS  M00100 NORMAL TISSUE MORPHOLOGY
T62350 GASTROESOPHAGEAL JUNCTION  M00100 NORMAL TISSUE 
MORPHOLOGY + 8.5 intermediate 3.77 0.7-4 normal
19890410K B-HLADQ2_DQ8-PCR B -HLAKeli 16.01.2018 15:25
HLA-analysis: HLA-DQ2.5 positive. The analysis detected the following risk alleles related to celiac disease: HLA-
DQA1*05 and HLA-DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms 
may occur in up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies are also 
found.
HLA-DQ2.5, DQB1*02 
homozygosity or single 
DQB1*02 allele
1:10 (very high) or 
1:35 (high)
1-3: T64300 DUODENUM AND STOMACH M00100 NORMAL TISSUE 
MORPHOLOGY - 0.6 neg 2.82 0.7-4 normal
19700612K B-HLADQ2_DQ8-PCR B -HLAKeli 17.01.2018 16:18
HLA-analysis: HLA-DQ2.5 positive. The analysis detected the following risk alleles related to celiac disease: HLA-
DQA1*05 and HLA-DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms 
may occur in up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies are also 
found.
HLA-DQ2.5, DQB1*02 
homozygosity or single 
DQB1*02 allele
1:10 (very high) or 
1:35 (high)
T64300 DUODENUM  M00100 NORMAL TISSUE MORPHOLOGY
T63600 GASTRIC ANTRUM  M43000 CHRONIC GASTRITIS ACTIVE 
HELICOBACTER+++
T63600 GASTRIC ANTRUM  M73320 INTESTINAL METAPLASIA AND ATROPHY 
MILD
T63500 GASTRIC CORPUS  M43000 CHRONIC GASTRITIS ACTIVE 
HELICOBACTER+++ - <0.6 neg 1.70 0.7-4 normal
19640626V B-HLADQ2_DQ8-PCR B -HLAKeli 21.01.2018 20:23
HLA-analysis: HLA-DQ2.5 positive. The analysis detected the following risk alleles related to celiac disease: HLA-
DQA1*05 and HLA-DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms 
may occur in up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies are also 
found.
HLA-DQ2.5, DQB1*02 
homozygosity or single 
DQB1*02 allele
1:10 (very high) or 
1:35 (high)
1: T64300 DUODENUM   M00100 NORMAL TISSUE MORPHOLOGY
2-3: T63000 STOMACH   M43000 CHRONIC GASTRITIS
4: T62000 ESOPHAGUS   M43000 CHRONIC INFLAMMATION - <0.6 neg 1.97 0.7-4 normal
19610615S B-HLADQ2_DQ8-PCR B -HLAKeli 31.01.2018 16:00
HLA-analysis: HLA-DQ2.5 positive. The analysis detected the following risk alleles related to celiac disease: HLA-
DQA1*05 and HLA-DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms 
may occur in up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies are also 
found.
HLA-DQ2.5, DQB1*02 
homozygosity or single 
DQB1*02 allele
1:10 (very high) or 
1:35 (high) T64300 DUODENUM M00100 NO DIAGNOSTIC ABNORMALITY
- CD diagnosed, 
control test, 
EXCLUDED 28.0 pos 2.53 0.7-4 normal
19800906K B-HLADQ2_DQ8-PCR B -HLAKeli 01.02.2018 16:35
HLA-analysis: HLA-DQ2.5 positive. The analysis detected the following risk alleles related to celiac disease: HLA-
DQA1*05 and HLA-DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms 
may occur in up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies are also 
found.
HLA-DQ2.5, DQB1*02 
homozygosity or single 
DQB1*02 allele
1:10 (very high) or 
1:35 (high)
I T64300 DUODENUM M00100 NORMAL FINDING
II T63600 GASTRIC ANTRUM, JA CORPUS M00100 NORMAL FINDING
IV T62000 ESOPHAGUS M73330 GASTRIC METAPLASIA - <0.6 neg 1.19 0.7-4 normal
19970324K B-HLADQ2_DQ8-PCR B -HLAKeli 09.02.2018 15:55
HLA-analysis: HLA-DQ2.5 positive. The analysis detected the following risk alleles related to celiac disease: HLA-
DQA1*05 and HLA-DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms 
may occur in up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies are also 
found.
HLA-DQ2.5, DQB1*02 
homozygosity or single 
DQB1*02 allele
1:10 (very high) or 
1:35 (high)
T64300 DUODENUM  M00100 NORMAL TISSUE MORPHOLOGY
T63600 GASTRIC ANTRUM  M00100 NORMAL TISSUE MORPHOLOGY
T63500 GASTRIC CORPUS  M00100 NORMAL TISSUE MORPHOLOGY
T62000 ESOPHAGUS  M00100 NORMAL TISSUE MORPHOLOGY - <0.6 neg 1.48 0.7-4 normal
19820329J B-HLADQ2_DQ8-PCR B -HLAKeli 09.02.2018 15:56
HLA-analysis: HLA-DQ2.5 positive. The analysis detected the following risk alleles related to celiac disease: HLA-
DQA1*05 and HLA-DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms 
may occur in up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies are also 
found.
HLA-DQ2.5, DQB1*02 
homozygosity or single 
DQB1*02 allele
1:10 (very high) or 
1:35 (high)
T64300 DUODENUM M58000 ATROPHY, MODERATE
T63600 GASTRIC ANTRUM M00100 NORMAL TISSUE MORPHOLOGY
T63500 GASTRIC CORPUS M40000 GASTRITIS, CHRONIC, MILD ++ 31.0 pos 1.60 0.7-4 normal
19620508P B-HLADQ2_DQ8-PCR B -HLAKeli 07.03.2018 16:25
HLA-analysis: HLA-DQ2.5 positive. The analysis detected the following risk alleles related to celiac disease: HLA-
DQA1*05 and HLA-DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms 
may occur in up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies are also 
found.
HLA-DQ2.5, DQB1*02 
homozygosity or single 
DQB1*02 allele
1:10 (very high) or 
1:35 (high)
1-3:T64300 DUODENUM AND STOMACH M00100 NORMAL TISSUE 
MORPHOLOGY - <0.6 neg 1.61 0.7-4 normal
19650612V B-HLADQ2_DQ8-PCR B -HLAKeli 07.03.2018 16:25
HLA-analysis: HLA-DQ2.5 positive. The analysis detected the following risk alleles related to celiac disease: HLA-
DQA1*05 and HLA-DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms 
may occur in up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies are also 
found.
HLA-DQ2.5, DQB1*02 
homozygosity or single 
DQB1*02 allele
1:10 (very high) or 
1:35 (high)
T64300 DUODENUM M40000 INFLAMMATION MILD 
T63000 STOMACH M43000 CHRONIC GASTRITIS 
T62000 ESOPHAGUS M00100 NO PATHOLOGIC DIAGNOSIS + 56.0 pos 2.40 0.7-4 normal
19750210L B-HLADQ2_DQ8-PCR B -HLAKeli 11.03.2018 18:38
HLA-analysis: HLA-DQ2.5 positive. The analysis detected the following risk alleles related to celiac disease: HLA-
DQA1*05 and HLA-DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms 
may occur in up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies are also 
found.
HLA-DQ2.5, DQB1*02 
homozygosity or single 
DQB1*02 allele
1:10 (very high) or 
1:35 (high)
I T64300 DUODENUM M58000 ATROPHY, MILD
II T63600 GASTRIC ANTRUM M00100 NORMAL TISSUE MORPHOLOGY
III T63500 GASTRIC CORPUS M00100 NORMAL TISSUE MORPHOLOGY
IV T62000 ESOPHAGUS M09350 MORPHOLOGICAL DESCRIPTION ONLY ++ 6.5 neg 3.26 0.7-4 normal
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19541211L B-HLADQ2_DQ8-PCR B -HLAKeli 21.03.2018 16:43
HLA-analysis: HLA-DQ2.5 positive. The analysis detected the following risk alleles related to celiac disease: HLA-
DQA1*05 and HLA-DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms 
may occur in up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies are also 
found.
HLA-DQ2.5, DQB1*02 
homozygosity or single 
DQB1*02 allele
1:10 (very high) or 
1:35 (high)
T64300 DUODENUM M58000 ATROPHY, MODERATE
T63600 GASTRIC ANTRUM M00100 NORMAL TISSUE MORPHOLOGY
T63500 GASTRIC CORPUS M43000 CHRONIC GASTRITIS, MILD
T62000 ESOPHAGUS M00100 NORMAL TISSUE MORPHOLOGY ++ 8.7 intermediate 2.21 0.7-4 normal
19600819R B-HLADQ2_DQ8-PCR B -HLAKeli 22.03.2018 15:36
HLA-analysis: HLA-DQ2.5 positive. The analysis detected the following risk alleles related to celiac disease: HLA-
DQA1*05 and HLA-DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms 
may occur in up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies are also 
found.
HLA-DQ2.5, DQB1*02 
homozygosity or single 
DQB1*02 allele
1:10 (very high) or 
1:35 (high)
T64300 DUODENUM M00100 NORMAL TISSUE MORPHOLOGY
T63000 STOMACH M43000 CHRONIC GASTRITIS - <0.6 neg 1.56 0.7-4 normal
19530926A B-HLADQ2_DQ8-PCR B -HLAKeli 25.03.2018 20:43
HLA-analysis: HLA-DQ2.5 positive. The analysis detected the following risk alleles related to celiac disease: HLA-
DQA1*05 and HLA-DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms 
may occur in up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies are also 
found.
HLA-DQ2.5, DQB1*02 
homozygosity or single 
DQB1*02 allele
1:10 (very high) or 
1:35 (high)
T64300 DUODENUM M00100 NORMAL TISSUE MORPHOLOGY
T63600 PYLORIC ANTRUM M43000 CHRONIC GASTRITIS
T63500 GASTRIC CORPUS M42000 SUPERFICIAL GASTRITIS - <0.6 neg 1.79 0.7-4 normal
20010305H B-HLADQ2_DQ8-PCR B -HLAKeli 05.04.2018 15:22
HLA-analysis: HLA-DQ2.5 positive. The analysis detected the following risk alleles related to celiac disease: HLA-
DQA1*05 and HLA-DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms 
may occur in up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies are also 
found.
HLA-DQ2.5, DQB1*02 
homozygosity or single 
DQB1*02 allele
1:10 (very high) or 
1:35 (high)
T64300 DUODENUM M00100 NO PATHOLOGIC DIAGNOSIS
T63600 GASTRIC ANTRUM M43000 CHRONIC GASTRITIS
T63500 GASTRIC CORPUS M00100 NO PATHOLOGIC DIAGNOSIS - <0.6 neg 1.44 0.6-3.5 normal
19621009H B-HLADQ2_DQ8-PCR B -HLAKeli 08.04.2018 23:48
HLA-analysis: HLA-DQ2.5 positive. The analysis detected the following risk alleles related to celiac disease: HLA-
DQA1*05 and HLA-DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms 
may occur in up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies are also 
found.
HLA-DQ2.5, DQB1*02 
homozygosity or single 
DQB1*02 allele
1:10 (very high) or 
1:35 (high) T64300 DUODENUM M58000 PARTIAL VILLOUS ATROPHY ++ 8.5 intermediate 1.69 0.7-4 normal
19791015H B-HLADQ2_DQ8-PCR B -HLAKeli 12.04.2018 14:47
HLA-analysis: HLA-DQ2.5 positive. The analysis detected the following risk alleles related to celiac disease: HLA-
DQA1*05 and HLA-DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms 
may occur in up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies are also 
found.
HLA-DQ2.5, DQB1*02 
homozygosity or single 
DQB1*02 allele
1:10 (very high) or 
1:35 (high)
T64300 DUODENUM M00100 NORMAL TISSUE MORPHOLOGY
T63600 GASTRIC ANTRUM  M00100 NORMAL TISSUE MORPHOLOGY
T63500 GASTRIC CORPUS  M00100 NORMAL TISSUE MORPHOLOGY
T62000 ESOPHAGUS M09350 MORPHOLOGICAL DESCRIPTION ONLY - <0.6 neg 1.53 0.7-4 normal
19861211K B-HLADQ2_DQ8-PCR B -HLAKeli 27.04.2018 15:02
HLA-analysis: HLA-DQ2.5 positive. The analysis detected the following risk alleles related to celiac disease: HLA-
DQA1*05 and HLA-DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms 
may occur in up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies are also 
found.
HLA-DQ2.5, DQB1*02 
homozygosity or single 
DQB1*02 allele
1:10 (very high) or 
1:35 (high)
T64300 DUODENUM M00100 NORMAL TISSUE MORPHOLOGY
T63600 PYLORIC ANTRUM M43000 CHRONIC GASTRITIS
T63500 GASTRIC CORPUS M42000 SUPERFICIAL GASTRITIS - <0.6 neg 1.79 0.7-4 normal
19780321H B-HLADQ2_DQ8-PCR B -HLAKeli 27.04.2018 15:02
HLA-analysis: HLA-DQ2.5 positive. The analysis detected the following risk alleles related to celiac disease: HLA-
DQA1*05 and HLA-DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms 
may occur in up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies are also 
found.
HLA-DQ2.5, DQB1*02 
homozygosity or single 
DQB1*02 allele
1:10 (very high) or 
1:35 (high)
1: T64300 DUODENUM  M82611 VILLOUS ADENOMA
2: T64400 DUODENAL BULBUS  M09350 MORPHOLOGICAL DESCRIPTION 
ONLY
3-4: T63000 STOMACH  M00100 NORMAL TISSUE MORPHOLOGY ++ >128.0 pos 3.23 0.7-4 normal
19470221C B-HLADQ2_DQ8-PCR B -HLAKeli 29.04.2018 17:25
HLA-analysis: HLA-DQ2.5 positive. The analysis detected the following risk alleles related to celiac disease: HLA-
DQA1*05 and HLA-DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms 
may occur in up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies are also 
found.
HLA-DQ2.5, DQB1*02 
homozygosity or single 
DQB1*02 allele
1:10 (very high) or 
1:35 (high)
T64300 DUODENUM  M00100 NORMAL TISSUE MORPHOLOGY
T64400 DUODENAL BULBUS  M14110 EROSION
T63000 STOMACH  M00100 NORMAL TISSUE MORPHOLOGY - <0.6 neg 2.89 0.7-4 normal
19880825K B-HLADQ2_DQ8-PCR B -HLAKeli 24.05.2018 14:36
HLA-analysis: HLA-DQ2.5 positive. The analysis detected the following risk alleles related to celiac disease: HLA-
DQA1*05 and HLA-DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms 
may occur in up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies are also 
found.
HLA-DQ2.5, DQB1*02 
homozygosity or single 
DQB1*02 allele
1:10 (very high) or 
1:35 (high)
T64300 DUODENUM M00100 NORMAL TISSUE MORPHOLOGY
T63600 GASTRIC ANTRUM M43000 CHRONIC GASTRITIS, MILD
T63600 GASTRIC ANTRUM M73320 INTESTINAL METAPLASIA AND ATROPHY 
MILD
T63500 GASTRIC CORPUS M00100 NORMAL TISSUE MORPHOLOGY - 3.1 neg 1.12 0.7-4 normal
19990111P B-HLADQ2_DQ8-PCR B -HLAKeli 25.05.2018 15:46
HLA-analysis: HLA-DQ2.5 positive. The analysis detected the following risk alleles related to celiac disease: HLA-
DQA1*05 and HLA-DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms 
may occur in up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies are also 
found.
HLA-DQ2.5, DQB1*02 
homozygosity or single 
DQB1*02 allele
1:10 (very high) or 
1:35 (high)
T64300 DUODENUM M58000 ATROPHY  MODERATE
T63600 GASTRIC ANTRUM  M00100 NORMAL TISSUE MORPHOLOGY
T63500 GASTRIC CORPUS  M43000 CHRONIC GASTRITIS  MILD
T62000 ESOPHAGUS  M00100 NORMAL TISSUE MORPHOLOGY ++ 15.0 pos 2.58 0.6-3.5 normal
19691023L B-HLADQ2_DQ8-PCR B -HLAKeli 25.05.2018 15:46
HLA-analysis: HLA-DQ2.5 positive. The analysis detected the following risk alleles related to celiac disease: HLA-
DQA1*05 and HLA-DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms 
may occur in up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies are also 
found.
HLA-DQ2.5, DQB1*02 
homozygosity or single 
DQB1*02 allele
1:10 (very high) or 
1:35 (high)
T64300 DUODENUM  M58000 ATROPHY MILD
T63600 GASTRIC ANTRUM  M00100 NORMAL TISSUE MORPHOLOGY
T63500 GASTRIC CORPUS  M43000 CHRONIC GASTRITIS MILD
T62000 ESOPHAGUS  M73320 INTESTINAL METAPLASIA ++ 11.0 pos 1.80 0.7-4 normal
19560527K B-HLADQ2_DQ8-PCR B -HLAKeli 27.05.2018 16:16
HLA-analysis: HLA-DQ2.5 positive. The analysis detected the following risk alleles related to celiac disease: HLA-
DQA1*05 and HLA-DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms 
may occur in up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies are also 
found.
HLA-DQ2.5, DQB1*02 
homozygosity or single 
DQB1*02 allele
1:10 (very high) or 
1:35 (high)
T64300 DUODENUM  M58000 ATROPHY SEVERE
T63000 STOMACH   M00100 NORMAL TISSUE MORPHOLOGY
T62000 ESOPHAGUS  M00100 NO DIAGNOSTIC ABNORMALITY +++ 8.8 intermediate 1.10 0.7-4 normal
19750519B B-HLADQ2_DQ8-PCR B -HLAKeli 27.05.2018 16:16
HLA-analysis: HLA-DQ2.5 positive. The analysis detected the following risk alleles related to celiac disease: HLA-
DQA1*05 and HLA-DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms 
may occur in up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies are also 
found.
HLA-DQ2.5, DQB1*02 
homozygosity or single 
DQB1*02 allele
1:10 (very high) or 
1:35 (high)
I T64300 DUODENUM M40000 INFLAMMATION, SEE TEXT
II-III T63000 STOMACH M00100 NORMAL TISSUE MORPHOLOGY
IV T62000 ESOPHAGUS M40000 ESOPHAGITIS, MILD + 0.6 neg 4.42 0.7-4 elevated
19560502C B-HLADQ2_DQ8-PCR B -HLAKeli 31.05.2018 16:32
HLA-analysis: HLA-DQ2.5 positive. The analysis detected the following risk alleles related to celiac disease: HLA-
DQA1*05 and HLA-DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms 
may occur in up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies are also 
found.
HLA-DQ2.5, DQB1*02 
homozygosity or single 
DQB1*02 allele
1:10 (very high) or 
1:35 (high)
T64300 DUODENUM M00100 NORMAL TISSUE MORPHOLOGY
T63600 GASTRIC ANTRUM M00100 NORMAL TISSUE MORPHOLOGY
T63500 GASTRIC CORPUS M00100 NORMAL TISSUE MORPHOLOGY - <0.6 neg 1.98 0.7-4 normal
19661124L B-HLADQ2_DQ8-PCR B -HLAKeli 08.06.2018 16:05
HLA-analysis: HLA-DQ2.5 positive. The analysis detected the following risk alleles related to celiac disease: HLA-
DQA1*05 and HLA-DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms 
may occur in up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies are also 
found.
HLA-DQ2.5, DQB1*02 
homozygosity or single 
DQB1*02 allele
1:10 (very high) or 
1:35 (high)
T64300 DUODENUM  M00100 NORMAL TISSUE MORPHOLOGY
T63000 STOMACH M43000 CHRONIC GASTRITIS 
T62000 ESOPHAGUS  M00100 NORMAL TISSUE MORPHOLOGY - 1.4 neg 2.17 0.7-4 normal
19640505M B-HLADQ2_DQ8-PCR B -HLAKeli 11.06.2018 07:07
HLA-analysis: HLA-DQ2.5 positive. The analysis detected the following risk alleles related to celiac disease: HLA-
DQA1*05 and HLA-DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms 
may occur in up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies are also 
found.
HLA-DQ2.5, DQB1*02 
homozygosity or single 
DQB1*02 allele
1:10 (very high) or 
1:35 (high)
T64300 DUODENUM M58000 PARTIAL VILLOUS ATROPHY WITH 
INFLAMMATION
T63000 STOMACH M43000 CHRONIC GASTRITIS helicot ++ ++ 23.0 pos 2.94 0.7-4 normal
19730722I B-HLADQ2_DQ8-PCR B -HLAKeli 11.06.2018 07:06
HLA-analysis: HLA-DQ2.5 positive. The analysis detected the following risk alleles related to celiac disease: HLA-
DQA1*05 and HLA-DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms 
may occur in up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies are also 
found.
HLA-DQ2.5, DQB1*02 
homozygosity or single 
DQB1*02 allele
1:10 (very high) or 
1:35 (high)
T64300 DUODENUM   M00100 NORMAL TISSUE MORPHOLOGY
T63600 GASTRIC ANTRUM  M43000 CHRONIC GASTRITIS, MILD
T63500 GASTRIC CORPUS  M43000 CHRONIC GASTRITI, MILD - <0.6 neg 1.73 0.7-4 normal
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19921130K B-HLADQ2_DQ8-PCR B -HLAKeli 13.06.2018 16:26
HLA-analysis: HLA-DQ2.5 positive. The analysis detected the following risk alleles related to celiac disease: HLA-
DQA1*05 and HLA-DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms 
may occur in up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies are also 
found.
HLA-DQ2.5, DQB1*02 
homozygosity or single 
DQB1*02 allele
1:10 (very high) or 
1:35 (high)
T64300 DUODENUM M00100 NORMAL TISSUE MORPHOLOGY
T63600 GASTRIC ANTRUM M00100 NORMAL TISSUE MORPHOLOGY
T63500 GASTRIC CORPUS M43000 CHRONIC GASTRITIS - <0.6 neg 2.00 0.7-4 normal
19730617I B-HLADQ2_DQ8-PCR B -HLAKeli 26.06.2018 15:57
HLA-analysis: HLA-DQ2.5 positive. The analysis detected the following risk alleles related to celiac disease: HLA-
DQA1*05 and HLA-DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms 
may occur in up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies are also 
found.
HLA-DQ2.5, DQB1*02 
homozygosity or single 
DQB1*02 allele
1:10 (very high) or 
1:35 (high)
T64300 DUODENUM   M00100 NORMAL TISSUE MORPHOLOGY
T63600 GASTRIC ANTRUM  M00100 NO DIAGNOSTIC ABNORMALITY
T63500 GASTRIC CORPUS  M00100 NO DIAGNOSTIC ABNORMALITY
T62000 ESOPHAGUS  M40000 ESOPHAGITIS MILD - <0.6 neg 1.93 0.7-4 normal
19610327K B-HLADQ2_DQ8-PCR B -HLAKeli 06.07.2018 15:46
HLA-analysis: HLA-DQ2.5 positive. The analysis detected the following risk alleles related to celiac disease: HLA-
DQA1*05 and HLA-DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms 
may occur in up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies are also 
found.
HLA-DQ2.5, DQB1*02 
homozygosity or single 
DQB1*02 allele
1:10 (very high) or 
1:35 (high)
T64300 DUODENUM  M00100 NORMAL TISSUE MORPHOLOGY
T64400 DUODENAL BULBUS  M00100 NORMAL TISSUE MORPHOLOGY
T63600 GASTRIC ANTRUM M43000 CHRONIC GASTRITIS  ACTIVE, 
HELICOBACTER +++
T63500 GASTRIC CORPUS  M43000 CHRONIC GASTRITIS ACTIVE, 
HELICOBACTER +++
T63500 GASTRIC CORPUS  M58000 ATROPHY  MILD - 0.8 neg 2.32 0.7-4 normal
19760726S B-HLADQ2_DQ8-PCR B -HLAKeli 02.08.2018 17:06
HLA-analysis: HLA-DQ2.5 positive. The analysis detected the following risk alleles related to celiac disease: HLA-
DQA1*05 and HLA-DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms 
may occur in up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies are also 
found.
HLA-DQ2.5, DQB1*02 
homozygosity or single 
DQB1*02 allele
1:10 (very high) or 
1:35 (high)
T64300 DUODENUM M58000 ATROPHY, MODERATE/SEVERE
T63000 STOMACH M43000 CHRONIC GASTRITIS
T62000 ESOPHAGUS M00100 NORMAL TISSUE MORPHOLOGY +++ 129.0 pos 3.35 0.7-4 normal
20020620O B-HLADQ2_DQ8-PCR B -HLAKeli 07.08.2018 15:16
HLA-analysis: HLA-DQ2.5 positive. The analysis detected the following risk alleles related to celiac disease: HLA-
DQA1*05 and HLA-DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms 
may occur in up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies are also 
found.
HLA-DQ2.5, DQB1*02 
homozygosity or single 
DQB1*02 allele
1:10 (very high) or 
1:35 (high)
T64300 DUODENUM M58000 ATROPHY, MODERATE
T63600 GASTRIC ANTRUM M00100 NORMAL TISSUE MORPHOLOGY
T63500 GASTRIC CORPUS M43000 CHRONIC GASTRITIS, MILD
T62000 ESOPHAGUS M00100 NORMAL TISSUE MORPHOLOGY ++ 2.1 neg 1.18 0.6-3.5 normal
19650112M B-HLADQ2_DQ8-PCR B -HLAKeli 10.08.2018 15:30
HLA-analysis: HLA-DQ2.5 positive. The analysis detected the following risk alleles related to celiac disease: HLA-
DQA1*05 and HLA-DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms 
may occur in up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies are also 
found.
HLA-DQ2.5, DQB1*02 
homozygosity or single 
DQB1*02 allele
1:10 (very high) or 
1:35 (high)
T64300 DUODENUM M58007 TOTAL VILLOUS ATROPHY WITH INFLAMMATION
T63600 GASTRIC ANTRUM M43000 CHRONIC GASTRITIS
T63500 GASTRIC CORPUS M43000 CHRONIC GASTRITIS
T62000 ESOPHAGUS M00100 NO DIAGNOSTIC ABNORMALITY +++ 118.0 pos 1.30 0.7-4 normal
19860906P B-HLADQ2_DQ8-PCR B -HLAKeli 10.08.2018 15:31
HLA-analysis: HLA-DQ2.5 positive. The analysis detected the following risk alleles related to celiac disease: HLA-
DQA1*05 and HLA-DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms 
may occur in up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies are also 
found.
HLA-DQ2.5, DQB1*02 
homozygosity or single 
DQB1*02 allele
1:10 (very high) or 
1:35 (high)
T64300 DUODENUM M58005 SUBTOTAL VILLOUS ATROPHY
T63600 GASTRIC ANTRUM M09350 REACTIVE CHANGES
T63500 GASTRIC CORPUS M00100 NO DIAGNOSTIC ABNORMALITY ++ 78.0 pos 1.50 0.7-4 normal
19770818K B-HLADQ2_DQ8-PCR B -HLAKeli 19.08.2018 18:25
HLA-analysis: HLA-DQ2.5 positive. The analysis detected the following risk alleles related to celiac disease: HLA-
DQA1*05 and HLA-DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms 
may occur in up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies are also 
found.
HLA-DQ2.5, DQB1*02 
homozygosity or single 
DQB1*02 allele
1:10 (very high) or 
1:35 (high)
T64300 DUODENUM  M00100 NORMAL TISSUE MORPHOLOGY
T63000 STOMACH  M00100 NORMAL TISSUE MORPHOLOGY
T62000 ESOPHAGUS  M40000 ESOPHAGITIS - <0.6 neg 1.60 0.7-4 normal
19730619R B-HLADQ2_DQ8-PCR B -HLAKeli 26.08.2018 14:40
HLA-analysis: HLA-DQ2.5 positive. The analysis detected the following risk alleles related to celiac disease: HLA-
DQA1*05 and HLA-DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms 
may occur in up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies are also 
found.
HLA-DQ2.5, DQB1*02 
homozygosity or single 
DQB1*02 allele
1:10 (very high) or 
1:35 (high)
T64300 DUODENUM  M00100 NORMAL TISSUE MORPHOLOGY
T63600 GASTRIC ANTRUM  M00100 NORMAL TISSUE MORPHOLOGY
T63500 GASTRIC CORPUS  M76800 POLYP, CYSTIC
T62000 ESOPHAGUS  M40000 ESOPHAGITIS  (EOSINOPHILIC ESOPHAGITIS?) - <0.6 neg 0.82 0.7-4 normal
19800416M B-HLADQ2_DQ8-PCR B -HLAKeli 02.09.2018 14:50
HLA-analysis: HLA-DQ2.5 positive. The analysis detected the following risk alleles related to celiac disease: HLA-
DQA1*05 and HLA-DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms 
may occur in up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies are also 
found.
HLA-DQ2.5, DQB1*02 
homozygosity or single 
DQB1*02 allele
1:10 (very high) or 
1:35 (high)
T64300 DUODENUM M09350 MORPHOLOGICAL DESCRIPTION ONLY, IEA +, 
SEE THE STATEMENT 
T63000 STOMACH M00100 NO DIAGNOSTIC ABNORMALITY 
T62000 ESOPHAGUS M40000 ESOPHAGITIS, MILD + 5.6 neg 4.54 0.7-4 elevated
19700925I B-HLADQ2_DQ8-PCR B -HLAKeli 06.09.2018 15:51
HLA-analysis: HLA-DQ2.5 positive. The analysis detected the following risk alleles related to celiac disease: HLA-
DQA1*05 and HLA-DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms 
may occur in up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies are also 
found.
HLA-DQ2.5, DQB1*02 
homozygosity or single 
DQB1*02 allele
1:10 (very high) or 
1:35 (high)
T64300 DUODENUM  M58000 ATROPHY MODERATE
T63000 STOMACH  M00100 NORMAL TISSUE MORPHOLOGY
T62000 ESOPHAGUS  M80001 SUSPECTED MALIGNANCY, SEVERE
T62000 ESOPHAGUS  M40000 ESOPHAGITIS ++ 5.7 neg 3.72 0.7-4 normal
19770211K B-HLADQ2_DQ8-PCR B -HLAKeli 26.09.2018 15:56
HLA-analysis: HLA-DQ2.5 positive. The analysis detected the following risk alleles related to celiac disease: HLA-
DQA1*05 and HLA-DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms 
may occur in up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies are also 
found.
HLA-DQ2.5, DQB1*02 
homozygosity or single 
DQB1*02 allele
1:10 (very high) or 
1:35 (high)
T64300 DUODENUM M09350 MORPHOLOGICAL DESCRIPTION ONLY (mild 
intraepithelial lymphosytosis)
T64400 DUODENAL BULBUS M58000 ATROPHY, MILD
T63600 GASTRIC ANTRUM M00100 NO DIAGNOSTIC ABNORMALITY
T62350 GASTRO-ESOPHAGEAL JUNCTION M73320 INTESTINAL 
METAPLASIA?
+ CD diagnosed, 
control test, 
EXCLUDED 8.3 intermediate 2.37 0.7-4 normal
19870707N B-HLADQ2_DQ8-PCR B -HLAKeli 30.09.2018 12:50
HLA-analysis: HLA-DQ2.5 positive. The analysis detected the following risk alleles related to celiac disease: HLA-
DQA1*05 and HLA-DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms 
may occur in up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies are also 
found.
HLA-DQ2.5, DQB1*02 
homozygosity or single 
DQB1*02 allele
1:10 (very high) or 
1:35 (high)
T64300 DUODENUM M00100 NORMAL TISSUE MORPHOLOGY
T63600 GASTRIC ANTRUM M00100 NORMAL TISSUE MORPHOLOGY
T63500 GASTRIC CORPUS M00100 NORMAL TISSUE MORPHOLOGY - <0.6 neg 0.96 0.7-4 normal
19710205V B-HLADQ2_DQ8-PCR B -HLAKeli 04.10.2018 15:26
HLA-analysis: HLA-DQ2.5 positive. The analysis detected the following risk alleles related to celiac disease: HLA-
DQA1*05 and HLA-DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms 
may occur in up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies are also 
found.
HLA-DQ2.5, DQB1*02 
homozygosity or single 
DQB1*02 allele
1:10 (very high) or 
1:35 (high)
T64300 DUODENUM M00100 NO DIAGNOSTIC ABNORMALITY
T63600 GASTRIC ANTRUM M43000 CHRONIC GASTRITIS
T63500 GASTRIC CORPUS M58010 ATROPHIC GASTRITIS - <0.6 neg 1.98 0.7-4 normal
19911106T B-HLADQ2_DQ8-PCR B -HLAKeli 04.10.2018 15:25
HLA-analysis: HLA-DQ2.5 positive. The analysis detected the following risk alleles related to celiac disease: HLA-
DQA1*05 and HLA-DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms 
may occur in up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies are also 
found.
HLA-DQ2.5, DQB1*02 
homozygosity or single 
DQB1*02 allele
1:10 (very high) or 
1:35 (high)
T64300 DUODENUM M00100 NORMAL TISSUE MORPHOLOGY
T63000 STOMACH M43000 CHRONIC GASTRITIS
T62000 ESOPHAGUS M00100 NORMAL TISSUE MORPHOLOGY - <0.6 neg 0.71 0.7-4 normal
19690809V B-HLADQ2_DQ8-PCR B -HLAKeli 26.10.2018 16:30
HLA-analysis: HLA-DQ2.5 positive. The analysis detected the following risk alleles related to celiac disease: HLA-
DQA1*05 and HLA-DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms 
may occur in up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies are also 
found.
HLA-DQ2.5, DQB1*02 
homozygosity or single 
DQB1*02 allele
1:10 (very high) or 
1:35 (high)
T64300 DUODENUM M00100 NORMAL TISSUE MORPHOLOGY
T63600 GASTRIC ANTRUM M00100 NORMAL TISSUE MORPHOLOGY
T63500 GASTRIC CORPUS M43000 CHRONIC GASTRITIS, MILD - 1.4 neg 4.34 0.7-4 elevated
19850723K B-HLADQ2_DQ8-PCR B -HLAKeli 08.11.2018 16:30
HLA-analysis: HLA-DQ2.5 positive. The analysis detected the following risk alleles related to celiac disease: HLA-
DQA1*05 and HLA-DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms 
may occur in up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies are also 
found.
HLA-DQ2.5, DQB1*02 
homozygosity or single 
DQB1*02 allele
1:10 (very high) or 
1:35 (high)
T64300 DUODENUM  M00100 NORMAL TISSUE MORPHOLOGY
T63600 GASTRIC ANTRUM  M00100 NORMAL TISSUE MORPHOLOGY
T63500 GASTRIC CORPUS  M43000 CHRONIC GASTRITIS MILD - 0.6 neg 3.10 0.7-4 normal
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APPENDIX 1 – Clinical laboratory diagnostics results
Internal ID Mnemonic 
 Test 
Shortname  B -HLAKeli ValTime Resu
lt ext
erna
l com
ment
 (B -
HLAK
eli)
HLAD
Q2_D
Q8 g
enot
ype
RISK PADGAST statement Histology grade tTGAbA result U/ml
tTGAbA result 
interpretation IgA result g/l
IgA reference 
range (age 
dependent)
IgA result 
interpretation
19550325K B-HLADQ2_DQ8-PCR B -HLAKeli 09.11.2018 15:25
HLA-analysis: HLA-DQ2.5 positive. The analysis detected the following risk alleles related to celiac disease: HLA-
DQA1*05 and HLA-DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms 
may occur in up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies are also 
found.
HLA-DQ2.5, DQB1*02 
homozygosity or single 
DQB1*02 allele
1:10 (very high) or 
1:35 (high)
T64300 DUODENUM  M58000 ATROPHY SEVERE
T63000 STOMACH  M43000 CHRONIC GASTRITIS MILD +++ 60.0 pos 2.75 0.7-4 normal
19630208L B-HLADQ2_DQ8-PCR B -HLAKeli 09.11.2018 15:25
HLA-analysis: HLA-DQ2.5 positive. The analysis detected the following risk alleles related to celiac disease: HLA-
DQA1*05 and HLA-DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms 
may occur in up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies are also 
found.
HLA-DQ2.5, DQB1*02 
homozygosity or single 
DQB1*02 allele
1:10 (very high) or 
1:35 (high)
T64300 DUODENUM  M58000 ATROPHY SEVERE
T63000 STOMACH  M43000 CHRONIC GASTRITIS MILD
T62000 ESOPHAGUS  M00100 NORMAL TISSUE MORPHOLOGY +++ 33.0 pos 3.04 0.7-4 normal
20000625Y B-HLADQ2_DQ8-PCR B -HLAKeli 16.11.2018 15:41
HLA-analysis: HLA-DQ2.5 positive. The analysis detected the following risk alleles related to celiac disease: HLA-
DQA1*05 and HLA-DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms 
may occur in up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies are also 
found.
HLA-DQ2.5, DQB1*02 
homozygosity or single 
DQB1*02 allele
1:10 (very high) or 
1:35 (high)
I T64300 DUODENUM M00100 NORMAL TISSUE MORPHOLOGY
II T63600 PYLORIC ANTRUM M00100 NORMAL TISSUE MORPHOLOGY - <0.6 neg 0.65 0.6-3.5 normal
19700323K B-HLADQ2_DQ8-PCR B -HLAKeli 28.11.2018 16:35
HLA-analysis: HLA-DQ2.5 positive. The analysis detected the following risk alleles related to celiac disease: HLA-
DQA1*05 and HLA-DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms 
may occur in up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies are also 
found.
HLA-DQ2.5, DQB1*02 
homozygosity or single 
DQB1*02 allele
1:10 (very high) or 
1:35 (high)
T64300 DUODENUM M00100 NORMAL TISSUE MORPHOLOGY
T63000 STOMACH M00100 NORMAL TISSUE MORPHOLOGY
T62000 ESOPHAGUS M40000 ESOPHAGITIS
T62000 ESOPHAGUS M69700 ATYPIA, REGENERATIVE, SEE TEXT - <0.6 neg 1.98 0.7-4 normal
19820510K B-HLADQ2_DQ8-PCR B -HLAKeli 06.12.2018 15:35
HLA-analysis: HLA-DQ2.5 positive. The analysis detected the following risk alleles related to celiac disease: HLA-
DQA1*05 and HLA-DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms 
may occur in up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies are also 
found.
HLA-DQ2.5, DQB1*02 
homozygosity or single 
DQB1*02 allele
1:10 (very high) or 
1:35 (high)
T64300 DUODENUM  M58000 ATROPHY MILD
T63600 GASTRIC ANTRUM  M00100 NORMAL TISSUE MORPHOLOGY
T63500 GASTRIC CORPUS  M00100 NORMAL TISSUE MORPHOLOGY ++ 4.8 neg 1.43
19700409A B-HLADQ2_DQ8-PCR B -HLAKeli 23.12.2018 12:15
HLA-analysis: HLA-DQ2.5 positive. The analysis detected the following risk alleles related to celiac disease: HLA-
DQA1*05 and HLA-DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms 
may occur in up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies are also 
found.
HLA-DQ2.5, DQB1*02 
homozygosity or single 
DQB1*02 allele
1:10 (very high) or 
1:35 (high)
T64300 DUODENUM  M00100 NORMAL TISSUE MORPHOLOGY
T63600 GASTRIC ANTRUM  M00100 NORMAL TISSUE MORPHOLOGY
T63500 GASTRIC CORPUS  M76800 POLYP  CYSTIC
T62350 CARDIO-ESOPHAGEAL JUNCTION  M00100 NORMAL TISSUE 
MORPHOLOGY
T62000 ESOPHAGUS  M00100 NORMAL TISSUE MORPHOLOGY
- CD diagnosed, 
control test, 
EXCLUDED <0.6 neg 0.95 0.7-4 normal
19590408E B-HLADQ2_DQ8-PCR B -HLAKeli 27.01.2019 12:10
HLA-analysis: HLA-DQ2.5 positive. The analysis detected the following risk alleles related to celiac disease: HLA-
DQA1*05 and HLA-DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms 
may occur in up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies are also 
found.
HLA-DQ2.5, DQB1*02 
homozygosity or single 
DQB1*02 allele
1:10 (very high) or 
1:35 (high)
T64300 DUODENUM  M58000 ATROPHY MILD
T63600 GASTRIC ANTRUM  M40000 GASTRITIS  REACTIVE
T63500 GASTRIC CORPUS  M00100 NORMAL TISSUE MORPHOLOGY + 10.0 intermediate 1.42 0.7-4 normal
19760319L B-HLADQ2_DQ8-PCR B -HLAKeli 10.02.2019 19:26
HLA-analysis: HLA-DQ2.5 positive. The analysis detected the following risk alleles related to celiac disease: HLA-
DQA1*05 and HLA-DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms 
may occur in up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies are also 
found.
HLA-DQ2.5, DQB1*02 
homozygosity or single 
DQB1*02 allele
1:10 (very high) or 
1:35 (high)
T64300 DUODENUM  M00100 NORMAL TISSUE MORPHOLOGY
T63600 GASTRIC ANTRUM  M00100 NORMAL TISSUE MORPHOLOGY
T63500 GASTRIC CORPUS  M76800 POLYP, CYSTIC - <0.6 neg 2.65 0.7-4 normal
19521213Y B-HLADQ2_DQ8-PCR B -HLAKeli 13.02.2019 16:00
HLA-analysis: HLA-DQ2.5 positive. The analysis detected the following risk alleles related to celiac disease: HLA-
DQA1*05 and HLA-DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms 
may occur in up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies are also 
found.
HLA-DQ2.5, DQB1*02 
homozygosity or single 
DQB1*02 allele
1:10 (very high) or 
1:35 (high)
T64300 DUODENUM M40000 INFLAMMATION, see text
T63000 STOMACH M00100 NO DIAGNOSTIC ABNORMALITY
T62000 ESOPHAGUS M43000 CHRONIC ESOPHAGITIS + 4.6 neg 2.82 0.7-4 normal
19550925T B-HLADQ2_DQ8-PCR B -HLAKeli 14.02.2019 14:45
HLA-analysis: HLA-DQ2.5 positive. The analysis detected the following risk alleles related to celiac disease: HLA-
DQA1*05 and HLA-DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms 
may occur in up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies are also 
found.
HLA-DQ2.5, DQB1*02 
homozygosity or single 
DQB1*02 allele
1:10 (very high) or 
1:35 (high)
T64300 DUODENUM  M40000 INFLAMMATION ACTIVE, MILD
T64300 DUODENUM  M58000 ATROPHY, FOKAALINEN
T63600 GASTRIC ANTRUM  M43000 CHRONIC GASTRITIS MILD
T63500 GASTRIC CORPUS  M76800 POLYP, CYSTIC
T63500 GASTRIC CORPUS  M43000 CHRONIC GASTRITIS MILD
T62000 ESOPHAGUS  M09350 MORPHOLOGICAL DESCRIPTION ONLY ++ <0.6 neg 1.60 0.7-4 normal
20001103T B-HLADQ2_DQ8-PCR B -HLAKeli 20.02.2019 15:35
HLA-analysis: HLA-DQ2.5 positive. The analysis detected the following risk alleles related to celiac disease: HLA-
DQA1*05 and HLA-DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms 
may occur in up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies are also 
found.
HLA-DQ2.5, DQB1*02 
homozygosity or single 
DQB1*02 allele
1:10 (very high) or 
1:35 (high)
T64300 DUODENUM M40000 INFLAMMATION, MILD
T63600 GASTRIC ANTRUM M00100 NO DIAGNOSTIC ABNORMALITY
T63500 GASTRIC CORPUS M43000 CHRONIC GASTRITIS, MILD + <0.6 neg 0.81 0.6-3.5 normal
19631214N B-HLADQ2_DQ8-PCR B -HLAKeli 20.02.2019 15:35
HLA-analysis: HLA-DQ2.5 positive. The analysis detected the following risk alleles related to celiac disease: HLA-
DQA1*05 and HLA-DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms 
may occur in up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies are also 
found.
HLA-DQ2.5, DQB1*02 
homozygosity or single 
DQB1*02 allele
1:10 (very high) or 
1:35 (high)
T64300 DUODENUM M00100 NORMAL TISSUE MORPHOLOGY
T63600 GASTRIC ANTRUM M00100 NORMAL TISSUE MORPHOLOGY
T63500 GASTRIC CORPUS M00100 NORMAL TISSUE MORPHOLOGY
T62000 ESOPHAGUS M00100 NO DIAGNOSTIC ABNORMALITY - <0.6 neg 1.34 0.7-4 normal
19731216M B-HLADQ2_DQ8-PCR B -HLAKeli 13.03.2019 15:41
HLA-analysis: HLA-DQ2.5 positive. The analysis detected the following risk alleles related to celiac disease: HLA-
DQA1*05 and HLA-DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms 
may occur in up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies are also 
found.
HLA-DQ2.5, DQB1*02 
homozygosity or single 
DQB1*02 allele
1:10 (very high) or 
1:35 (high)
T64300 DUODENUM M58000 ATROPHY, MILD
T63600 GASTRIC ANTRUM M00100 NORMAL FINDING
T63500 GASTRIC CORPUS M00100 NORMAL FINDING ++ 10.0 intermediate 1.98 0.7-4 normal
19710603T B-HLADQ2_DQ8-PCR B -HLAKeli 27.03.2019 16:01
HLA-analysis: HLA-DQ2.5 positive. The analysis detected the following risk alleles related to celiac disease: HLA-
DQA1*05 and HLA-DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms 
may occur in up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies are also 
found.
HLA-DQ2.5, DQB1*02 
homozygosity or single 
DQB1*02 allele
1:10 (very high) or 
1:35 (high)
T64300 DUODENUM  M58000 VILLOUS ATROPHY
T64300 DUODENUM  M40000 INFLAMMATION
T63600 GASTRIC ANTRUM  M00100 NORMAL TISSUE MORPHOLOGY
T63500 GASTRIC CORPUS  M00100 NORMAL TISSUE MORPHOLOGY
T62000 ESOPHAGUS  M00100 NORMAL TISSUE MORPHOLOGY ++ 25.0 pos 1.92 0.7-4 normal
20090113O B-HLADQ2_DQ8-PCR B -HLAKeli 29.03.2019 15:51
HLA-analysis: HLA-DQ2.5 positive. The analysis detected the following risk alleles related to celiac disease: HLA-
DQA1*05 and HLA-DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms 
may occur in up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies are also 
found.
HLA-DQ2.5, DQB1*02 
homozygosity or single 
DQB1*02 allele
1:10 (very high) or 
1:35 (high)
T64300 DUODENUM M00100 NORMAL TISSUE MORPHOLOGY
T63600 PYLORIC ANTRUM M43000 CHRONIC GASTRITIS
T63500 GASTRIC CORPUS M42000 SUPERFICIAL GASTRITIS - <0.6 neg 1.79 0.7-4 normal
19770510S B-HLADQ2_DQ8-PCR B -HLAKeli 29.03.2019 15:51
HLA-analysis: HLA-DQ2.5 positive. The analysis detected the following risk alleles related to celiac disease: HLA-
DQA1*05 and HLA-DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms 
may occur in up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies are also 
found.
HLA-DQ2.5, DQB1*02 
homozygosity or single 
DQB1*02 allele
1:10 (very high) or 
1:35 (high)
T64300 DUODENUM  M40000 INFLAMMATION  MILD, SEE TEXT
T63600 GASTRIC ANTRUM  M00100 NORMAL TISSUE MORPHOLOGY
T63500 GASTRIC CORPUS  M00100 NORMAL TISSUE MORPHOLOGY + 5.0 neg 1.47 0.7-4 normal
19920221L B-HLADQ2_DQ8-PCR B -HLAKeli 09.05.2019 15:02
HLA-analysis: HLA-DQ2.5 positive. The analysis detected the following risk alleles related to celiac disease: HLA-
DQA1*05 and HLA-DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms 
may occur in up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies are also 
found.
HLA-DQ2.5, DQB1*02 
homozygosity or single 
DQB1*02 allele
1:10 (very high) or 
1:35 (high)
T64300 DUODENUM M00100 NORMAL TISSUE MORPHOLOGY
T63600 GASTRIC ANTRUM M00100 NORMAL TISSUE MORPHOLOGY
T63500 GASTRIC CORPUS M00100 NORMAL TISSUE MORPHOLOGY
T62000 ESOPHAGUS M40000 ESOPHAGITIS, SEE TEXT - 0.9 neg 2.78 0.7-4 normal
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19590526M B-HLADQ2_DQ8-PCR B -HLAKeli 10.05.2019 15:45
HLA-analysis: HLA-DQ2.5 positive. The analysis detected the following risk alleles related to celiac disease: HLA-
DQA1*05 and HLA-DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms 
may occur in up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies are also 
found.
HLA-DQ2.5, DQB1*02 
homozygosity or single 
DQB1*02 allele
1:10 (very high) or 
1:35 (high)
T64300 DUODENUM M40000 INFLAMMATION MILD
T63600 GASTRIC ANTRUM M00100 NORMAL TISSUE MORPHOLOGY
T63500 GASTRIC CORPUS M00100 NORMAL TISSUE MORPHOLOGY + 3.6 neg 2.71 0.7-4 normal
19810727L B-HLADQ2_DQ8-PCR B -HLAKeli 23.05.2019 15:35
HLA-analysis: HLA-DQ2.5 positive. The analysis detected the following risk alleles related to celiac disease: HLA-
DQA1*05 and HLA-DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms 
may occur in up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies are also 
found.
HLA-DQ2.5, DQB1*02 
homozygosity or single 
DQB1*02 allele
1:10 (very high) or 
1:35 (high)
1. T64300 DUODENUM  M58000 VILLOUS ATROPHY
T63600 GASTRIC ANTRUM  M43000 CHRONIC GASTRITIS
T63500 GASTRIC CORPUS  M00100 NORMAL TISSUE MORPHOLOGY ++ 15.0 pos 1.62 0.7-4 normal
19670507M B-HLADQ2_DQ8-PCR B -HLAKeli 24.05.2019 17:15
HLA-analysis: HLA-DQ2.5 positive. The analysis detected the following risk alleles related to celiac disease: HLA-
DQA1*05 and HLA-DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms 
may occur in up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies are also 
found.
HLA-DQ2.5, DQB1*02 
homozygosity or single 
DQB1*02 allele
1:10 (very high) or 
1:35 (high)
T64300 DUODENUM M58000 PARTIAL VILLOUS ATROPHY
T63000 STOMACH M00100 NORMAL TISSUE MORPHOLOGY
T62000 ESOPHAGUS M00100 NORMAL TISSUE MORPHOLOGY ++ 8.0 intermediate 1.43 0.7-4 normal
19610717V B-HLADQ2_DQ8-PCR B -HLAKeli 03.07.2019 15:38
HLA-analysis: HLA-DQ2.5 positive. The analysis detected the following risk alleles related to celiac disease: HLA-
DQA1*05 and HLA-DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms 
may occur in up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies are also 
found.
HLA-DQ2.5, DQB1*02 
homozygosity or single 
DQB1*02 allele
1:10 (very high) or 
1:35 (high)
T64300 DUODENUM M00100 NORMAL TISSUE MORPHOLOGY
T63600 GASTRIC ANTRUM M00100 NORMAL TISSUE MORPHOLOGY
T63500 GASTRIC CORPUS M00100 NORMAL TISSUE MORPHOLOGY
T62350 CARDIO-ESOPHAGEAL JUNCTION M00100 NO DIAGNOSTIC 
ABNORMALITY - <0.6 neg 3.27 0.7-4 normal
19830505M B-HLADQ2_DQ8-PCR B -HLAKeli 04.07.2019 14:21
HLA-analysis: HLA-DQ2.5 positive. The analysis detected the following risk alleles related to celiac disease: HLA-
DQA1*05 and HLA-DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms 
may occur in up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies are also 
found.
HLA-DQ2.5, DQB1*02 
homozygosity or single 
DQB1*02 allele
1:10 (very high) or 
1:35 (high)
T64300 DUODENUM M00100 NORMAL TISSUE MORPHOLOGY
T63600 GASTRIC ANTRUM M43000 CHRONIC GASTRITIS
T63500 GASTRIC CORPUS M43000 CHRONIC GASTRITIS - 0.9 neg 1.76 0.7-4 normal
19870530V B-HLADQ2_DQ8-PCR B -HLAKeli 04.07.2019 14:21
HLA-analysis: HLA-DQ2.5 positive. The analysis detected the following risk alleles related to celiac disease: HLA-
DQA1*05 and HLA-DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms 
may occur in up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies are also 
found.
HLA-DQ2.5, DQB1*02 
homozygosity or single 
DQB1*02 allele
1:10 (very high) or 
1:35 (high)
T64300 DUODENUM  M58000 ATROPHY, MODERATE
T63600 GASTRIC ANTRUM  M00100 NORMAL TISSUE MORPHOLOGY
T63500 GASTRIC CORPUS  M00100 NORMAL TISSUE MORPHOLOGY
T62000 ESOPHAGUS  M40000 ESOPHAGITIS ++ >128.0 pos 1.15 0.7-4 normal
19690321R B-HLADQ2_DQ8-PCR B -HLAKeli 25.09.2019 15:56
HLA-analysis: HLA-DQ2.5 positive. The analysis detected the following risk alleles related to celiac disease: HLA-
DQA1*05 and HLA-DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms 
may occur in up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies are also 
found.
HLA-DQ2.5, DQB1*02 
homozygosity or single 
DQB1*02 allele
1:10 (very high) or 
1:35 (high)
T64300 DUODENUM  M00100 NORMAL TISSUE MORPHOLOGY
T63600 GASTRIC ANTRUM M00100 NORMAL TISSUE MORPHOLOGY
T63500 GASTRIC CORPUS  M58010 ATROPHIC GASTRITIS - 0.7 neg 1.43 0.7-4 normal
19600515M B-HLADQ2_DQ8-PCR B -HLAKeli 04.10.2019 16:57
HLA-analysis: HLA-DQ2.5 positive. The analysis detected the following risk alleles related to celiac disease: HLA-
DQA1*05 and HLA-DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms 
may occur in up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies are also 
found.
HLA-DQ2.5, DQB1*02 
homozygosity or single 
DQB1*02 allele
1:10 (very high) or 
1:35 (high)
T64300 DUODENUM M00100 NORMAL TISSUE MORPHOLOGY
T63600 GASTRIC ANTRUM M00100 NORMAL TISSUE MORPHOLOGY
T63500 GASTRIC CORPUS M76800 POLYP, CYSTIC - <0.6 neg 2.25 0.7-4 normal
19850303P B-HLADQ2_DQ8-PCR B -HLAKeli 11.10.2019 15:52
HLA-analysis: HLA-DQ2.5 positive. The analysis detected the following risk alleles related to celiac disease: HLA-
DQA1*05 and HLA-DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms 
may occur in up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies are also 
found.
HLA-DQ2.5, DQB1*02 
homozygosity or single 
DQB1*02 allele
1:10 (very high) or 
1:35 (high)
T64300 DUODENUM  M09350 MORPHOLOGICAL DESCRIPTION ONLY (MILD 
INTRAEPITHELIAL LYMPHOSYTOSIS)
T63600 GASTRIC ANTRUM  M00100 NORMAL TISSUE MORPHOLOGY
T63500 GASTRIC CORPUS  M00100 NORMAL TISSUE MORPHOLOGY
T62350 GASTROESOPHAGEAL JUNCTION  M00100 NORMAL TISSUE 
MORPHOLOGY + 8.5 intermediate 3.77 0.7-4 normal
19880101A B-HLADQ2_DQ8-PCR B -HLAKeli 17.10.2019 15:20
HLA-analysis: HLA-DQ2.5 positive. The analysis detected the following risk alleles related to celiac disease: HLA-
DQA1*05 and HLA-DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms 
may occur in up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies are also 
found.
HLA-DQ2.5, DQB1*02 
homozygosity or single 
DQB1*02 allele
1:10 (very high) or 
1:35 (high)
T64300 DUODENUM M00100 NORMAL TISSUE MORPHOLOGY
T63600 PYLORIC ANTRUM M43000 CHRONIC GASTRITIS
T63500 GASTRIC CORPUS M42000 SUPERFICIAL GASTRITIS - <0.6 neg 1.79 0.7-4 normal
20140612D B-HLADQ2_DQ8-PCR B -HLAKeli 27.06.2019 15:58
HLA-analysis: HLA-DQ2.5 positive. The analysis detected the following risk alleles related to celiac disease: HLA-
DQA1*05 and HLA-DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms 
may occur in up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies are also 
found.
HLA-DQ2.5, DQB1*02 
homozygosity or single 
DQB1*02 allele
1:10 (very high) or 
1:35 (high)
T64300 DUODENUM M00100 NORMAL TISSUE MORPHOLOGY
T63600 PYLORIC ANTRUM M43000 CHRONIC GASTRITIS
T63500 GASTRIC CORPUS M42000 SUPERFICIAL GASTRITIS - <0.6 neg 1.79 0.7-4 normal
19760607H B-HLADQ2_DQ8-PCR B -HLAKeli 14.02.2018 15:43
HLA-analysis: HLA-DQ2 positive. The analysis detected the following risk allele related to celiac disease: HLA-
DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms may occur in up to 
30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac disease if the patient 
has symptoms similar to celiac disease and if the disease-associated antibodies are also found.
HLA-DQ2.x, DQB1*02 
homozygosity or  single 
DQB1*02 allele 
1:26 (high) or 1:210 
(low)
T64300 DUODENUM M00100 NO DIAGNOSTIC ABNORMALITY 
T63000 STOMACH M00100 NORMAL TISSUE MORPHOLOGY 
T62000 ESOPHAGUS M00100 NORMAL TISSUE MORPHOLOGY - 0.6 neg 2.23 0.7-4 normal
19950123M B-HLADQ2_DQ8-PCR B -HLAKeli 01.03.2018 16:32
HLA-analysis: HLA-DQ2 positive. The analysis detected the following risk allele related to celiac disease: HLA-
DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms may occur in up to 
30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac disease if the patient 
has symptoms similar to celiac disease and if the disease-associated antibodies are also found.
HLA-DQ2.x, DQB1*02 
homozygosity or  single 
DQB1*02 allele 
1:26 (high) or 1:210 
(low)
1: T64300 DUODENUM   M00100 NORMAL TISSUE MORPHOLOGY
2-3: T63000 STOMACH   M43000 CHRONIC GASTRITIS, MILD
4: T62000 ESOPHAGUS   M00100 NORMAL TISSUE MORPHOLOGY - <0.6 neg 0.70 0.7-4 normal
19840421P B-HLADQ2_DQ8-PCR B -HLAKeli 05.04.2018 15:22
HLA-analysis: HLA-DQ2 positive. The analysis detected the following risk allele related to celiac disease: HLA-
DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms may occur in up to 
30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac disease if the patient 
has symptoms similar to celiac disease and if the disease-associated antibodies are also found.
HLA-DQ2.x, DQB1*02 
homozygosity or  single 
DQB1*02 allele 
1:26 (high) or 1:210 
(low)
T64300 DUODENUM  M00100 NORMAL TISSUE MORPHOLOGY
T63600 GASTRIC ANTRUM  M00100 NORMAL TISSUE MORPHOLOGY
T63500 GASTRIC CORPUS  M00100 NORMAL TISSUE MORPHOLOGY - <0.6 neg 1.89 0.7-4 normal
19660410T B-HLADQ2_DQ8-PCR B -HLAKeli 15.04.2018 19:11
HLA-analysis: HLA-DQ2 positive. The analysis detected the following risk allele related to celiac disease: HLA-
DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms may occur in up to 
30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac disease if the patient 
has symptoms similar to celiac disease and if the disease-associated antibodies are also found.
HLA-DQ2.x, DQB1*02 
homozygosity or  single 
DQB1*02 allele 
1:26 (high) or 1:210 
(low)
I T64300 DUODENUM M40000 DUODENITIS, see text
II - III T63000 STOMACH M00120 NORMAL CELLULAR MORPHOLOGY
IV T63500 GASTRIC CORPUS M75630 FUNDIC GLAND POLYP
V T62000 ESOPHAGUS M00100 NO DIAGNOSTIC ABNORMALITY + <0.6 neg 1.32 0.7-4 normal
19610123J B-HLADQ2_DQ8-PCR B -HLAKeli 27.04.2018 15:02
HLA-analysis: HLA-DQ2 positive. The analysis detected the following risk allele related to celiac disease: HLA-
DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms may occur in up to 
30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac disease if the patient 
has symptoms similar to celiac disease and if the disease-associated antibodies are also found.
HLA-DQ2.x, DQB1*02 
homozygosity or  single 
DQB1*02 allele 
1:26 (high) or 1:210 
(low)
T64300 DUODENUM M00100 NORMAL TISSUE MORPHOLOGY 
T63600 GASTRIC ANTRUM M40000 GASTRITIS REACTIVE 
T63500 GASTRIC CORPUS M00100 NORMAL TISSUE MORPHOLOGY 
T62000 ESOPHAGUS M40000 ESOPHAGITIS - 1.0 neg 5.01 0.7-4 elevated
19660129S B-HLADQ2_DQ8-PCR B -HLAKeli 26.04.2018 14:16
HLA-analysis: HLA-DQ2 positive. The analysis detected the following risk allele related to celiac disease: HLA-
DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms may occur in up to 
30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac disease if the patient 
has symptoms similar to celiac disease and if the disease-associated antibodies are also found.
HLA-DQ2.x, DQB1*02 
homozygosity or  single 
DQB1*02 allele 
1:26 (high) or 1:210 
(low)
T64300 DUODENUM  M00100 NORMAL TISSUE MORPHOLOGY
T63000 STOMACH  M43000 CHRONIC GASTRITIS - <0.6 neg 2.27 0.7-4 normal
19760323A B-HLADQ2_DQ8-PCR B -HLAKeli 01.06.2018 16:26
HLA-analysis: HLA-DQ2 positive. The analysis detected the following risk allele related to celiac disease: HLA-
DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms may occur in up to 
30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac disease if the patient 
has symptoms similar to celiac disease and if the disease-associated antibodies are also found.
HLA-DQ2.x, DQB1*02 
homozygosity or  single 
DQB1*02 allele 
1:26 (high) or 1:210 
(low)
1: T64300 DUODENUM  M58000 PARTIAL VILLOUS ATROPHY
2-3: T63000 STOMACH  M00100 NORMAL TISSUE MORPHOLOGY
4: T62000 ESOPHAGUS  M00100 NORMAL TISSUE MORPHOLOGY ++ 9.4 intermediate 3.63 0.7-4 normal
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APPENDIX 1 – Clinical laboratory diagnostics results
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19950918R B-HLADQ2_DQ8-PCR B -HLAKeli 20.06.2018 15:51
HLA-analysis: HLA-DQ2 positive. The analysis detected the following risk allele related to celiac disease: HLA-
DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms may occur in up to 
30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac disease if the patient 
has symptoms similar to celiac disease and if the disease-associated antibodies are also found.
HLA-DQ2.x, DQB1*02 
homozygosity or  single 
DQB1*02 allele 
1:26 (high) or 1:210 
(low)
T64300 DUODENUM M00100 NORMAL TISSUE MORPHOLOGY 
T63600 GASTRIC ANTRUM M00100 NO DIAGNOSTIC ABNORMALITY 
T63500 GASTRIC CORPUS M00100 NORMAL TISSUE MORPHOLOGY
T62000 ESOPHAGUS M00100 NORMAL TISSUE MORPHOLOGY - <0.6 neg 2.95 0.7-4 normal
19920906T B-HLADQ2_DQ8-PCR B -HLAKeli 22.06.2018 14:51
HLA-analysis: HLA-DQ2 positive. The analysis detected the following risk allele related to celiac disease: HLA-
DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms may occur in up to 
30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac disease if the patient 
has symptoms similar to celiac disease and if the disease-associated antibodies are also found.
HLA-DQ2.x, DQB1*02 
homozygosity or  single 
DQB1*02 allele 
1:26 (high) or 1:210 
(low)
T64300 DUODENUM M00100 NORMAL TISSUE MORPHOLOGY
T63600 GASTRIC ANTRUM  M43000 CHRONIC GASTRITIS, HELICOBACTER ++
T63500 GASTRIC CORPUS  M43000 CHRONIC GASTRITIS, HELICOBACTER + - 0.6 neg 1.97 0.7-4 normal
19750829A B-HLADQ2_DQ8-PCR B -HLAKeli 29.06.2018 17:01
HLA-analysis: HLA-DQ2 positive. The analysis detected the following risk allele related to celiac disease: HLA-
DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms may occur in up to 
30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac disease if the patient 
has symptoms similar to celiac disease and if the disease-associated antibodies are also found.
HLA-DQ2.x, DQB1*02 
homozygosity or  single 
DQB1*02 allele 
1:26 (high) or 1:210 
(low)
T64300 DUODENUM M00100 NORMAL TISSUE MORPHOLOGY
T63000 STOMACH M00100 NORMAL TISSUE MORPHOLOGY
T62000 ESOPHAGUS M09350 MORPHOLOGICAL DESCRIPTION ONLY - 1.0 neg 3.29 0.7-4 normal
19951229F B-HLADQ2_DQ8-PCR B -HLAKeli 16.07.2018 15:50
HLA-analysis: HLA-DQ2 positive. The analysis detected the following risk allele related to celiac disease: HLA-
DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms may occur in up to 
30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac disease if the patient 
has symptoms similar to celiac disease and if the disease-associated antibodies are also found.
HLA-DQ2.x, DQB1*02 
homozygosity or  single 
DQB1*02 allele 
1:26 (high) or 1:210 
(low)
T64300 DUODENUM  M00100 NORMAL TISSUE MORPHOLOGY
T63600 GASTRIC ANTRUM  M43000 CHRONIC GASTRITIS MILD
T63500 GASTRIC CORPUS  M00100 NORMAL TISSUE MORPHOLOGY
T63500 GASTRIC FUNDUS  M00100 NO DIAGNOSTIC ABNORMALITY - <0.6 neg 2.03 0.7-4 normal
19870609K B-HLADQ2_DQ8-PCR B -HLAKeli 06.08.2018 15:41
HLA-analysis: HLA-DQ2 positive. The analysis detected the following risk allele related to celiac disease: HLA-
DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms may occur in up to 
30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac disease if the patient 
has symptoms similar to celiac disease and if the disease-associated antibodies are also found.
HLA-DQ2.x, DQB1*02 
homozygosity or  single 
DQB1*02 allele 
1:26 (high) or 1:210 
(low)
T64300 DUODENUM M00100 NO DIAGNOSTIC ABNORMALITY
T63600 GASTRIC ANTRUM M00100 NO DIAGNOSTIC ABNORMALITY
T63500 GASTRIC CORPUS M43000 CHRONIC GASTRITIS - <0.6 neg 2.10 0.7-4 normal
19650429I B-HLADQ2_DQ8-PCR B -HLAKeli 02.09.2018 14:50
HLA-analysis: HLA-DQ2 positive. The analysis detected the following risk allele related to celiac disease: HLA-
DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms may occur in up to 
30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac disease if the patient 
has symptoms similar to celiac disease and if the disease-associated antibodies are also found.
HLA-DQ2.x, DQB1*02 
homozygosity or  single 
DQB1*02 allele 
1:26 (high) or 1:210 
(low)
T64300 DUODENUM M43000 CHRONIC INFLAMMATION
T63600 GASTRIC ANTRUM M43000 CHRONIC GASTRITIS
T63500 GASTRIC CORPUS M43000 CHRONIC GASTRITIS
T62000 ESOPHAGUS M00100 NO DIAGNOSTIC ABNORMALITY + <0.6 neg 2.26 0.7-4 normal
19710226K B-HLADQ2_DQ8-PCR B -HLAKeli 26.10.2018 16:30
HLA-analysis: HLA-DQ2 positive. The analysis detected the following risk allele related to celiac disease: HLA-
DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms may occur in up to 
30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac disease if the patient 
has symptoms similar to celiac disease and if the disease-associated antibodies are also found.
HLA-DQ2.x, DQB1*02 
homozygosity or  single 
DQB1*02 allele 
1:26 (high) or 1:210 
(low)
T64300 DUODENUM  M00100 NORMAL TISSUE MORPHOLOGY
T63600 GASTRIC ANTRUM  M43000 CHRONIC GASTRITIS
T63500 GASTRIC CORPUS  M43000 CHRONIC GASTRITIS  ACTIVE - <0.6 neg 2.32 0.7-4 normal
19950122V B-HLADQ2_DQ8-PCR B -HLAKeli 02.11.2018 14:45
HLA-analysis: HLA-DQ2 positive. The analysis detected the following risk allele related to celiac disease: HLA-
DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms may occur in up to 
30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac disease if the patient 
has symptoms similar to celiac disease and if the disease-associated antibodies are also found.
HLA-DQ2.x, DQB1*02 
homozygosity or  single 
DQB1*02 allele 
1:26 (high) or 1:210 
(low)
T64300 DUODENUM M00100 NORMAL TISSUE MORPHOLOGY
T63600 GASTRIC ANTRUM  M00100 NORMAL TISSUE MORPHOLOGY
T63500 GASTRIC CORPUS  M43000 CHRONIC GASTRITIS  MILD - <0.6 neg 2.01 0.7-4 normal
20000831V B-HLADQ2_DQ8-PCR B -HLAKeli 30.11.2018 16:16
HLA-analysis: HLA-DQ2 positive. The analysis detected the following risk allele related to celiac disease: HLA-
DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms may occur in up to 
30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac disease if the patient 
has symptoms similar to celiac disease and if the disease-associated antibodies are also found.
HLA-DQ2.x, DQB1*02 
homozygosity or  single 
DQB1*02 allele 
1:26 (high) or 1:210 
(low)
T64300 DUODENUM M58000 PARTIAL VILLOUS ATROPHY
T63600 GASTRIC ANTRUM M43000 CHRONIC GASTRITIS
T63500 GASTRIC CORPUS M00100 NO DIAGNOSTIC ABNORMALITY
T62000 ESOPHAGUS M00100 NORMAL TISSUE MORPHOLOGY ++ 34.0 pos 1.88 0.6-3.5 normal
19661014L B-HLADQ2_DQ8-PCR B -HLAKeli 02.12.2018 13:35
HLA-analysis: HLA-DQ2 positive. The analysis detected the following risk allele related to celiac disease: HLA-
DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms may occur in up to 
30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac disease if the patient 
has symptoms similar to celiac disease and if the disease-associated antibodies are also found.
HLA-DQ2.x, DQB1*02 
homozygosity or  single 
DQB1*02 allele 
1:26 (high) or 1:210 
(low)
T64300 DUODENUM M00100 NORMAL TISSUE MORPHOLOGY
T63600 GASTRIC ANTRUM M43000 CHRONIC GASTRITIS, MILD
T63500 GASTRIC CORPUS M43000 CHRONIC GASTRITIS - 2.0 neg 2.20 0.7-4 normal
19960214A B-HLADQ2_DQ8-PCR B -HLAKeli 14.12.2018 16:25
HLA-analysis: HLA-DQ2 positive. The analysis detected the following risk allele related to celiac disease: HLA-
DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms may occur in up to 
30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac disease if the patient 
has symptoms similar to celiac disease and if the disease-associated antibodies are also found.
HLA-DQ2.x, DQB1*02 
homozygosity or  single 
DQB1*02 allele 
1:26 (high) or 1:210 
(low)
T64300 DUODENUM M00100 NORMAL TISSUE MORPHOLOGY
T63600 GASTRIC ANTRUM M43000 CHRONIC GASTRITIS, MILD
T63500 GASTRIC CORPUS M43000 CHRONIC GASTRITIS, MILD - <0.6 neg 1.78 0.7-4 normal
19770715T B-HLADQ2_DQ8-PCR B -HLAKeli 10.05.2019 15:45
HLA-analysis: HLA-DQ2 positive. The analysis detected the following risk allele related to celiac disease: HLA-
DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms may occur in up to 
30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac disease if the patient 
has symptoms similar to celiac disease and if the disease-associated antibodies are also found.
HLA-DQ2.x, DQB1*02 
homozygosity or  single 
DQB1*02 allele 
1:26 (high) or 1:210 
(low)
T64300 DUODENUM  M00100 NORMAL TISSUE MORPHOLOGY
T63600 GASTRIC ANTRUM  M40000 GASTRITIS, REACTIVE
T63500 GASTRIC CORPUS  M00100 NORMAL TISSUE MORPHOLOGY - 1.5 neg 4.89 0.7-4 elevated
19650624J B-HLADQ2_DQ8-PCR B -HLAKeli 09.10.2019 16:26
HLA-analysis: HLA-DQ2 positive. The analysis detected the following risk allele related to celiac disease: HLA-
DQB1*02. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms may occur in up to 
30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac disease if the patient 
has symptoms similar to celiac disease and if the disease-associated antibodies are also found.
HLA-DQ2.x, DQB1*02 
homozygosity or  single 
DQB1*02 allele 
1:26 (high) or 1:210 
(low)
I T64300 DUODENUM M58000 PARTIAL VILLOUS ATROPHY, WITH 
INFLAMMATION
II-IV T50100 GASTROSCOPIC BIOPSY SPECIMEN M00100 NO DIAGNOSTIC 
ABNORMALITY ++ <0.6 neg 1.10 0.7-4 normal
19920414M B-HLADQ2_DQ8-PCR B -HLAKeli 15.01.2018 07:07
HLA-analysis: HLA-DQ8 positive. The analysis detected the following risk allele related to celiac disease: HLA-
DQB1*0302. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms may occur in up to 
30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac disease if the patient 
has symptoms similar to celiac disease and if the disease-associated antibodies are also found. HLA-DQ8 1:89 (high)
T64300 DUODENUM M00100 NORMAL TISSUE MORPHOLOGY 
T63600 GASTRIC ANTRUM M00100 NORMAL TISSUE MORPHOLOGY 
T63500 GASTRIC CORPUS M00100 NORMAL TISSUE MORPHOLOGY - <0.6 neg 0.85 0.7-4 normal
19781202R B-HLADQ2_DQ8-PCR B -HLAKeli 17.01.2018 16:18
HLA-analysis: HLA-DQ8 positive. The analysis detected the following risk allele related to celiac disease: HLA-
DQB1*0302. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms may occur in up to 
30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac disease if the patient 
has symptoms similar to celiac disease and if the disease-associated antibodies are also found. HLA-DQ8 1:89 (high)
T64300 DUODENUM M00100 NORMAL TISSUE MORPHOLOGY 
T63600 GASTRIC ANTRUM M00100 NORMAL TISSUE MORPHOLOGY 
T63500 GASTRIC CORPUS M00100 NORMAL TISSUE MORPHOLOGY 
T62000 ESOPHAGUS M00100 NORMAL TISSUE MORPHOLOGY - 0.9 neg 3.36 0.7-4 normal
19941121N B-HLADQ2_DQ8-PCR B -HLAKeli 18.01.2018 16:26
HLA-analysis: HLA-DQ8 positive. The analysis detected the following risk allele related to celiac disease: HLA-
DQB1*0302. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms may occur in up to 
30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac disease if the patient 
has symptoms similar to celiac disease and if the disease-associated antibodies are also found. HLA-DQ8 1:89 (high)
T64300 DUODENUM M00100 NORMAL TISSUE MORPHOLOGY
T63000 STOMACH M43000 CHRONIC GASTRITIS, MILD - <0.6 neg 1.76 0.7-4 normal
19870304M B-HLADQ2_DQ8-PCR B -HLAKeli 26.02.2018 07:07
HLA-analysis: HLA-DQ8 positive. The analysis detected the following risk allele related to celiac disease: HLA-
DQB1*0302. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms may occur in up to 
30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac disease if the patient 
has symptoms similar to celiac disease and if the disease-associated antibodies are also found. HLA-DQ8 1:89 (high)
T64300 DUODENUM M00100 NORMAL FINDING
T63000 STOMACH M43000 CHRONIC GASTRITIS, helicobacter +
T62000 ESOPHAGUS M00100 NORMAL FINDING - 0.8 neg 5.55 0.7-4 elevated
19620510L B-HLADQ2_DQ8-PCR B -HLAKeli 15.03.2018 16:25
HLA-analysis: HLA-DQ8 positive. The analysis detected the following risk allele related to celiac disease: HLA-
DQB1*0302. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms may occur in up to 
30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac disease if the patient 
has symptoms similar to celiac disease and if the disease-associated antibodies are also found. HLA-DQ8 1:89 (high)
I T64300 DUODENUM M00100 NORMAL TISSUE MORPHOLOGY
II - III T63000 STOMACH M43000 CHRONIC GASTRITIS, HELIKOT +
IV T62000 ESOPHAGUS M43000 CHRONIC INFLAMMATION
IV T62000 ESOPHAGUS M72000 HYPERPLASIA, SEE TEXT - <0.6 neg 1.01 0.7-4 normal
Risk classification of HLA-DQx.5 allele in Celiac Disease HLA genotyping test 6
APPENDIX 1 – Clinical laboratory diagnostics results
Internal ID Mnemonic 
 Test 
Shortname  B -HLAKeli ValTime Resu
lt ext
erna
l com
ment
 (B -
HLAK
eli)
HLAD
Q2_D
Q8 g
enot
ype
RISK PADGAST statement Histology grade tTGAbA result U/ml
tTGAbA result 
interpretation IgA result g/l
IgA reference 
range (age 
dependent)
IgA result 
interpretation
19590407T B-HLADQ2_DQ8-PCR B -HLAKeli 28.03.2018 16:11
HLA-analysis: HLA-DQ8 positive. The analysis detected the following risk allele related to celiac disease: HLA-
DQB1*0302. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms may occur in up to 
30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac disease if the patient 
has symptoms similar to celiac disease and if the disease-associated antibodies are also found. HLA-DQ8 1:89 (high)
T64300 DUODENUM M00100 NORMAL TISSUE MORPHOLOGY 
T63600 GASTRIC ANTRUM M43000 GASTRITIS CHRONIC 
T63500 GASTRIC CORPUS M76800 POLYP, CYSTIC 
T62000 ESOPHAGUS M40000 ESOPHAGITIS - 0.8 neg 4.52 0.7-4 elevated
20000816S B-HLADQ2_DQ8-PCR B -HLAKeli 25.04.2018 16:03
HLA-analysis: HLA-DQ8 positive. The analysis detected the following risk allele related to celiac disease: HLA-
DQB1*0302. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms may occur in up to 
30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac disease if the patient 
has symptoms similar to celiac disease and if the disease-associated antibodies are also found. HLA-DQ8 1:89 (high)
T64300 DUODENUM M00100 NORMAL TISSUE MORPHOLOGY
T63600 GASTRIC ANTRUM M00100 NORMAL TISSUE MORPHOLOGY
T63500 GASTRIC CORPUS M00100 NORMAL TISSUE MORPHOLOGY - <0.6 neg 0.98 0.6-3.5 normal
19820213L B-HLADQ2_DQ8-PCR B -HLAKeli 25.04.2018 16:03
HLA-analysis: HLA-DQ8 positive. The analysis detected the following risk allele related to celiac disease: HLA-
DQB1*0302. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms may occur in up to 
30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac disease if the patient 
has symptoms similar to celiac disease and if the disease-associated antibodies are also found. HLA-DQ8 1:89 (high)
T64300 DUODENUM  M00100 NORMAL TISSUE MORPHOLOGY
T63600 GASTRIC ANTRUM  M00100 NORMAL TISSUE MORPHOLOGY
T63500 GASTRIC CORPUS  M00100 NORMAL TISSUE MORPHOLOGY
T62000 ESOPHAGUS  M40000 ESOPHAGITIS MILD - <0.6 neg 1.50 0.7-4 normal
19980926K B-HLADQ2_DQ8-PCR B -HLAKeli 29.04.2018 17:25
HLA-analysis: HLA-DQ8 positive. The analysis detected the following risk allele related to celiac disease: HLA-
DQB1*0302. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms may occur in up to 
30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac disease if the patient 
has symptoms similar to celiac disease and if the disease-associated antibodies are also found. HLA-DQ8 1:89 (high)
1. T64300 DUODENUM  M40000 INFLAMMATION, MILD
2-3.  T63000 STOMACH  M43000 CHRONIC GASTRITIS, MILD + 0.9 neg 2.72 0.6-3.5 normal
19621008L B-HLADQ2_DQ8-PCR B -HLAKeli 29.04.2018 17:25
HLA-analysis: HLA-DQ8 positive. The analysis detected the following risk allele related to celiac disease: HLA-
DQB1*0302. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms may occur in up to 
30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac disease if the patient 
has symptoms similar to celiac disease and if the disease-associated antibodies are also found. HLA-DQ8 1:89 (high)
T64300 DUODENUM  M00100 NORMAL TISSUE MORPHOLOGY
T63600 GASTRIC ANTRUM  M40000 GASTRITIS REACTIVE
T63500 GASTRIC CORPUS  M00100 NO DIAGNOSTIC ABNORMALITY - <0.6 neg 1.39 0.7-4 normal
19580428P B-HLADQ2_DQ8-PCR B -HLAKeli 04.05.2018 15:50
HLA-analysis: HLA-DQ8 positive. The analysis detected the following risk allele related to celiac disease: HLA-
DQB1*0302. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms may occur in up to 
30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac disease if the patient 
has symptoms similar to celiac disease and if the disease-associated antibodies are also found. HLA-DQ8 1:89 (high)
I T64300 DUODENUM M00100 NO DIAGNOSTIC ABNORMALITY
II T63600 GASTRIC ANTRUM M43000 CHRONIC GASTRITIS, INACTIVE
II T63600 GASTRIC ANTRUM M73320 INTESTINAL METAPLASIA
I T63500 GASTRIC CORPUS M43000 CHRONIC GASTRITIS, ACTIVE, 
HELICOBACTER + - <0.6 neg 3.93 0.7-4 normal
19820606H B-HLADQ2_DQ8-PCR B -HLAKeli 25.05.2018 15:46
HLA-analysis: HLA-DQ8 positive. The analysis detected the following risk allele related to celiac disease: HLA-
DQB1*0302. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms may occur in up to 
30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac disease if the patient 
has symptoms similar to celiac disease and if the disease-associated antibodies are also found. HLA-DQ8 1:89 (high)
T64300 DUODENUM  M00100 NORMAL TISSUE MORPHOLOGY
T63000 STOMACH  M00100 NORMAL TISSUE MORPHOLOGY - <0.6 neg 1.78 0.7-4 normal
19890810T B-HLADQ2_DQ8-PCR B -HLAKeli 07.06.2018 15:26
HLA-analysis: HLA-DQ8 positive. The analysis detected the following risk allele related to celiac disease: HLA-
DQB1*0302. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms may occur in up to 
30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac disease if the patient 
has symptoms similar to celiac disease and if the disease-associated antibodies are also found. HLA-DQ8 1:89 (high)
T64300 DUODENUM  M73330 GASTRIC METAPLASIA, FOCAL
T63600 GASTRIC ANTRUM  M00100 NORMAL TISSUE MORPHOLOGY
T63500 GASTRIC CORPUS  M00100 NORMAL TISSUE MORPHOLOGY - <0.6 neg 1.28 0.7-4 normal
19590906A B-HLADQ2_DQ8-PCR B -HLAKeli 11.06.2018 07:07
HLA-analysis: HLA-DQ8 positive. The analysis detected the following risk allele related to celiac disease: HLA-
DQB1*0302. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms may occur in up to 
30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac disease if the patient 
has symptoms similar to celiac disease and if the disease-associated antibodies are also found. HLA-DQ8 1:89 (high)
T64300 DUODENUM  M00100 NORMAL TISSUE MORPHOLOGY
T64400 DUODENAL BULBUS  M72040 HYPERPLASTIC POLYP
T63600 GASTRIC ANTRUM  M00100 NORMAL TISSUE MORPHOLOGY
T63500 GASTRIC CORPUS M00100 NORMAL TISSUE MORPHOLOGY - <0.6 neg 1.51 0.7-4 normal
19670922K B-HLADQ2_DQ8-PCR B -HLAKeli 06.07.2018 15:46
HLA-analysis: HLA-DQ8 positive. The analysis detected the following risk allele related to celiac disease: HLA-
DQB1*0302. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms may occur in up to 
30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac disease if the patient 
has symptoms similar to celiac disease and if the disease-associated antibodies are also found. HLA-DQ8 1:89 (high)
T64300 DUODENUM M09350 MORPHOLOGICAL DESCRIPTION ONLY, 
BULBITIS
T63000 STOMACH M09350 REACTIVE CHANGES
T62000 ESOPHAGUS M73330 GASTRIC METAPLASIA - <0.6 neg 2.35 0.7-4 normal
19801205T B-HLADQ2_DQ8-PCR B -HLAKeli 06.08.2018 16:35
HLA-analysis: HLA-DQ8 positive. The analysis detected the following risk allele related to celiac disease: HLA-
DQB1*0302. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms may occur in up to 
30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac disease if the patient 
has symptoms similar to celiac disease and if the disease-associated antibodies are also found. HLA-DQ8 1:89 (high)
T64300 DUODENUM M00100 NORMAL TISSUE MORPHOLOGY
T63600 GASTRIC ANTRUM M43000 CHRONIC GASTRITIS, ACTIVE
T63500 GASTRIC CORPUS M00100 NORMAL TISSUE MORPHOLOGY
T62000 ESOPHAGUS M00100 NORMAL TISSUE MORPHOLOGY - 3.2 neg 2.52 0.7-4 normal
19730612H B-HLADQ2_DQ8-PCR B -HLAKeli 09.08.2018 15:55
HLA-analysis: HLA-DQ8 positive. The analysis detected the following risk allele related to celiac disease: HLA-
DQB1*0302. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms may occur in up to 
30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac disease if the patient 
has symptoms similar to celiac disease and if the disease-associated antibodies are also found. HLA-DQ8 1:89 (high)
T64300 DUODENUM M00100 NORMAL TISSUE MORPHOLOGY
T63600 GASTRIC ANTRUM M00100 NORMAL TISSUE MORPHOLOGY
T63500 GASTRIC CORPUS M40000 GASTRITIS, CHRONIC, MILD - <0.6 neg 2.77 0.7-4 normal
19790430R B-HLADQ2_DQ8-PCR B -HLAKeli 04.09.2018 15:56
HLA-analysis: HLA-DQ8 positive. The analysis detected the following risk allele related to celiac disease: HLA-
DQB1*0302. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms may occur in up to 
30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac disease if the patient 
has symptoms similar to celiac disease and if the disease-associated antibodies are also found. HLA-DQ8 1:89 (high)
T64300 DUODENUM  M00100 NORMAL TISSUE MORPHOLOGY
T63000 STOMACH  M43000 CHRONIC GASTRITIS ACTIVE (HELICOBACTER 
PYLORI)
T62000 ESOPHAGUS  M00100 NORMAL TISSUE MORPHOLOGY - <0.6 neg 1.66 0.7-4 normal
20040520P B-HLADQ2_DQ8-PCR B -HLAKeli 05.09.2018 16:40
HLA-analysis: HLA-DQ8 positive. The analysis detected the following risk allele related to celiac disease: HLA-
DQB1*0302. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms may occur in up to 
30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac disease if the patient 
has symptoms similar to celiac disease and if the disease-associated antibodies are also found. HLA-DQ8 1:89 (high)
T64300 DUODENUM  M00100 NO DIAGNOSTIC ABNORMALITY
T63600 GASTRIC ANTRUM  M00100 NORMAL TISSUE MORPHOLOGY
T63500 GASTRIC CORPUS  M00100 NORMAL TISSUE MORPHOLOGY - <0.6 neg 1.71 0.5-2.5 normal
19571117J B-HLADQ2_DQ8-PCR B -HLAKeli 14.09.2018 15:55
HLA-analysis: HLA-DQ8 positive. The analysis detected the following risk allele related to celiac disease: HLA-
DQB1*0302. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms may occur in up to 
30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac disease if the patient 
has symptoms similar to celiac disease and if the disease-associated antibodies are also found. HLA-DQ8 1:89 (high)
T64300 DUODENUM M00100 NORMAL TISSUE MORPHOLOGY
T63600 GASTRIC ANTRUM M00100 NORMAL TISSUE MORPHOLOGY
T63500 GASTRIC CORPUS M43000 CHRONIC GASTRITIS, MILD - <0.6 neg 1.58 0.7-4 normal
19591230T B-HLADQ2_DQ8-PCR B -HLAKeli 19.09.2018 16:11
HLA-analysis: HLA-DQ8 positive. The analysis detected the following risk allele related to celiac disease: HLA-
DQB1*0302. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms may occur in up to 
30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac disease if the patient 
has symptoms similar to celiac disease and if the disease-associated antibodies are also found. HLA-DQ8 1:89 (high)
I T64300 DUODENUM M00100 NORMAL TISSUE MORPHOLOGY
II T63600 GASTRIC ANTRUM M40000 GASTRITIS, CHRONIC, MILD
III T63500 GASTRIC CORPUS M58010 ATROPHIC GASTRITIS - 0.8 neg 4.16 0.7-4 elevated
19950927M B-HLADQ2_DQ8-PCR B -HLAKeli 12.10.2018 09:40
HLA-analysis: HLA-DQ8 positive. The analysis detected the following risk allele related to celiac disease: HLA-
DQB1*0302. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms may occur in up to 
30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac disease if the patient 
has symptoms similar to celiac disease and if the disease-associated antibodies are also found. HLA-DQ8 1:89 (high)
T64300 DUODENUM  M00100 NO PATHOLOGIC DIAGNOSIS
T63600 GASTRIC ANTRUM  M79900 REGENERATION
T63600 GASTRIC ANTRUM  M73320 INTESTINAL METAPLASIA
T63500 GASTRIC CORPUS  M00100 NO PATHOLOGIC DIAGNOSIS - 0.6 neg 3.88 0.7-4 normal
19620116A B-HLADQ2_DQ8-PCR B -HLAKeli 17.10.2018 16:10
HLA-analysis: HLA-DQ8 positive. The analysis detected the following risk allele related to celiac disease: HLA-
DQB1*0302. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms may occur in up to 
30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac disease if the patient 
has symptoms similar to celiac disease and if the disease-associated antibodies are also found. HLA-DQ8 1:89 (high)
1,2: T64300 DUODENUM M09350 MORPHOLOGICAL DESCRIPTION ONLY
3: T63600 GASTRIC ANTRUM M43000 CHRONIC GASTRITIS ( HELICOBACTER 
+)
4: T63500 GASTRIC CORPUS M43000 CHRONIC GASTRITIS - 0.8 neg 3.82 0.7-4 normal
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19530113P B-HLADQ2_DQ8-PCR B -HLAKeli 22.10.2018 09:45
HLA-analysis: HLA-DQ8 positive. The analysis detected the following risk allele related to celiac disease: HLA-
DQB1*0302. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms may occur in up to 
30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac disease if the patient 
has symptoms similar to celiac disease and if the disease-associated antibodies are also found. HLA-DQ8 1:89 (high)
T64300 DUODENUM M09350 MORPHOLOGICAL DESCRIPTION ONLY
T63000 STOMACH M00100 NO DIAGNOSTIC ABNORMALITY + <0.6 neg 4.11 0.7-4 elevated
19790711H B-HLADQ2_DQ8-PCR B -HLAKeli 22.10.2018 09:45
HLA-analysis: HLA-DQ8 positive. The analysis detected the following risk allele related to celiac disease: HLA-
DQB1*0302. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms may occur in up to 
30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac disease if the patient 
has symptoms similar to celiac disease and if the disease-associated antibodies are also found. HLA-DQ8 1:89 (high)
T64300 DUODENUM M00100 NORMAL TISSUE MORPHOLOGY
T63600 GASTRIC ANTRUM M00100 NORMAL TISSUE MORPHOLOGY
T63500 GASTRIC CORPUS M43000 CHRONIC GASTRITIS, LEVIS - <0.6 neg 2.97 0.7-4 normal
19641117P B-HLADQ2_DQ8-PCR B -HLAKeli 11.11.2018 15:30
HLA-analysis: HLA-DQ8 positive. The analysis detected the following risk allele related to celiac disease: HLA-
DQB1*0302. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms may occur in up to 
30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac disease if the patient 
has symptoms similar to celiac disease and if the disease-associated antibodies are also found. HLA-DQ8 1:89 (high)
1 T64300 DUODENUM M00100 NORMAL TISSUE MORPHOLOGY
2-4 T63000 STOMACH M43000 CHRONIC GASTRITIS - <0.6 neg 1.12 0.7-4 normal
19780608N B-HLADQ2_DQ8-PCR B -HLAKeli 21.11.2018 16:00
HLA-analysis: HLA-DQ8 positive. The analysis detected the following risk allele related to celiac disease: HLA-
DQB1*0302. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms may occur in up to 
30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac disease if the patient 
has symptoms similar to celiac disease and if the disease-associated antibodies are also found. HLA-DQ8 1:89 (high)
T64300 DUODENUM  M00100 NORMAL TISSUE MORPHOLOGY  
T63600 GASTRIC ANTRUM M00100 NORMAL TISSUE MORPHOLOGY  
T63500 GASTRIC CORPUS M76800 POLYP
T62000 ESOPHAGUS  M00100 NORMAL TISSUE MORPHOLOGY - <0.6 neg 1.75 0.7-4 normal
19770118N B-HLADQ2_DQ8-PCR B -HLAKeli 20.12.2018 16:40
HLA-analysis: HLA-DQ8 positive. The analysis detected the following risk allele related to celiac disease: HLA-
DQB1*0302. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms may occur in up to 
30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac disease if the patient 
has symptoms similar to celiac disease and if the disease-associated antibodies are also found. HLA-DQ8 1:89 (high)
T64300 DUODENUM  M00100 NORMAL TISSUE MORPHOLOGY
T63600 GASTRIC ANTRUM  M43000 CHRONIC GASTRITIS, LEVIS
T63500 GASTRIC CORPUS  M43000 CHRONIC GASTRITIS, LEVIS
T62000 ESOPHAGUS  M00100 NORMAL TISSUE MORPHOLOGY - <0.6 neg 1.76 0.7-4 normal
19840317G B-HLADQ2_DQ8-PCR B -HLAKeli 10.01.2019 16:07
HLA-analysis: HLA-DQ8 positive. The analysis detected the following risk allele related to celiac disease: HLA-
DQB1*0302. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms may occur in up to 
30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac disease if the patient 
has symptoms similar to celiac disease and if the disease-associated antibodies are also found. HLA-DQ8 1:89 (high)
T64300 DUODENUM  M58000 VILLOUS ATROPHY
T64300 DUODENUM  M40000 DUODENITIS
T63600 GASTRIC ANTRUM  M43000 CHRONIC GASTRITIS
T63500 GASTRIC CORPUS  M00100 NORMAL TISSUE MORPHOLOGY
ADD. STATETEMENT PAD:
T64300 DUODENUM  M58000 PARTIAL VILLOUS ATROPHY
T64300 DUODENUM  M40000 DUODENITIS
T63600 GASTRIC ANTRUM  M43000 CHRONIC GASTRITIS
T63500 GASTRIC CORPUS  M43000 CHRONIC GASTRITIS ++ 23.0 pos 1.99 0.7-4 normal
19930414H B-HLADQ2_DQ8-PCR B -HLAKeli 23.01.2019 15:14
HLA-analysis: HLA-DQ8 positive. The analysis detected the following risk allele related to celiac disease: HLA-
DQB1*0302. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms may occur in up to 
30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac disease if the patient 
has symptoms similar to celiac disease and if the disease-associated antibodies are also found. HLA-DQ8 1:89 (high)
T64300 DUODENUM M00100 NORMAL FINDING
T63600 GASTRIC ANTRUM M00100 NORMAL FINDING
T63500 GASTRIC CORPUS M00100 NORMAL FINDING - <0.6 neg 0.96 0.7-4 normal
19790711H B-HLADQ2_DQ8-PCR B -HLAKeli 27.01.2019 12:10
HLA-analysis: HLA-DQ8 positive. The analysis detected the following risk allele related to celiac disease: HLA-
DQB1*0302. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms may occur in up to 
30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac disease if the patient 
has symptoms similar to celiac disease and if the disease-associated antibodies are also found. HLA-DQ8 1:89 (high)
T64300 DUODENUM M00100 NORMAL TISSUE MORPHOLOGY
T63600 GASTRIC ANTRUM M00100 NORMAL TISSUE MORPHOLOGY
T63500 GASTRIC CORPUS M43000 CHRONIC GASTRITIS, LEVIS - <0.6 neg 2.97 0.7-4 normal
19931121R B-HLADQ2_DQ8-PCR B -HLAKeli 14.02.2019 14:45
HLA-analysis: HLA-DQ8 positive. The analysis detected the following risk allele related to celiac disease: HLA-
DQB1*0302. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms may occur in up to 
30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac disease if the patient 
has symptoms similar to celiac disease and if the disease-associated antibodies are also found. HLA-DQ8 1:89 (high)
T64300 DUODENUM M00100 NORMAL TISSUE MORPHOLOGY
T63600 GASTRIC ANTRUM M00100 NORMAL TISSUE MORPHOLOGY
T63500 GASTRIC CORPUS M00100 NO DIAGNOSTIC ABNORMALITY
T62000 ESOPHAGUS M09350 MORPHOLOGICAL DESCRIPTION ONLY - <0.6 neg 1.58 0.7-4 normal
19490701M B-HLADQ2_DQ8-PCR B -HLAKeli 22.04.2019 16:55
HLA-analysis: HLA-DQ8 positive. The analysis detected the following risk allele related to celiac disease: HLA-
DQB1*0302. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms may occur in up to 
30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac disease if the patient 
has symptoms similar to celiac disease and if the disease-associated antibodies are also found. HLA-DQ8 1:89 (high)
T64300 DUODENUM   M40000 INFLAMMATION, MILD
T63600 GASTRIC ANTRUM  M43000 CHRONIC GASTRITIS
T63500 GASTRIC CORPUS  M43000 CHRONIC GASTRITIS
T62000 ESOPHAGUS  M00100 NO DIAGNOSTIC ABNORMALITY + 0.8 neg 2.56 0.7-4 normal
19720122O B-HLADQ2_DQ8-PCR B -HLAKeli 20.05.2019 15:41
HLA-analysis: HLA-DQ8 positive. The analysis detected the following risk allele related to celiac disease: HLA-
DQB1*0302. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms may occur in up to 
30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac disease if the patient 
has symptoms similar to celiac disease and if the disease-associated antibodies are also found. HLA-DQ8 1:89 (high)
1:  T64300 DUODENUM M09350 MORPHOLOGICAL DESCRIPTION ONLY
2-4. STOMACH  M00100 NO DIAGNOSTIC ABNORMALITY + <0.6 neg 2.49 0.7-4 normal
19840714B B-HLADQ2_DQ8-PCR B -HLAKeli 19.07.2019 15:00
HLA-analysis: HLA-DQ8 positive. The analysis detected the following risk allele related to celiac disease: HLA-
DQB1*0302. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms may occur in up to 
30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac disease if the patient 
has symptoms similar to celiac disease and if the disease-associated antibodies are also found. HLA-DQ8 1:89 (high)
T64300 DUODENUM  M00100 NORMAL TISSUE MORPHOLOGY
T63600 GASTRIC ANTRUM M00100 NO DIAGNOSTIC ABNORMALITY
T63500 GASTRIC CORPUS  M43000 CHRONIC GASTRITIS, MILD
T62000 ESOPHAGUS  M00100 NO DIAGNOSTIC ABNORMALITY - 0.7 neg 5.92 0.7-4 elevated
19881014P B-HLADQ2_DQ8-PCR B -HLAKeli 16.08.2019 15:50
HLA-analysis: HLA-DQ8 positive. The analysis detected the following risk allele related to celiac disease: HLA-
DQB1*0302. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms may occur in up to 
30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac disease if the patient 
has symptoms similar to celiac disease and if the disease-associated antibodies are also found. HLA-DQ8 1:89 (high)
T64300 DUODENUM  M09350 MORPHOLOGICAL DESCRIPTION ONLY, SEE 
THE ADDITIONAL STATEMENT
T63000 STOMACH  M00100 NORMAL TISSUE MORPHOLOGY
ADD. STATEMENT PAD:
T64300 DUODENUM  M58000 ATROPHY, SEE TEXT
T63600 GASTRIC ANTRUM  M40000 GASTRITIS REACTIVE
T63500 GASTRIC CORPUS  M00100 NORMAL TISSUE MORPHOLOGY +++ 27.0 pos 2.14 0.7-4 normal
19820518V B-HLADQ2_DQ8-PCR B -HLAKeli 28.08.2019 16:19
HLA-analysis: HLA-DQ8 positive. The analysis detected the following risk allele related to celiac disease: HLA-
DQB1*0302. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms may occur in up to 
30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac disease if the patient 
has symptoms similar to celiac disease and if the disease-associated antibodies are also found. HLA-DQ8 1:89 (high)
T64300 DUODENUM M00100 NORMAL TISSUE MORPHOLOGY
T63600 GASTRIC ANTRUM M43000 CHRONIC GASTRITIS
T63500 GASTRIC CORPUS M58010 ATROPHIC GASTRITIS - <0.6 neg 1.14 0.7-4 normal
19911120V B-HLADQ2_DQ8-PCR B -HLAKeli 09.09.2019 15:28
HLA-analysis: HLA-DQ8 positive. The analysis detected the following risk allele related to celiac disease: HLA-
DQB1*0302. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms may occur in up to 
30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac disease if the patient 
has symptoms similar to celiac disease and if the disease-associated antibodies are also found. HLA-DQ8 1:89 (high)
1 T64300 DUODENUM M00100 NORMAL FINDING
2-3 T63000 STOMACH M43000 CHRONIC GASTRITIS, helikobacter +
4 T64400 DUODENAL BULBUS M40000 INFLAMMATION, active - 0.8 neg 2.11 0.7-4 normal
19500518H B-HLADQ2_DQ8-PCR B -HLAKeli 06.06.2019 15:42
HLA-analysis: HLA-DQ8 positive. The analysis detected the following risk allele related to celiac disease: HLA-
DQB1*0302. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms may occur in up to 
30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac disease if the patient 
has symptoms similar to celiac disease and if the disease-associated antibodies are also found. HLA-DQ8 1:89 (high)
T64300 DUODENUM M00100 NORMAL TISSUE MORPHOLOGY
T63600 PYLORIC ANTRUM M43000 CHRONIC GASTRITIS
T63500 GASTRIC CORPUS M42000 SUPERFICIAL GASTRITIS - <0.6 neg 1.79 0.7-4 normal
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19870930V B-HLADQ2_DQ8-PCR B -HLAKeli 02.02.2018 15:41
HLA-analysis: HLA-DQ2 and HLA-DQ8 positive. The analysis detected the following risk alleles related to celiac 
disease: HLA-DQB1*02 and HLA-DQB1*0302. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or 
DQ8 isoforms may occur in up to 30% of healthy individuals.The finding of the risk haplotype supports the 
diagnosis of celiac disease if the patient has symptoms similar to celiac disease and if the disease-associated 
antibodies are also found.
HLA-DQ8 + HLA-
DQ2.x, single 
DQB1*02 allele 1:24 (high)
T64300 DUODENUM M00100 NO DIAGNOSTIC ABNORMALITY
T63000 STOMACH M00100 NORMAL TISSUE MORPHOLOGY - <0.6 neg 2.08 0.7-4 normal
19790314H B-HLADQ2_DQ8-PCR B -HLAKeli 04.02.2018 15:56
HLA-analysis: HLA-DQ2 and HLA-DQ8 positive. The analysis detected the following risk alleles related to celiac 
disease: HLA-DQB1*02 and HLA-DQB1*0302. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or 
DQ8 isoforms may occur in up to 30% of healthy individuals.The finding of the risk haplotype supports the 
diagnosis of celiac disease if the patient has symptoms similar to celiac disease and if the disease-associated 
antibodies are also found.
HLA-DQ8 + HLA-
DQ2.x, single 
DQB1*02 allele 1:24 (high)
T64300 DUODENUM M00100 NORMAL TISSUE MORPHOLOGY 
T63000 STOMACH M00100 NORMAL TISSUE MORPHOLOGY 
T62000 ESOPHAGUS M40000 ESOPHAGITIS (EOSINOFIILINEN ESOFAGIITTI?) - <0.6 neg 2.08 0.7-4 normal
19510826O B-HLADQ2_DQ8-PCR B -HLAKeli 04.10.2019 16:49
HLA-analysis: HLA-DQ2 and HLA-DQ8 positive. The analysis detected the following risk alleles related to celiac 
disease: HLA-DQB1*02 and HLA-DQB1*0302. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or 
DQ8 isoforms may occur in up to 30% of healthy individuals.The finding of the risk haplotype supports the 
diagnosis of celiac disease if the patient has symptoms similar to celiac disease and if the disease-associated 
antibodies are also found.
HLA-DQ8 + HLA-
DQ2.x, single 
DQB1*02 allele 1:24 (high)
T64300 DUODENUM  M58000 ATROPHY, MILD
T63600 GASTRIC ANTRUM  M43000 CHRONIC GASTRITIS, MILD
T63500 GASTRIC CORPUS M43000 CHRONIC GASTRITIS, MILD
T63500 GASTRIC CORPUS  M58000 ATROPHY, MILD ++ <0.6 neg 1.08 0.7-4 normal
19650517R B-HLADQ2_DQ8-PCR B -HLAKeli 18.02.2018 18:27
HLA-analysis: negative. No association was found between the risk haplotypes  HLA-DQ2 and HLA-DQ8 
and celiac disease. The patient has no increased risk of developing celiac disease OR HLA-analysis: 
HLA-DQX.5 positive. The analysis detected the following low-risk allele related to celiac disease: HLA-
DQA1*05. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms may occur in 
up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies 
are also found. HLA-DQx.5
1:1842 (extremely 
low)
T64300 DUODENUM M00100 NORMAL TISSUE MORPHOLOGY
T63500 GASTRIC CORPUS M00100 NORMAL TISSUE MORPHOLOGY
T63300 GASTRIC CARDIA M76800 POLYP
T62000 ESOPHAGUS M00100 NORMAL TISSUE MORPHOLOGY - <0.6 neg 2.65 0.7-4 normal
19600428L B-HLADQ2_DQ8-PCR B -HLAKeli 09.03.2018 15:16
HLA-analysis: negative. No association was found between the risk haplotypes  HLA-DQ2 and HLA-DQ8 
and celiac disease. The patient has no increased risk of developing celiac disease OR HLA-analysis: 
HLA-DQX.5 positive. The analysis detected the following low-risk allele related to celiac disease: HLA-
DQA1*05. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms may occur in 
up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies 
are also found. HLA-DQx.5
1:1842 (extremely 
low)
T64300 DUODENUM   M09350 MORPHOLOGICAL DESCRIPTION ONLY, SEE 
THE STATEMENT
T63000 STOMACH   M00100 NO DIAGNOSTIC ABNORMALITY
T62000 ESOPHAGUS   M73320 INTESTINAL METAPLASIA
T62000 ESOPHAGUS   M73330 GASTRIC METAPLASIA + <0.6 neg 2.10 0.7-4 normal
19800327K B-HLADQ2_DQ8-PCR B -HLAKeli 01.04.2018 17:53
HLA-analysis: negative. No association was found between the risk haplotypes  HLA-DQ2 and HLA-DQ8 
and celiac disease. The patient has no increased risk of developing celiac disease OR HLA-analysis: 
HLA-DQX.5 positive. The analysis detected the following low-risk allele related to celiac disease: HLA-
DQA1*05. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms may occur in 
up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies 
are also found. HLA-DQx.5
1:1842 (extremely 
low)
T64300 DUODENUM M00100 NORMAL TISS
UE MORPHOLOGY
T63600 GASTRIC ANTRUM M00100 NORMAL TISSUE MORPHOLOGY
T63500 GASTRIC CORPUS M00100 NORMAL TISSUE MORPHOLOGY - <0.6 neg 2.64 0.7-4 normal
19580625M B-HLADQ2_DQ8-PCR B -HLAKeli 05.04.2018 15:21
HLA-analysis: negative. No association was found between the risk haplotypes  HLA-DQ2 and HLA-DQ8 
and celiac disease. The patient has no increased risk of developing celiac disease OR HLA-analysis: 
HLA-DQX.5 positive. The analysis detected the following low-risk allele related to celiac disease: HLA-
DQA1*05. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms may occur in 
up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies 
are also found. HLA-DQx.5
1:1842 (extremely 
low)
T64300 DUODENUM M00100 NO DIAGNOSTIC ABNORMALITY 
T63000 STOMACH M00100 NO DIAGNOSTIC ABNORMALITY 
T62000 ESOPHAGUS M09350 MORPHOLOGICAL DESCRIPTION ONLY - <0.6 neg 3.35 0.7-4 normal
19551001S B-HLADQ2_DQ8-PCR B -HLAKeli 06.05.2018 21:10
HLA-analysis: negative. No association was found between the risk haplotypes  HLA-DQ2 and HLA-DQ8 
and celiac disease. The patient has no increased risk of developing celiac disease OR HLA-analysis: 
HLA-DQX.5 positive. The analysis detected the following low-risk allele related to celiac disease: HLA-
DQA1*05. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms may occur in 
up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies 
are also found. HLA-DQx.5
1:1842 (extremely 
low)
1: T64300 DUODENUM   M43000 CHRONIC INFLAMMATION
1-2: T63000 STOMACH   M43000 CHRONIC GASTRITIS
1: T63500 GASTRIC CORPUS   M75630 FUNDIC GLAND POLYP + 0.9 neg 3.71 0.7-4 normal
19810316S B-HLADQ2_DQ8-PCR B -HLAKeli 13.05.2018 18:22
HLA-analysis: negative. No association was found between the risk haplotypes  HLA-DQ2 and HLA-DQ8 
and celiac disease. The patient has no increased risk of developing celiac disease OR HLA-analysis: 
HLA-DQX.5 positive. The analysis detected the following low-risk allele related to celiac disease: HLA-
DQA1*05. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms may occur in 
up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies 
are also found. HLA-DQx.5
1:1842 (extremely 
low)
T64300 DUODENUM M58000 VILLOUS ATROPHY
T63600 GASTRIC ANTRUM M00100 NORMAL TISSUE MORPHOLOGY
T63500 GASTRIC CORPUS M76800 POLYP ++ <0.6 neg 1.26 0.7-4 normal
19590106R B-HLADQ2_DQ8-PCR B -HLAKeli 14.06.2018 16:26
HLA-analysis: negative. No association was found between the risk haplotypes  HLA-DQ2 and HLA-DQ8 
and celiac disease. The patient has no increased risk of developing celiac disease OR HLA-analysis: 
HLA-DQX.5 positive. The analysis detected the following low-risk allele related to celiac disease: HLA-
DQA1*05. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms may occur in 
up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies 
are also found. HLA-DQx.5
1:1842 (extremely 
low)
T64300 DUODENUM  M09350 MORPHOLOGICAL DESCRIPTION ONLY
T63000 STOMACH  M00100 NORMAL TISSUE MORPHOLOGY
T62350 CARDIO-ESOPHAGEAL JUNCTION M00100 NORMAL TISSUE 
MORPHOLOGY + <0.6 neg 2.44 0.7-4 normal
19780609R B-HLADQ2_DQ8-PCR B -HLAKeli 19.08.2018 18:25
HLA-analysis: negative. No association was found between the risk haplotypes  HLA-DQ2 and HLA-DQ8 
and celiac disease. The patient has no increased risk of developing celiac disease OR HLA-analysis: 
HLA-DQX.5 positive. The analysis detected the following low-risk allele related to celiac disease: HLA-
DQA1*05. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms may occur in 
up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies 
are also found. HLA-DQx.5
1:1842 (extremely 
low)
T64300 DUODENUM  M00100 NORMAL TISSUE MORPHOLOGY
T63600 GASTRIC ANTRUM  M43000 CHRONIC GASTRITIS
T63500 GASTRIC CORPUS  M43000 CHRONIC GASTRITIS
T62350 CARDIO-ESOPHAGEAL JUNCTION
T62000 ESOPHAGUS  M00100 NORMAL TISSUE MORPHOLOGY - <0.6 neg 2.50 0.7-4 normal
19640414N B-HLADQ2_DQ8-PCR B -HLAKeli 05.10.2018 16:31
HLA-analysis: negative. No association was found between the risk haplotypes  HLA-DQ2 and HLA-DQ8 
and celiac disease. The patient has no increased risk of developing celiac disease OR HLA-analysis: 
HLA-DQX.5 positive. The analysis detected the following low-risk allele related to celiac disease: HLA-
DQA1*05. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms may occur in 
up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies 
are also found. HLA-DQx.5
1:1842 (extremely 
low)
T64300 DUODENUM M00100 NORMAL TISSUE MORPHOLOGY 
T63600 PYLORIC ANTRUM M00100 NORMAL TISSUE MORPHOLOGY 
T63500 GASTRIC CORPUS M75630 FUNDIC GLAND POLYP 
T63500 GASTRIC CORPUS M09350 CHANGES NOT DIAGNOSTIC 
T62000 ESOPHAGUS M09070 NO ORGANOID TISSUE RECEIVED - <0.6 neg 3.15 0.7-4 normal
19560601A B-HLADQ2_DQ8-PCR B -HLAKeli 05.10.2018 16:30
HLA-analysis: negative. No association was found between the risk haplotypes  HLA-DQ2 and HLA-DQ8 
and celiac disease. The patient has no increased risk of developing celiac disease OR HLA-analysis: 
HLA-DQX.5 positive. The analysis detected the following low-risk allele related to celiac disease: HLA-
DQA1*05. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms may occur in 
up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies 
are also found. HLA-DQx.5
1:1842 (extremely 
low)
T64300 DUODENUM M00100 NORMAL TISSUE MORPHOLOGY
T63600 GASTRIC ANTRUM M00100 NORMAL TISSUE MORPHOLOGY
T63500 GASTRIC CORPUS M00100 NORMAL TISSUE MORPHOLOGY
T62000 ESOPHAGUS M00100 NORMAL TISSUE MORPHOLOGY - <0.6 neg 2.00 0.7-4 normal
19730923K B-HLADQ2_DQ8-PCR B -HLAKeli 31.10.2018 15:10
HLA-analysis: negative. No association was found between the risk haplotypes  HLA-DQ2 and HLA-DQ8 
and celiac disease. The patient has no increased risk of developing celiac disease OR HLA-analysis: 
HLA-DQX.5 positive. The analysis detected the following low-risk allele related to celiac disease: HLA-
DQA1*05. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms may occur in 
up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies 
are also found. HLA-DQx.5
1:1842 (extremely 
low)
T64300 DUODENUM M00100 NORMAL TISSUE MORPHOLOGY 
T63600 GASTRIC ANTRUM M43000 CHRONIC GASTRITIS 
T63500 GASTRIC CORPUS M43000 CHRONIC GASTRITIS 
T62000 ESOPHAGUS M26000 HETEROTOPHY, SAMPLE IV 
T62000 ESOPHAGUS M00100 NORMAL TISSUE MORPHOLOGY, SAMPLE V - 1.0 neg 4.05 0.7-4 elevated
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19590919L B-HLADQ2_DQ8-PCR B -HLAKeli 22.11.2018 15:45
HLA-analysis: negative. No association was found between the risk haplotypes  HLA-DQ2 and HLA-DQ8 
and celiac disease. The patient has no increased risk of developing celiac disease OR HLA-analysis: 
HLA-DQX.5 positive. The analysis detected the following low-risk allele related to celiac disease: HLA-
DQA1*05. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms may occur in 
up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies 
are also found. HLA-DQx.5
1:1842 (extremely 
low)
T64300 DUODENUM M00100 NORMAL TISSUE MORPHOLOGY  
T63600 GASTRIC ANTRUM  M00100 NORMAL TISSUE MORPHOLOGY  
T63500 GASTRIC CORPUS  M00100 NORMAL TISSUE MORPHOLOGY  
T62000 ESOPHAGUS  M00100 NORMAL TISSUE MORPHOLOGY - <0.6 neg 1.96 0.7-4 normal
19500413L B-HLADQ2_DQ8-PCR B -HLAKeli 30.01.2019 15:20
HLA-analysis: negative. No association was found between the risk haplotypes  HLA-DQ2 and HLA-DQ8 
and celiac disease. The patient has no increased risk of developing celiac disease OR HLA-analysis: 
HLA-DQX.5 positive. The analysis detected the following low-risk allele related to celiac disease: HLA-
DQA1*05. The risk alleles are not sufficient for the diagnosis as HLA-DQ2 or DQ8 isoforms may occur in 
up to 30% of healthy individuals. The finding of the risk haplotype supports the diagnosis of celiac 
disease if the patient has symptoms similar to celiac disease and if the disease-associated antibodies 
are also found. HLA-DQx.5
1:1842 (extremely 
low)
T64300 DUODENUM M00100 NORMAL FINDING
T63000 STOMACH M58010 ATROPHIC GASTRITIS - <0.6 neg 1.57 0.7-4 normal
19630917H B-HLADQ2_DQ8-PCR B -HLAKeli 10.01.2018 17:42
HLA-analysis: negative. No association was found between the risk haplotypes  HLA-DQ2 and HLA-DQ8 and 
celiac disease. The patient has no increased risk of developing celiac disease. HLA-DQx.x 1:2518 (extremely low)
T64300 DUODENUM  M00100 NO DIAGNOSTIC ABNORMALITY
T63600 GASTRIC ANTRUM  M43000 CHRONIC GASTRITIS INACTIVE
T63600 GASTRIC ANTRUM  M73320 INTESTINAL METAPLASIA
T63500 GASTRIC CORPUS  M43000 CHRONIC GASTRITIS INACTIVE
T63500 GASTRIC CORPUS  M58000 ATROPHY
T62000 ESOPHAGUS  M73330 BARRETT'S SYNDROME - 0.7 neg 4.52 0.7-4 elevated
19830319P B-HLADQ2_DQ8-PCR B -HLAKeli 21.01.2018 20:23
HLA-analysis: negative. No association was found between the risk haplotypes  HLA-DQ2 and HLA-DQ8 and 
celiac disease. The patient has no increased risk of developing celiac disease. HLA-DQx.x 1:2518 (extremely low)
T64300 DUODENUM  M00100 NORMAL TISSUE MORPHOLOGY
T63000  STOMACH  M00100 NORMAL TISSUE MORPHOLOGY
T62000 ESOPHAGUS  M09350 MORPHOLOGICAL DESCRIPTION ONLY - 0.6 neg 1.99 0.7-4 normal
19830310P B-HLADQ2_DQ8-PCR B -HLAKeli 23.01.2018 15:35
HLA-analysis: negative. No association was found between the risk haplotypes  HLA-DQ2 and HLA-DQ8 and 
celiac disease. The patient has no increased risk of developing celiac disease. HLA-DQx.x 1:2518 (extremely low)
1-3: T64300 DUODENUM AND STOMACH M00100 NORMAL TISSUE 
MORPHOLOGY
4: T62000 ESOPHAGUS M43000 CHRONIC INFLAMMATION, MILD - <0.6 neg 2.76 0.7-4 normal
19590613H B-HLADQ2_DQ8-PCR B -HLAKeli 11.02.2018 20:52
HLA-analysis: negative. No association was found between the risk haplotypes  HLA-DQ2 and HLA-DQ8 and 
celiac disease. The patient has no increased risk of developing celiac disease. HLA-DQx.x 1:2518 (extremely low)
1: T64300 DUODENUM M40000 DUODENITIS, SEE TEXT
2-4: T50100 GASTROSCOPIC BIOPSY SPECIMEN M00100 NO DIAGNOSTIC 
ABNORMALITY
5: T63500 GASTRIC FUNDUS M09350 MORPHOLOGICAL DESCRIPTION ONLY + <0.6 neg 2.46 0.7-4 normal
19780202B B-HLADQ2_DQ8-PCR B -HLAKeli 21.02.2018 16:11
HLA-analysis: negative. No association was found between the risk haplotypes  HLA-DQ2 and HLA-DQ8 and 
celiac disease. The patient has no increased risk of developing celiac disease. HLA-DQx.x 1:2518 (extremely low)
T64300 DUODENUM   M00100 NORMAL TISSUE MORPHOLOGY
T63600 GASTRIC ANTRUM   M00100 NORMAL TISSUE MORPHOLOGY
T63500 GASTRIC CORPUS   M00100 NORMAL TISSUE MORPHOLOGY
T62000 ESOPHAGUS   M00100 NORMAL TISSUE MORPHOLOGY - <0.6 neg 2.77 0.7-4 normal
19530610L B-HLADQ2_DQ8-PCR B -HLAKeli 26.02.2018 07:07
HLA-analysis: negative. No association was found between the risk haplotypes  HLA-DQ2 and HLA-DQ8 and 
celiac disease. The patient has no increased risk of developing celiac disease. HLA-DQx.x 1:2518 (extremely low)
1 T64300 DUODENUM M43000 INFLAMMATION CHRONIC, SEE TEXT 
2 T63600 GASTRIC ANTRUM M00100 NO DIAGNOSTIC ABNORMALITY 
3-4 T63500 GASTRIC CORPUS M00100 NO DIAGNOSTIC ABNORMALITY 
5 T62000 ESOPHAGUS M43000 INFLAMMATION CHRONIC 
5 T62000 ESOPHAGUS M09350 REACTIVE CHANGES (HYPERPLASY) + <0.6 neg 2.30 0.7-4 normal
19580406R B-HLADQ2_DQ8-PCR B -HLAKeli 02.10.2019 15:53
HLA-analysis: negative. No association was found between the risk haplotypes  HLA-DQ2 and HLA-DQ8 and 
celiac disease. The patient has no increased risk of developing celiac disease. HLA-DQx.x 1:2518 (extremely low)
T64300 DUODENUM M40000 INFLAMMATION, mild
T63600 GASTRIC ANTRUM M00100 NO DIAGNOSTIC ABNORMALITY
T63500 GASTRIC CORPUS M00100 NO DIAGNOSTIC ABNORMALITY + <0.6 neg 2.43 0.7-4 normal
19850426K B-HLADQ2_DQ8-PCR B -HLAKeli 07.03.2018 16:26
HLA-analysis: negative. No association was found between the risk haplotypes  HLA-DQ2 and HLA-DQ8 and 
celiac disease. The patient has no increased risk of developing celiac disease. HLA-DQx.x 1:2518 (extremely low)
T64300 DUODENUM M00100 NORMAL TISSUE MORPHOLOGY 
T63000 STOMACH M00100 NORMAL TISSUE MORPHOLOGY
T62350 GASTROESOPHAGEAL JUNCTION M00100 NO DIAGNOSTIC 
ABNORMALITY - <0.6 neg 0.78 0.7-4 normal
19560514K B-HLADQ2_DQ8-PCR B -HLAKeli 14.03.2018 15:32
HLA-analysis: negative. No association was found between the risk haplotypes  HLA-DQ2 and HLA-DQ8 and 
celiac disease. The patient has no increased risk of developing celiac disease. HLA-DQx.x 1:2518 (extremely low)
T64300 DUODENUM  M00100 NORMAL TISSUE MORPHOLOGY
T63000 STOMACH M00100 NO DIAGNOSTIC ABNORMALITY - <0.6 neg 2.27 0.7-4 normal
19921030R B-HLADQ2_DQ8-PCR B -HLAKeli 22.03.2018 15:36
HLA-analysis: negative. No association was found between the risk haplotypes  HLA-DQ2 and HLA-DQ8 and 
celiac disease. The patient has no increased risk of developing celiac disease. HLA-DQx.x 1:2518 (extremely low)
T64300 DUODENUM  M00100 NORMAL TISSUE MORPHOLOGY
T63600 GASTRIC ANTRUM  M43000 CHRONIC GASTRITIS MILD
T63500 GASTRIC CORPUS  M00100 NORMAL TISSUE MORPHOLOGY
T62000 ESOPHAGUS  M00100 NORMAL TISSUE MORPHOLOGY - <0.6 neg 1.97 0.7-4 normal
19820220T B-HLADQ2_DQ8-PCR B -HLAKeli 29.03.2018 15:11
HLA-analysis: negative. No association was found between the risk haplotypes  HLA-DQ2 and HLA-DQ8 and 
celiac disease. The patient has no increased risk of developing celiac disease. HLA-DQx.x 1:2518 (extremely low)
1. T64300 DUODENUM  M09350 MORPHOLOGICAL DESCRIPTION ONLY
1-2. T63000 STOMACH  M00100 NO DIAGNOSTIC ABNORMALITY
3. T62350 CARDIO-ESOPHAGEAL JUNCTION  M43000 CHRONIC 
INFLAMMATION, SEE TEXT
3. T62350 CARDIO-ESOPHAGEAL JUNCTION  M72000 HYPERPLASIA, SEE 
TEXT + <0.6 neg 1.69 0.7-4 normal
19770504K B-HLADQ2_DQ8-PCR B -HLAKeli 06.04.2018 16:35
HLA-analysis: negative. No association was found between the risk haplotypes  HLA-DQ2 and HLA-DQ8 and 
celiac disease. The patient has no increased risk of developing celiac disease. HLA-DQx.x 1:2518 (extremely low)
T64300 DUODENUM M00100 NORMAL TISSUE MORPHOLOGY
T63600 GASTRIC ANTRUM M00100 NORMAL TISSUE MORPHOLOGY
T63500 GASTRIC CORPUS M00100 NORMAL TISSUE MORPHOLOGY
T62000 ESOPHAGUS M00100 NORMAL TISSUE MORPHOLOGY - <0.6 neg 2.16 0.7-4 normal
19760727N B-HLADQ2_DQ8-PCR B -HLAKeli 26.04.2018 14:11
HLA-analysis: negative. No association was found between the risk haplotypes  HLA-DQ2 and HLA-DQ8 and 
celiac disease. The patient has no increased risk of developing celiac disease. HLA-DQx.x 1:2518 (extremely low)
I T64300 DUODENUM M00100 NORMAL TISSUE MORPHOLOGY
II T63600 GASTRIC ANTRUM M00100 NORMAL TISSUE MORPHOLOGY
III T63500 GASTRIC CORPUS M00100 NORMAL TISSUE MORPHOLOGY - <0.6 neg 3.17 0.7-4 normal
19980328A B-HLADQ2_DQ8-PCR B -HLAKeli 10.05.2018 15:30
HLA-analysis: negative. No association was found between the risk haplotypes  HLA-DQ2 and HLA-DQ8 and 
celiac disease. The patient has no increased risk of developing celiac disease. HLA-DQx.x 1:2518 (extremely low)
T64300 DUODENUM M00100 NORMAL TISSUE MORPHOLOGY
T63600 PYLORIC ANTRUM M43000 CHRONIC GASTRITIS
T63500 GASTRIC CORPUS M42000 SUPERFICIAL GASTRITIS - <0.6 neg 1.79 0.7-4 normal
19760410K B-HLADQ2_DQ8-PCR B -HLAKeli 18.05.2018 10:13
HLA-analysis: negative. No association was found between the risk haplotypes  HLA-DQ2 and HLA-DQ8 and 
celiac disease. The patient has no increased risk of developing celiac disease. HLA-DQx.x 1:2518 (extremely low)
T64300 DUODENUM  M00100 NO PATHOLOGIC DIAGNOSIS
T63000 STOMACH  M43000 CHRONIC GASTRITIS - <0.6 neg 2.44 0.7-4 normal
19630119Y B-HLADQ2_DQ8-PCR B -HLAKeli 23.05.2018 16:05
HLA-analysis: negative. No association was found between the risk haplotypes  HLA-DQ2 and HLA-DQ8 and 
celiac disease. The patient has no increased risk of developing celiac disease. HLA-DQx.x 1:2518 (extremely low)
T64300 DUODENUM M58000 VILLOUS ATROPHY
T63600 GASTRIC ANTRUM M00100 NORMAL TISSUE MORPHOLOGY
T63500 GASTRIC CORPUS M76800 POLYP
T62000 ESOPHAGUS M73330 BARRETT'S SYNDROME ++ <0.6 neg 1.80 0.7-4 normal
19691115K B-HLADQ2_DQ8-PCR B -HLAKeli 31.05.2018 16:32
HLA-analysis: negative. No association was found between the risk haplotypes  HLA-DQ2 and HLA-DQ8 and 
celiac disease. The patient has no increased risk of developing celiac disease. HLA-DQx.x 1:2518 (extremely low)
T64300 DUODENUM  M00100 NORMAL TISSUE MORPHOLOGY
T63600 GASTRIC ANTRUM  M00100 NORMAL TISSUE MORPHOLOGY
T63500 GASTRIC CORPUS  M76800 POLYP,   CYSTIC - <0.6 neg 3.03 0.7-4 normal
19831219K B-HLADQ2_DQ8-PCR B -HLAKeli 30.05.2018 16:36
HLA-analysis: negative. No association was found between the risk haplotypes  HLA-DQ2 and HLA-DQ8 and 
celiac disease. The patient has no increased risk of developing celiac disease. HLA-DQx.x 1:2518 (extremely low)
T64300 DUODENUM M00100 NORMAL TISSUE MORPHOLOGY 
T63000 STOMACH M00100 NORMAL TISSUE MORPHOLOGY 
T62000 ESOPHAGUS M40000 ESOPHAGITIS MILD - 0.6 neg 3.07 0.7-4 normal
19691113R B-HLADQ2_DQ8-PCR B -HLAKeli 04.06.2018 07:06
HLA-analysis: negative. No association was found between the risk haplotypes  HLA-DQ2 and HLA-DQ8 and 
celiac disease. The patient has no increased risk of developing celiac disease. HLA-DQx.x 1:2518 (extremely low)
1:T64300 DUODENUM M00100 NORMAL TISSUE MORPHOLOGY
2:T63600 GASTRIC ANTRUM M00100 NORMAL TISSUE MORPHOLOGY
3:T63500 GASTRIC CORPUS M00100 NORMAL TISSUE MORPHOLOGY
4: T63500 GASTRIC CORPUS M75630 FUNDIC GLAND POLYP - <0.6 neg 1.76 0.7-4 normal
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APPENDIX 1 – Clinical laboratory diagnostics results
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19580116F B-HLADQ2_DQ8-PCR B -HLAKeli 25.07.2018 14:31
HLA-analysis: negative. No association was found between the risk haplotypes  HLA-DQ2 and HLA-DQ8 and 
celiac disease. The patient has no increased risk of developing celiac disease. HLA-DQx.x 1:2518 (extremely low)
1. T64300 DUODENUM M40000 INFLAMMATION, SEE TEXT
2. T64400 DUODENAL BULBUS  M09350 MORPHOLOGICAL DESCRIPTION 
ONLY
3. T63600 GASTRIC ANTRUM M00100 NORMAL TISSUE MORPHOLOGY
4. T63500 GASTRIC CORPUS M00100 NORMAL TISSUE MORPHOLOGY
5. T62000 ESOPHAGUS  M00100 NORMAL TISSUE MORPHOLOGY + <0.6 neg 2.34 0.7-4 normal
19920804V B-HLADQ2_DQ8-PCR B -HLAKeli 30.07.2018 16:17
HLA-analysis: negative. No association was found between the risk haplotypes  HLA-DQ2 and HLA-DQ8 and 
celiac disease. The patient has no increased risk of developing celiac disease. HLA-DQx.x 1:2518 (extremely low)
T64300 DUODENUM M00100 NORMAL TISSUE MORPHOLOGY'
T63000 STOMACH M43000 CHRONIC GASTRITIS - <0.6 neg 1.39 0.7-4 normal
19830730K B-HLADQ2_DQ8-PCR B -HLAKeli 07.09.2018 16:21
HLA-analysis: negative. No association was found between the risk haplotypes  HLA-DQ2 and HLA-DQ8 and 
celiac disease. The patient has no increased risk of developing celiac disease. HLA-DQx.x 1:2518 (extremely low)
I T64300 DUODENUM M09350 MORPHOLOGICAL DESCRIPTION ONLY
II T63600 GASTRIC ANTRUM M00100 NORMAL TISSUE MORPHOLOGY
III T63500 GASTRIC CORPUS M00100 NORMAL TISSUE MORPHOLOGY
IV T62350 GASTROESOPHAGEAL JUNCTION (VENTRIKKELITYYPPINEN 
LIMAKALVO) M43000 CHRONIC INFLAMMATION, MILD + <0.6 neg 1.56 0.7-4 normal
19850907G B-HLADQ2_DQ8-PCR B -HLAKeli 07.09.2018 16:20
HLA-analysis: negative. No association was found between the risk haplotypes  HLA-DQ2 and HLA-DQ8 and 
celiac disease. The patient has no increased risk of developing celiac disease. HLA-DQx.x 1:2518 (extremely low)
T64300 DUODENUM  M00100 NORMAL TISSUE MORPHOLOGY
T63600 GASTRIC ANTRUM  M43000 CHRONIC GASTRITIS, ACTIVE, helikobacter 
+++
T63500 GASTRIC CORPUS  M43000 CHRONIC GASTRITIS, ACTIVE - <0.6 neg 0.72 0.7-4 normal
19760322L B-HLADQ2_DQ8-PCR B -HLAKeli 23.09.2018 16:20
HLA-analysis: negative. No association was found between the risk haplotypes  HLA-DQ2 and HLA-DQ8 and 
celiac disease. The patient has no increased risk of developing celiac disease. HLA-DQx.x 1:2518 (extremely low)
T64300 DUODENUM  M00100 NORMAL TISSUE MORPHOLOGY
T63000 STOMACH  M43000 CHRONIC GASTRITIS - <0.6 neg 2.05 0.7-4 normal
19590724O B-HLADQ2_DQ8-PCR B -HLAKeli 23.09.2018 16:20
HLA-analysis: negative. No association was found between the risk haplotypes  HLA-DQ2 and HLA-DQ8 and 
celiac disease. The patient has no increased risk of developing celiac disease. HLA-DQx.x 1:2518 (extremely low)
T64300 DUODENUM  M00100 NORMAL TISSUE MORPHOLOGY
T63000 STOMACH  M00100 NORMAL TISSUE MORPHOLOGY
T62000 ESOPHAGUS  M00100 NO DIAGNOSTIC ABNORMALITY - 2.9 neg 1.80 0.7-4 normal
19930823A B-HLADQ2_DQ8-PCR B -HLAKeli 30.09.2018 12:50
HLA-analysis: negative. No association was found between the risk haplotypes  HLA-DQ2 and HLA-DQ8 and 
celiac disease. The patient has no increased risk of developing celiac disease. HLA-DQx.x 1:2518 (extremely low)
T64300 DUODENUM M00100 NORMAL TISSUE MORPHOLOGY
T63600 PYLORIC ANTRUM M43000 CHRONIC GASTRITIS
T63500 GASTRIC CORPUS M42000 SUPERFICIAL GASTRITIS - <0.6 neg 1.79 0.7-4 normal
19550603H B-HLADQ2_DQ8-PCR B -HLAKeli 09.11.2018 15:25
HLA-analysis: negative. No association was found between the risk haplotypes  HLA-DQ2 and HLA-DQ8 and 
celiac disease. The patient has no increased risk of developing celiac disease. HLA-DQx.x 1:2518 (extremely low)
T64300 DUODENUM  M00100 NORMAL TISSUE MORPHOLOGY
T63600 GASTRIC ANTRUM  M00100 NORMAL TISSUE MORPHOLOGY
T63500 GASTRIC CORPUS  M43000 CHRONIC GASTRITIS MILD - <0.6 neg 2.48 0.7-4 normal
19831011J B-HLADQ2_DQ8-PCR B -HLAKeli 11.11.2018 15:30
HLA-analysis: negative. No association was found between the risk haplotypes  HLA-DQ2 and HLA-DQ8 and 
celiac disease. The patient has no increased risk of developing celiac disease. HLA-DQx.x 1:2518 (extremely low)
T64300 DUODENUM  M00100 NORMAL TISSUE MORPHOLOGY
T63600 GASTRIC ANTRUM  M09350 MORPHOLOGICAL DESCRIPTION ONLY
T63500 GASTRIC CORPUS M00100 NORMAL TISSUE MORPHOLOGY - <0.6 neg 2.21 0.7-4 normal
19550819F B-HLADQ2_DQ8-PCR B -HLAKeli 15.11.2018 15:46
HLA-analysis: negative. No association was found between the risk haplotypes  HLA-DQ2 and HLA-DQ8 and 
celiac disease. The patient has no increased risk of developing celiac disease. HLA-DQx.x 1:2518 (extremely low)
1-2 T64300 DUODENUM M00100 NORMAL TISSUE MORPHOLOGY
3-4 T63000 STOMACH M43000 CHRONIC GASTRITIS, helikobacter +
5 T62000 ESOPHAGUS M00100 NO DIAGNOSTIC ABNORMALITY - <0.6 neg 2.89 0.7-4 normal
19790508V B-HLADQ2_DQ8-PCR B -HLAKeli 16.11.2018 15:40
HLA-analysis: negative. No association was found between the risk haplotypes  HLA-DQ2 and HLA-DQ8 and 
celiac disease. The patient has no increased risk of developing celiac disease. HLA-DQx.x 1:2518 (extremely low)
T64300 DUODENUM M00100 NORMAL TISSUE MORPHOLOGY
T63000 STOMACH M43000 CHRONIC GASTRITIS
T62000 ESOPHAGUS M43000 CHRONIC ESOPHAGITIS - <0.6 neg 1.61 0.7-4 normal
19770512V B-HLADQ2_DQ8-PCR B -HLAKeli 18.11.2018 15:20
HLA-analysis: negative. No association was found between the risk haplotypes  HLA-DQ2 and HLA-DQ8 and 
celiac disease. The patient has no increased risk of developing celiac disease. HLA-DQx.x 1:2518 (extremely low)
T64300 DUODENUM M00100 NORMAL TISSUE MORPHOLOGY
T63600 GASTRIC ANTRUM M43000 CHRONIC GASTRITIS
T63500 GASTRIC CORPUS M58010 ATROPHIC GASTRITIS - <0.6 neg 1.12 0.7-4 normal
19700529K B-HLADQ2_DQ8-PCR B -HLAKeli 18.11.2018 15:20
HLA-analysis: negative. No association was found between the risk haplotypes  HLA-DQ2 and HLA-DQ8 and 
celiac disease. The patient has no increased risk of developing celiac disease. HLA-DQx.x 1:2518 (extremely low)
T64300 DUODENUM M00100 NORMAL TISSUE MORPHOLOGY
T63600 GASTRIC ANTRUM M00100  NORMAL TISSUE MORPHOLOGY
T63500 GASTRIC CORPUS M00100 NORMAL TISSUE MORPHOLOGY - <0.6 neg 2.99 0.7-4 normal
19830714H B-HLADQ2_DQ8-PCR B -HLAKeli 06.12.2018 15:35
HLA-analysis: negative. No association was found between the risk haplotypes  HLA-DQ2 and HLA-DQ8 and 
celiac disease. The patient has no increased risk of developing celiac disease. HLA-DQx.x 1:2518 (extremely low)
T64300 DUODENUM M00100 NORMAL TISSUE MORPHOLOGY
T63600 GASTRIC ANTRUM M43000 CHRONIC GASTRITIS MILD
T63500 GASTRIC CORPUS M43000 CHRONIC GASTRITIS MILD
T62350 CARDIO-ESOPHAGEAL JUNCTION M40000 INFLAMMATION CHRONIC 
ACTIVE
T62000 ESOPHAGUS M09350 MORPHOLOGICAL DESCRIPTION ONLY 
(FUNGUS+) - 0.6 neg 2.95 0.7-4 normal
19981225K B-HLADQ2_DQ8-PCR B -HLAKeli 09.12.2018 15:25
HLA-analysis: negative. No association was found between the risk haplotypes  HLA-DQ2 and HLA-DQ8 and 
celiac disease. The patient has no increased risk of developing celiac disease. HLA-DQx.x 1:2518 (extremely low)
T64300 DUODENUM M00100 NORMAL TISSUE MORPHOLOGY
T63600 GASTRIC ANTRUM M43000 CHRONIC GASTRITIS, MILD
T63500 GASTRIC CORPUS M43000 CHRONIC GASTRITIS, MILD - <0.6 neg 1.92 0.6-3.5 normal
19750516R B-HLADQ2_DQ8-PCR B -HLAKeli 20.12.2018 16:40
HLA-analysis: negative. No association was found between the risk haplotypes  HLA-DQ2 and HLA-DQ8 and 
celiac disease. The patient has no increased risk of developing celiac disease. HLA-DQx.x 1:2518 (extremely low)
I T64300 DUODENUM M58000 VILLOUS ATROPHY
II T63600 GASTRIC ANTRUM M00100 NORMAL TISSUE MORPHOLOGY
III T63500 GASTRIC CORPUS M00100 NORMAL TISSUE MORPHOLOGY ++ <0.6 neg 2.26 0.7-4 normal
19650924T B-HLADQ2_DQ8-PCR B -HLAKeli 31.01.2019 15:55
HLA-analysis: negative. No association was found between the risk haplotypes  HLA-DQ2 and HLA-DQ8 and 
celiac disease. The patient has no increased risk of developing celiac disease. HLA-DQx.x 1:2518 (extremely low)
T64300 DUODENUM  M00100 NORMAL TISSUE MORPHOLOGY
T63600 GASTRIC ANTRUM  M00100 NORMAL TISSUE MORPHOLOGY
T63500 GASTRIC CORPUS  M43000 CHRONIC GASTRITIS  MILD - <0.6 neg 1.69 0.7-4 normal
19560521I B-HLADQ2_DQ8-PCR B -HLAKeli 15.02.2019 15:51
HLA-analysis: negative. No association was found between the risk haplotypes  HLA-DQ2 and HLA-DQ8 and 
celiac disease. The patient has no increased risk of developing celiac disease. HLA-DQx.x 1:2518 (extremely low)
T64300 DUODENUM  M00100 NORMAL TISSUE MORPHOLOGY
T63600 GASTRIC ANTRUM  M43000 CHRONIC GASTRITIS
T63500 GASTRIC CORPUS  M42000 SUPERFICIAL GASTRITIS - <0.6 neg 1.99 0.7-4 normal
19750311H B-HLADQ2_DQ8-PCR B -HLAKeli 31.03.2019 18:05
HLA-analysis: negative. No association was found between the risk haplotypes  HLA-DQ2 and HLA-DQ8 and 
celiac disease. The patient has no increased risk of developing celiac disease. HLA-DQx.x 1:2518 (extremely low)
T64300 DUODENUM M43000 CHRONIC INFLAMMATION, mild
T63000 STOMACH M00100 NORMAL TISSUE MORPHOLOGY
T67000 COLON M00100 NORMAL TISSUE MORPHOLOGY + <0.6 neg 2.67 0.7-4 normal
19790102T B-HLADQ2_DQ8-PCR B -HLAKeli 12.06.2019 15:59
HLA-analysis: negative. No association was found between the risk haplotypes  HLA-DQ2 and HLA-DQ8 and 
celiac disease. The patient has no increased risk of developing celiac disease. HLA-DQx.x 1:2518 (extremely low)
T64300 DUODENUM M40000 DUODENITIS, LEVIS
T63600 GASTRIC ANTRUM M00100 NORMAL TISSUE MORPHOLOGY
T63500 GASTRIC CORPUS M00100 NORMAL TISSUE MORPHOLOGY
T62000 ESOPHAGUS M00100 NORMAL TISSUE MORPHOLOGY + <0.6 neg 1.42 0.7-4 normal
19941125R B-HLADQ2_DQ8-PCR B -HLAKeli 24.07.2019 15:18
HLA-analysis: negative. No association was found between the risk haplotypes  HLA-DQ2 and HLA-DQ8 and 
celiac disease. The patient has no increased risk of developing celiac disease. HLA-DQx.x 1:2518 (extremely low)
T64300 DUODENUM  M00100 NORMAL TISSUE MORPHOLOGY
T63600 GASTRIC ANTRUM  M00100 NO DIAGNOSTIC ABNORMALITY
T63500 GASTRIC CORPUS  M43000 CHRONIC GASTRITIS
T62000 ESOPHAGUS  M43000 CHRONIC INFLAMMATION - <0.6 neg 0.90 0.7-4 normal
19830101M B-HLADQ2_DQ8-PCR B -HLAKeli 22.08.2019 16:31
HLA-analysis: negative. No association was found between the risk haplotypes  HLA-DQ2 and HLA-DQ8 and 
celiac disease. The patient has no increased risk of developing celiac disease. HLA-DQx.x 1:2518 (extremely low)
T64300 DUODENUM M00100 NORMAL TISSUE MORPHOLOGY
T63600 GASTRIC ANTRUM M00100 NORMAL TISSUE MORPHOLOGY
T63500 GASTRIC CORPUS M00100 NORMAL TISSUE MORPHOLOGY
T62000 ESOPHAGUS M00100 NORMAL TISSUE MORPHOLOGY - 0.8 neg 3.80 0.7-4 normal
19620917H B-HLADQ2_DQ8-PCR B -HLAKeli 28.08.2019 16:19
HLA-analysis: negative. No association was found between the risk haplotypes  HLA-DQ2 and HLA-DQ8 and 
celiac disease. The patient has no increased risk of developing celiac disease. HLA-DQx.x 1:2518 (extremely low)
1: T64300 DUODENUM M00100 NORMAL TISSUE MORPHOLOGY
2: T64400 DUODENAL BULBUS M73330 GASTRIC METAPLASIA
3,4: T63000 STOMACH M00100 NORMAL TISSUE MORPHOLOGY
5: T63500 GASTRIC CORPUS M82110 TUBULAR ADENOMA, LOW GRADE - <0.6 neg 1.45 0.7-4 normal
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19830320H B-HLADQ2_DQ8-PCR B -HLAKeli 02.09.2019 17:06
HLA-analysis: negative. No association was found between the risk haplotypes  HLA-DQ2 and HLA-DQ8 and 
celiac disease. The patient has no increased risk of developing celiac disease. HLA-DQx.x 1:2518 (extremely low)
T64300 DUODENUM M00100 NORMAL TISSUE MORPHOLOGY
T63600 PYLORIC ANTRUM M43000 CHRONIC GASTRITIS
T63500 GASTRIC CORPUS M42000 SUPERFICIAL GASTRITIS - <0.6 neg 1.79 0.7-4 normal
19661115V B-HLADQ2_DQ8-PCR B -HLAKeli 30.09.2019 16:54
HLA-analysis: negative. No association was found between the risk haplotypes  HLA-DQ2 and HLA-DQ8 and 
celiac disease. The patient has no increased risk of developing celiac disease. HLA-DQx.x 1:2518 (extremely low)
T64300 DUODENUM  M00100 NORMAL TISSUE MORPHOLOGY
T63600 GASTRIC ANTRUM  M43000 CHRONIC GASTRITIS
T63500 GASTRIC CORPUS  M43000 CHRONIC GASTRITIS
T62350 CARDIO-ESOPHAGEAL JUNCTION  M00100 NO DIAGNOSTIC 
ABNORMALITY
T62000 ESOPHAGUS  M00100 NO DIAGNOSTIC ABNORMALITY - 0.8 neg 4.27 0.7-4 elevated
19821125J B-HLADQ2_DQ8-PCR B -HLAKeli 16.10.2019 16:06
HLA-analysis: negative. No association was found between the risk haplotypes  HLA-DQ2 and HLA-DQ8 and 
celiac disease. The patient has no increased risk of developing celiac disease. HLA-DQx.x 1:2518 (extremely low)
T64300 DUODENUM M40000 INFLAMMATION (SEE ADDITIONAL STATEMENT)
T64300 DUODENUM M58000 ATROPHY, LEVIS
T63000 STOMACH M00100 NORMAL TISSUE MORPHOLOGY
T62000 ESOPHAGUS M00100 NORMAL TISSUE MORPHOLOGY ++ <0.6 neg 2.31 0.7-4 normal
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